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End-stage osteoarthritis is characterised by pain and reduced physical function, for 
which total knee arthroplasty (TKA) is recognised to be a highly effective procedure. 
Post-operative outcome and resultant function however is variable. Many factors are 
thought to influence outcome; in particular quadriceps muscle strength is one of the 
strongest predictors of the patient’s ability to perform functional tasks. Muscle 
atrophy has been shown to account for only a third of the variance in muscle power, 
the remainder is currently unexplained. In this thesis it is hypothesised that 
physiological and mechanical factors will affect muscle power post TKA.  
 
A new design of prosthesis with an axis of rotation of the knee based on new 
kinematical observations has been suggested to confer a mechanical advantage to the 
knee extensor mechanism by lengthening its moment arm, and thus reducing the 
muscular effort required to extend the knee, however this has not as yet been 
clinically demonstrated. A strong extensor mechanism is recognised as being 
paramount to the patients return to functional activity following TKA, but there has 
been no consideration as to the mechanisms how and to what extent the muscle tissue 
actually recovers. It is known that muscle satellite cells are essential for the 
regeneration of skeletal muscle and that these cells are activated following damage, 
but these have not been considered in relation to recovery from orthopaedic 
procedures. It is hypothesised that the number of satellite cells in the extensor 
mechanism will vary in the patient population and will influence muscle recovery.  
 
A double blind randomised controlled trial of 212 TKA patients was conducted to 
compare the new implant design with a traditional model. Patient outcome was 
assessed at four points over a one year period. The new implant was superior in 
measures of knee flexion, lower limb power output and by patient report 
questionnaire (Oxford Knee Score) Two-way ANOVA, p = <0.001 in all cases. 
Extensor mechanism power was significantly increased between all four assessment 
 
 II 
points in the new implant group, the control group demonstrating change between the 
second and third assessment only (p= <0.001).  
 
Analysis of the outcome assessments used demonstrated a changing relationship 
between function and patient report of that function. Regression models 
demonstrated that patient report of function became more consistent with direct 
functional assessment as the influence of pain diminished post-operatively. A 
hierarchical model is presented that highlights the limitation of patient report data in 
isolation. 
 
Muscle satellite cells were isolated from biopsies of the quadriceps muscle of 18 
patients at the time of surgery and counted by an immunofluorescent staining 
technique. The number of satellite cells detected accounted for a third of the post-
operative variance in power output (R
2
 = 36.6%). This was confirmed in another 
cohort of 11 patients with a more sensitive qPCR technique. It was further found that 
the activated satellite cells accounted for around two thirds of the change in post-
operative power output (R
2
 = 66.7%). 
 
In conclusion, both mechanical and physiological factors have a significant effect on 






I hereby declare that the work described within this document is my own, except 
where explicitly stated otherwise. This thesis has been composed by me alone, and 











There are many people who in various ways have contributed to this body of work 
and deserve my sincere gratitude. 
 
I have been exceedingly fortunate in my supervisory team who have expertly 
complemented the two arms of this thesis. It is through their active input at 
professional, academic and indeed personal levels that this work has been made 
possible.  
 
Prof. Hamish Simpson merits particular thanks for his general oversight of this 
thesis, continual pertinent advice, considerable insight into the muscle stem cell 
aspects and the far from inconsequential issue of arranging the funding required to 
bank-roll this endeavour. I have benefited from funding from both the Medical 
Research Council doctoral training scheme and from Stryker
UK
; I extend my thanks 
to both for their financial assistance. 
 
I am also very much indebted to Mr Paul Gaston for his general support, friendship, 
and refreshing application of shear common sense.  It is through his expertise in all 
things arthroplasty and considerable capacity to make complex technical issues 
comprehensible that I have been able to gain a meaningful understanding of the 
detailed technical and surgical influences that were key to the development of the 
RCT and indeed this thesis. I further acknowledge his considerable involvement with 
the development of the implant trial, and practical contribution throughout. 
Additionally, from a clinical perspective, the many hours we have shared post-
operative clinics has directly resulted in an exponential development of my 
orthopaedic patient management, for which I also thank him. 
 
Further thanks must go to the other consultants and wider arthroplasty team at RIE 
who have helped facilitate the smooth(ish) running of the clinical trial. Mr Sam 
 
 V 
Patton, Mr Richard Burnett, and Mr Colin Howie merit particular thanks and also Mr 
Gaston’s secretaries, Helen and latterly Cathy. 
 
Jennifer McLeish at the Queens Medical Research Centre has donated much of her 
time, and I thank her for technical assistance with the stem cells, development of the 
primers used, tireless explanation of the murky depths of qPCR, and that reassuring 
‘don’t worry, this always happens’ look while I attempted to optimise the staining 
protocols. 
 
Thanks also to the members of the Orthopaedic Engineering research group of which 
I have been a part for the last few years for their general support, coffee and 
crosswords (which despite their best efforts remain cryptic). Specific thanks to 
Debbie MacDonald for her expert assistance with the ethics applications, pertinent 
advice as regards running the clinical trial and in typesetting of this document. Also 
thanks to Robin Henderson for teaching me the finer points of stepwise regression 
modelling and to Rob Wallace for numerous Excel shortcuts and the occasional 
whiskey (with a spoon). 
 
Finally, and most importantly, I thank my family for putting up with all the hours I 
have spent on this project. Thesis write-ups are notorious for their perpetual nature, 
and despite my best efforts, it has required a certain selfishness to document this 
project. My apologies to my wife Anna for the exquisitely poor timing of the write-
up phase, which as a result has quite literally left her holding the baby, it is in no way 




1 INTRODUCTION, SCOPE AND OUTLINE ............................................ 1 
1.1 Introduction ............................................................................................................................ 1 
1.2 Scope of thesis and research hypothesis ............................................................................... 5 
1.3 Outline .................................................................................................................................... 6 
2 LITERATURE REVIEW .......................................................................... 8 
2.1 History and Development of Knee Arthroplasty ................................................................. 8 
Interpositional Arthroplasty ............................................................................................................... 8 
Hinges................................................................................................................................................ 9 
Condylar replacements .................................................................................................................... 10 
Modern developments ..................................................................................................................... 11 
2.2 Knee Arthroplasty Outcome ............................................................................................... 13 
Success of total knee arthroplasty ................................................................................................... 13 
Assessment of outcome ................................................................................................................... 15 
Performance measures ..................................................................................................................... 17 
2.3 Muscle Power and Functional Outcome ............................................................................ 18 
2.4 Single Radius Implant Design ............................................................................................. 21 
Clinical studies ................................................................................................................................ 24 
2.5 Muscle Regeneration ........................................................................................................... 29 
Muscle satellite cells ....................................................................................................................... 30 
Contribution to muscle hypertrophy ................................................................................................ 32 
Regulation of satellite cell activity .................................................................................................. 33 
Potential therapies ........................................................................................................................... 34 
Human studies ................................................................................................................................. 35 
Human muscle regeneration and the aging process ......................................................................... 36 
Clinical relevance ............................................................................................................................ 41 
3 THE INFLUENCE OF SINGLE RADIUS FEMORAL COMPONENT 
DESIGN ON POST-OPERATIVE FUNCTION: THE TRIMAX RCT ............ 44 
3.1 Introduction .......................................................................................................................... 44 
3.2 Methods ................................................................................................................................ 46 
Study design and ethical approval ................................................................................................... 46 
Patient recruitment .......................................................................................................................... 47 
Operative technique ......................................................................................................................... 48 
Follow-up and patient withdrawal ................................................................................................... 48 
Outcome assessments ...................................................................................................................... 51 
Oxford Knee Score ..................................................................................................................... 51 
Range of motion ......................................................................................................................... 52 
Functional assessment ................................................................................................................ 52 
Lower limb power output ........................................................................................................... 53 
Pain assessment .......................................................................................................................... 54 
Statistical analysis ........................................................................................................................... 55 
 
 VII 
3.3 Results ................................................................................................................................... 56 
Oxford Knee Score .......................................................................................................................... 57 
RCT results: 1 year outcome ...................................................................................................... 57 
Longitudinal change across the 4 time points ............................................................................. 58 
Range of motion – Flexion .............................................................................................................. 60 
RCT results: 1 year outcome ...................................................................................................... 60 
Longitudinal change across the 4 time points ............................................................................. 61 
Range of motion – Extension .......................................................................................................... 63 
RCT results: 1 year outcome ...................................................................................................... 63 
Longitudinal change across the 4 time points ............................................................................. 64 
Timed functional assessment ........................................................................................................... 66 
RCT results: 1 year outcome ...................................................................................................... 66 
Longitudinal change across the 4 time points ............................................................................. 67 
Lower Limb Power Output .............................................................................................................. 69 
RCT results: 1 year outcome ...................................................................................................... 69 
Longitudinal change across the 4 time points ............................................................................. 70 
Proportional lower limb power output ............................................................................................. 72 
RCT results: 1 year outcome ...................................................................................................... 72 
Longitudinal change across the 4 time points ............................................................................. 73 
Reported average pain score ............................................................................................................ 76 
RCT results: 1 year outcome ...................................................................................................... 76 
Longitudinal change across the 4 time points ............................................................................. 77 
Reported maximal pain score .......................................................................................................... 79 
RCT results: 1 year outcome ...................................................................................................... 79 
Longitudinal change across the 4 time points ............................................................................. 80 
3.4 Discussion ............................................................................................................................. 82 
Strengths and limitations ................................................................................................................. 87 
4 THE ROLE OF PATIENT REPORT AND PERFORMANCE 
ASSESSMENT IN DETERMINING OUTCOME FOLLOWING TKA ........... 91 
4.1 Introduction .......................................................................................................................... 91 
4.2 Methods ................................................................................................................................ 93 
Statistical analysis ........................................................................................................................... 94 
4.3 Results ................................................................................................................................... 94 
Relationship of OKS with pain and functional measures over time ................................................ 95 
Pre-operative predictors of 1 year patient outcome ....................................................................... 101 
4.4 Discussion ........................................................................................................................... 102 
Change over time ........................................................................................................................... 105 
5 INFLUENCE OF THE MUSCULATURE ON TKR OUTCOME: 
‘REGENERATIVE POTENTIAL’ OF THE MUSCLE – A PILOT STUDY .. 111 
5.1 Introduction ........................................................................................................................ 111 
5.2 Methods .............................................................................................................................. 112 
Patient recruitment ........................................................................................................................ 112 
Power output assessment ............................................................................................................... 113 
Muscle sampling............................................................................................................................ 114 
Histology ....................................................................................................................................... 114 
Statistical analysis ......................................................................................................................... 116 
 
 VIII 
5.3 Results ................................................................................................................................. 116 
Histology ....................................................................................................................................... 116 
Numbers of identified satellite cells .............................................................................................. 118 
Correlation of satellite cell number with patient age ..................................................................... 120 
Power output ................................................................................................................................. 120 
Change in power output between assessments .............................................................................. 121 
Correlation of satellite cell content and power output ................................................................... 123 
Regression analysis ................................................................................................................... 125 
5.4 Discussion ........................................................................................................................... 125 
6 INFLUENCE OF THE MUSCULATURE ON TKR OUTCOME: 
SATELLITE CELL ACTIVATION AND POWER OUTPUT ....................... 130 
6.1 Introduction ........................................................................................................................ 130 
6.2 Methods .............................................................................................................................. 134 
Patient recruitment and power output analysis .............................................................................. 134 
Muscle sampling............................................................................................................................ 135 
Histology ....................................................................................................................................... 135 
Immunofluorescence for Pax7 ....................................................................................................... 135 
RNA extraction.............................................................................................................................. 136 
Quantitative Real Time – PCR analysis ........................................................................................ 137 
Primers ...................................................................................................................................... 138 
Satellite cell markers................................................................................................................. 138 
Quantitative PCR ...................................................................................................................... 138 
Statistical analysis ......................................................................................................................... 139 
6.3 Results ................................................................................................................................. 139 
Immunofluorescence ..................................................................................................................... 139 
RT-PCR ......................................................................................................................................... 140 
Expression relative to the control .................................................................................................. 142 
Power output ................................................................................................................................. 145 
Change in power output between assessments .............................................................................. 145 
Correlation of satellite cell content and power output ................................................................... 146 
Correlation with markers of cell activation ................................................................................... 147 
Regression analysis ....................................................................................................................... 150 
6.4 Discussion ........................................................................................................................... 151 
7 CONCLUSIONS AND FUTURE DIRECTIONS .................................. 154 
7.1 Conclusions ......................................................................................................................... 154 
Mechanical influence .................................................................................................................... 155 
Physiological influence ................................................................................................................. 157 
7.2 Future directions ................................................................................................................ 159 
8 APPENDICES .................................................................................... 162 
Appendix A: Submitted paper ........................................................................................................ 162 
Appendix B: Conference abstracts ................................................................................................. 172 
Published abstracts ........................................................................................................................ 172 





 Combined Meeting of the Orthopaedic Associations, Glasgow, 2010 ................................... 173 
Physiotherapy Research Society, Middlesburgh, 2010 ................................................................. 174 
British Orthopaedic Research Society, Cardiff, 2010.................................................................... 175 
Orthopaedic Research Society, New Orleans, 2010 ...................................................................... 176 
Physiotherapy Research Society, Glasgow, 2009 .......................................................................... 177 
Appendix C: Statistical output (Chapter 3) ................................................................................... 179 
Oxford Knee Score ........................................................................................................................ 179 
1 year outcome ANOVA output .................................................................................................... 179 
Longitudinal between assessment and between group output ....................................................... 180 
Range of motion – Flexion ............................................................................................................ 181 
1 year outcome ANOVA output .................................................................................................... 181 
Longitudinal between assessment and between group output ....................................................... 182 
Range of motion – Extension ........................................................................................................ 183 
1 year outcome ANOVA output .................................................................................................... 183 
Longitudinal between assessment and between group output ....................................................... 184 
Timed functional assessment ......................................................................................................... 185 
1 year outcome ANOVA output .................................................................................................... 185 
Longitudinal between assessment and between group output ....................................................... 186 
Lower limb power output .............................................................................................................. 187 
1 year outcome ANOVA output .................................................................................................... 187 
Longitudinal between assessment and between group output ....................................................... 188 
Proportional lower limb power output ........................................................................................... 189 
1 year outcome ANOVA output .................................................................................................... 189 
Longitudinal between assessment and between group output ....................................................... 190 
Reported average pain score .......................................................................................................... 191 
1 year outcome ANOVA output .................................................................................................... 191 
Longitudinal between assessment and between group output ....................................................... 192 
Reported maximal pain score ........................................................................................................ 193 
1 year outcome ANOVA output .................................................................................................... 193 
Longitudinal between assessment and between group output ....................................................... 194 
Appendix D: Statistical output (Chapter 4) ................................................................................... 195 
Multiple linear regression analysis of predictors of OKS (12 month assessment) ........................ 195 
Multiple linear regression analysis of predictors of OKS (6 month assessment) .......................... 196 
Multiple linear regression analysis of predictors of OKS (6 week assessment) ............................ 197 
Multiple linear regression analysis of predictors of OKS (Pre-operative assessment) .................. 198 
Multiple linear regression analysis of pre-operative predictors of 12 month OKS ....................... 199 
Multiple linear regression analysis of pre-operative predictors of 6 month OKS ......................... 200 
Multiple linear regression analysis of pre-operative predictors of 6 week OKS ........................... 201 
Appendix E: Protocols (Chapter 5) ................................................................................................ 202 
H and E staining protocol .............................................................................................................. 202 
De-waxing protocol ....................................................................................................................... 202 
Antigen retrieval protocol.............................................................................................................. 202 
Appendix F: Statistical output (Chapter 5).................................................................................... 203 
Regression analysis of satellite cell PSI and post-operative change in power output ................... 203 
Regression analysis of satellite cell PSI and post-operative change in power-bodyweight ratio .. 203 
Regression analysis of pre-operative power output and post-operative change in power output .. 204 
Regression analysis of pre-operative power output and post-operative change in power-bodyweight 
ratio ............................................................................................................................................... 204 
Stepwise regression model of change in power output.................................................................. 205 
Stepwise regression model of change in power-bodyweight ratio ................................................ 205 
Appendix G: Protocols (Chapter 6) ................................................................................................ 206 
RNA purification protocol ............................................................................................................. 206 
cDNA Reverse Transcription Protocol .......................................................................................... 208 
 
 X 
Appendix H: Statistical output (Chapter 6) ................................................................................... 211 
Regression of Pax7 expression and post-operative change in power output ................................. 211 
Regression of Pax7 expression and post-operative change in power-bodyweight ratio ................ 211 
Regression of NCAM expression and post-operative change in power output ............................. 212 
Regression of NCAM expression and post-operative change in power-bodyweight ratio ............ 212 
Regression of CD34 expression and post-operative change in power output ................................ 213 
Regression of CD34 expression and post-operative change in power-bodyweight ratio .............. 213 
Stepwise regression model of change in power output.................................................................. 214 
Stepwise regression model of change in power-bodyweight ratio ................................................ 214 
Appendix I: Implant design differences ......................................................................................... 215 
Highlighted design differences between the implants used. .......................................................... 215 
BIBLIOGRAPHY ....................................................................................... 217 
 
 XI 
Table of Figures 
 
Figure 2.1 – Images showing the instant multi-centre of rotation implant design. The shifting 
centre of rotation is highlighted in both the Radiographic image (the Releaux method to 
show the ‘Instantaneous Centre of Rotation’ between two flexion angles) and the 
accompanying diagram which demonstrates the resultant implant design and the changing 
centre of rotation within. ........................................................................................................ 21 
 
Figure 2.2 – Images showing the single axis of rotation implant design. Radiograph 
highlighting the single flexion / extension axis from neutral to 100 degrees of knee flexion. 
The accompanying image demonstrates the same axis on the resultant implant design. ....... 22 
 
Figure 2.3 - Diagrammatic representation of the hypothesised reduction in quadriceps muscle 
force generation required to extend the knee as a result of the increased moment arm of the 
single axis of rotation ............................................................................................................. 23 
 
Figure 2.4 - Satellite cell anatomical location, occupying a sublaminar position in adult 
skeletal muscle. In the uninjured muscle fibre, the satellite cell is quiescent, however when 
injured, they increase their cytoplasmic content and develop cytoplasmic processes that 
allow for chemotaxis of the satellite cell along the myofiber to the site of damage. The 
satellite cells can be distinguished from the myonuclei as it lies beneath the basal lamina but 
above the plasmalemma. Bar = 1 µm..................................................................................... 31 
 
Figure 2.5 - Satellite cell response to myotrauma. Upon activation some of the satellite cells 
will re-establish a quiescent satellite cell pool through a process of self-renewal. Others will 
migrate to the damaged area and, depending on severity of injury, fuse to the existing 
myofiber or align and fuse to produce a new myofiber. In the regenerated myofiber, the 
newly fused satellite cell nuclei is located centrally, but later migrate to assume a more 
peripheral location. ................................................................................................................ 32 
 
Figure 2.6 - Model of satellite cell activation and progression through the myogenic 
program. Quiescent satellite cells express Pax7 and the myogenic regulatory factor (MRF) 
Myf5. Upon activation, they divide to produce a pool of muscle precursor cells. The cell 
progeny then follow one of two fates, self-renewal to give rise to another satellite cell, or 
differentiation to repair damaged myofibers. ......................................................................... 34 
 
Figure 3.1 - Diagrammatic representation of the patient seated on the leg extensor power rig, 
demonstrating the leg position at the start of the push. .......................................................... 54 
 
Figure 3.2 - Bar chart demonstrating the trial split of patient gender by implant group ........ 57 
 
Figure 3.3 - Graphical illustration of the repeated measures ANOVA for OKS. The overall 
change and trajectory of change in both groups is highlighted. Although the overall change is 
similar, the triathlon group demonstrates greater overall change in Oxford Knee Score. ..... 58 
 
Figure 3.4 - Boxplot of Oxford Knee Score, highlighting the similar pattern of reduction of 




Figure 3.5 - Graphical illustration of the repeated measures ANOVA for flexion, 
highlighting the differing trajectory of change in the implant groups. The Triathlon group 
achieves improvement in flexion following surgery, while the Kinemax group broadly 
achieves pre-operative levels of flexion. ................................................................................ 61 
 
Figure 3.6 - Change in flexion over the assessment period. Graph demonstrates the striking 
similarity of the change in flexion in both groups, and the superior results achieved by the 
Triathlon group. ..................................................................................................................... 62 
 
Figure 3.7 - Graphical illustration of the repeated measures ANOVA for extension. The 
reduction in mean flexion and similar trajectory of change in both groups is highlighted. ... 64 
 
Figure 3.8 - Change in extension over the assessment period. Graph demonstrates the similar 
early change in extension in both groups to 6 months, then the further improvement in the 
Triathlon group ...................................................................................................................... 65 
 
Figure 3.9 - Graphical illustration of the repeated measures ANOVA for timed functional 
assessment. The overall reduction following surgery and the similar trajectory of change in 
both groups is highlighted. ..................................................................................................... 67 
 
Figure 3.10 - Graph demonstrates the similar change in functional score in both groups. Data 
plotted at assessment time points highlighting the proportional change in extension over the 
year. ........................................................................................................................................ 68 
 
Figure 3.11 - Graphical illustration of the repeated measures ANOVA for lower limb power 
output. The overall increase in power following surgery is highlighted, and also the differing 
trajectory of change between the groups. ............................................................................... 70 
 
Figure 3.12 - Graph demonstrates the similar overall change in power output (W) over time, 
but also the divergence between groups at 6 weeks and 12 months assessments. ................. 71 
 
Figure 3.13 - Graphical illustration of the repeated measures ANOVA for proportional lower 
limb power output. The overall increase in power as a proportion of the contralateral limb 
following TKA is highlighted. The differing trajectory of the two groups is also apparent, the 
Triathlon group achieving greater relative improvement than the Kinemax. ........................ 73 
 
Figure 3.14 - Graph of change in power output, demonstrates the similar overall pattern of 
change in power output over time, but also the greater proportional increase for the Triathlon 
group. ..................................................................................................................................... 74 
 
Figure 3.15 - Graphical illustration of the repeated measures ANOVA for average pain score. 
The overall reduction on pain score following surgery is highlighted, and also the similar 
trajectory of change of the groups. ......................................................................................... 77 
 
Figure 3.16 - Boxplot highlighting the similar pattern of reduction of average pain score 
across the assessment period. The Triathlon group appear to report less pain at all assessment 
points. ..................................................................................................................................... 78 
 
Figure 3.17 - Graphical illustration of the repeated measures ANOVA for maximal pain. The 
overall reduction in pain score is apparent, and also the similar but significantly different 




Figure 3.18 - Boxplot highlighting the broadly similar pattern of reduction of maximal pain 
score across the assessment period, and the reduced score of the Triathlon group at 12 
months compared to the Kinemax group ............................................................................... 81 
 
Figure 4.1 - Relationship between Oxford Knee Score and pain report. Figure demonstrates 
the linear relationship between maximal pain report and the OKS at all 4 assessments. The 
top figure displays the regression on the underlying scatter plot of the data, the bottom figure 
the individual regression lines for clarity. The gradient of the regression lines are comparable 
at each post-operative assessment, though follow a different trajectory rep-operatively. ..... 96 
 
Figure 4.2 - Relationship between Oxford Knee score and power output. Figure demonstrates 
the linear relationship between maximal lower limb power output and the OKS at all 4 
assessments. The top figure displays the regression on the underlying scatter plot of the data, 
the bottom figure the individual regression lines for clarity. The gradient of the regression 
lines are broadly comparable at each assessment. ................................................................. 97 
 
Figure 4.3 - Relationship between Oxford Knee Score and functional assessment. Figure 
demonstrates the linear relationship between functional assessment (ALF) time and the OKS 
at all 4 assessments. The top figure displays the regression on the underlying scatter plot of 
the data, the bottom figure the individual regression lines for clarity. The gradient of the 
regression lines is similar at 6 and 12 months post-operatively, but notably different at the 
other assessments, highlighting the differing relationship between OKS and ALF score at the 
different assessment time points. ........................................................................................... 98 
 
Figure 4.4 - Clinical assessment framework. Figure displays a theoretical hierarchical model 
that demonstrates the differing levels of information assessed by the alternative types of 
outcome analysis. ................................................................................................................. 109 
 
Figure 5.1 - Examples of typical H&E staining of study tissue sections. Normal muscle 
architecture demonstrated in all samples. Haematoxylin stains the nuclei blue and eosin the 
collagen fibres pink. ............................................................................................................. 117 
 
Figure 5.2 - Multiple images of the section to confirm cell location. Immunofluorescent 
stain, merged with DAPI stain of myonuclei ....................................................................... 118 
 
Figure 5.3 - Immunofluorescence image of muscle satellite cells. Examples of typical 
staining profiles obtained. Separate samples demonstrating differing numbers of satellite 
cells identified with the staining protocol. ........................................................................... 119 
 
Figure 5.4 - Association of patient age and satellite cell number. Linear relationship found 
between patient age at time of surgery and satellite cell PSI. .............................................. 120 
 
Figure 5.5 - Improvement in power output between pre-operative and 6 weeks values ...... 122 
 
Figure 5.6 - Linear relationship found between positive staining index of satellite cells in 
muscle tissue samples and the subsequent change in individual maximal power output. Good 
correlation between variables r = 0.57, p = 0.02 .................................................................. 124 
 
Figure 5.7 - Linear relationship found between satellite cell positive staining index and 
individual change in power-bodyweight ratio, strong correlation between the variables r = 




Figure 6.1 - Diagram detailing the process of reverse transcription, where cDNA is produced 
from mRNA using the enzyme reverse transcriptase. .......................................................... 132 
 
Figure 6.2 – Explanation of the typical PCR output graph demonstrating the typical PCR 
output graph and logarithmic relationship. .......................................................................... 133 
 
Figure 6.3 - H &E and Immunofluorescent staining, highlighting destruction of muscle 
architecture. Examples of typical H&E staining (A) and immunofluorescence staining (B) of 
study tissue sections. Abnormal muscle architecture with disruption of myofibres 
demonstrated in all samples. Image A: Haematoxylin stains the nuclei blue and eosin the 
collagen fibres pink. Image B: DAPI nuclear staining (Blue) and Pax-7 fluorescent stain 
(bright green). It was not possible to confirm the location of the stained cells relative to the 
basal lamina. ........................................................................................................................ 140 
 
Figure 6.4 - Screen shot of PCR output graph showing 18s and Pax7 expression of all 11 
samples. ΔCt values (difference between cycle number that expression occurs) of 18s and 
Pax7 are highlighted by the black arrow bars for one of the 11 samples. ............................ 141 
 
Figure 6.5 - Relative expression of all satellite cell markers. Satellite cell content expressed 
relative to the control patient. Note the individual variation between the individual samples 
compared to the control, and also that the 3 markers of satellite cell are present to varying 
degrees. ................................................................................................................................ 143 
 
Figure 6.6 - Individual plots of satellite cell markers and relative gene expression relative to 
the control sample. No data was obtained on sample 7 suggesting a problem with the 
processing or storage of that specific tissue that prevented analysis. Pax7 expression (A) 
demonstrates the expected individual variation in satellite cell content. The NCAM 
expression (B) generally shows increased levels of activated satellite cells compared to the 
control sample though was not detected at all in 2 further samples, while the marker of 
quiescent cells CD34 (C) was consistently expressed less than in the control sample. ....... 144 
 
Figure 6.7 - Linear relationship found between the patients Pax7 expression and change in 
their maximal power output post TKA. Good correlation between the variables: r = 0.58, p = 
0.06 ...................................................................................................................................... 147 
 
Figure 6.8 - Linear relationship found between the patients Pax7 expression and their change 
in power-bodyweight ratio post TKA. Strong correlation between variables: r = 0.79, p = 
0.004 .................................................................................................................................... 147 
 
Figure 6.9 - Linear relationship found between the patients Pax7 expression and change in 
their maximal power output post TKA. Strong correlation between the variables: r = 0.83, p 
= 0.002 ................................................................................................................................. 148 
 
Figure 6.10 - Linear relationship found between the patients Pax7 expression and their 
change in power-bodyweight ratio post TKA. Strong correlation between variables: r = 0.84, 
p = 0.001 .............................................................................................................................. 148 
 
Figure 6.11 - No correlation was found between the patients CD34 expression and their 
change in maximal power output, between 6 and 26 weeks post TKA. Correlation between 




Figure 6.12 - No correlation was found between the patients CD34 expression and their 
change in power-bodyweight ratio post between 6 and 26 weeks post TKA. Correlation 
between variables: r = -0.02, p = 0.95 .................................................................................. 149 
 
 1 





The National Collaborating Centre for Chronic Conditions (NCC-CC) describes 
osteoarthritis as the most common disease of the joints, and one of the leading causes 
of pain and disability worldwide. The disease is responsible for considerable 
morbidity (NCC-CC, 2008) and it has recently been identified that patients with 
osteoarthritis have an excess mortality compared with the general population 
(Nuesch et al, 2011). 
 
Many therapeutic options are suggested as treatments of osteoarthritis; however the 
only intervention that demonstrates a large effect size in relieving chronic knee pain 
is total knee arthroplasty (Juni et al, 2006). The prosthetic implants are known to 
survive well and have low complication rates (U.S. National Institute for Health, 
consensus statement, 2003; British Orthopaedic Association / British Association for 
Surgery of the Knee position statement, 2010; Ethgen et al, 2004). Last year, in the 
UK alone, over 70,000 total knee replacements (TKA) were performed (National 
Joint Registry, accessed 2011)
 
while the surgical volume has been projected to 
increase dramatically in the next 20 years. An American projection of TKA surgical 
volume is for demand to grow by 673% by 2030, which would constitute some 3.5 
million procedures every year in the USA alone (Kurtz et al, 2007). Culliford et al 
(2010) in a review of UK procedures over a fifteen year period lend support to this 
view of dramatic increases in demand for TKA. 
 
Total knee arthroplasty is a very successful procedure, the American National 
Institute for Health (NIH) position statement (2003) explains that the success of 
primary TKA in most patients is strongly supported by more than 20 years of follow-
up data. That rapid and substantial improvement in the patient's pain, functional 
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status, and overall health-related quality of life is found in 90 percent of cases, and 
that around 85 percent of patients are satisfied with the results of surgery. Despite 
this, post-operative outcome and resultant function is variable (Hawker, 2006; Wylde 
et al, 2007).  
 
It is thought that factors relating to the surgeon (surgical volume and operating 
institution) inter-operative factors and perhaps post-operative rehabilitation affect 
subsequent patient outcome (Dennis et al, 2007; NIH consensus statement, 2003). 
Factors relating to the patient such as general physical condition pre-operatively are 
also thought to affect resultant post-operative outcome. Pre-operative quadriceps 
strength in particular is one of the strongest predictors of post-operative function in 
terms of the patient’s ability to perform functional tasks (Faulkner et al, 2008; 
Lingard et al, 2004; Lamb and Frost, 2003). Pilot work has shown however that 
muscle atrophy accounts for around only a third of this variance, the rest, in the short 
term, has been explained by failure of muscle activation following surgery (Mizner et 
al, 2005). Long term strength deficits though are well reported compared to the 
patients opposite limb or healthy controls (Huang et al, 1996; Silva et al, 2003). This 
discrepancy has not been explained. 
 
Developments in implant design have striven to improve patient outcome through a 
variety of technical changes, though the British Orthopaedic Association (BOA) / 
British Association for Surgery of the Knee (BASK) position statement on good 
practice in TKA (2010) notes that it is debatable whether there has been any 
meaningful improvement in prosthesis design since the blueprint of all modern 
‘condylar’ knee implant designs in the 1970s. 
 
Recently however a new theory of the underlying kinematic motion of the knee has 
emerged, that challenges the axis of rotation that all traditional knee implants are set 
to recreate (Hollister et al, 1993; Churchill et al, 1998). A new single-radius of 
curvature design based on this new kinematic theory may substantially improve the 
patient outcome by more closely matching the ‘normal’ kinematic motion of the knee 
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and as a result mechanically lengthening the moment arm of the extensor mechanism 
effectively reducing the effort needed from the quadriceps muscle to extend the knee 
(Hall et al, 2008; D’Lima et al, 2007; Wang et al, 2006). This theoretical advantage 
has not to date been clinically demonstrated. 
 
The mechanisms involved in the regulation of skeletal muscle growth and 
regeneration are of great scientific and clinical interest, as it is believed that 
therapeutic manipulation of these mechanisms can improve the quality of life of 
individuals suffering from a plethora of conditions as diverse as muscular dystrophy, 
chronic heart failure and indeed sarcopenia (Spangenberg and Booth, 2001). 
 
It is known that muscle satellite cells (myogenic precursor cells) are essential for the 
regeneration of skeletal muscle and that these cells are activated following damage; 
this process has been well described (Collins, 2005; Hawke and Garry, 2001). In the 
future it may be possible to regulate the proliferation of the satellite cells, via gene 
delivery to the skeletal muscle. We may further be able to isolate the satellite cells, 
genetically manipulate them and deliver them back to the muscle via the circulation 
(Spangenberg and Booth, 2001), to enhance muscle recovery and patient well being. 
This however will be dependant on substantial further advances in biological 
technology. 
 
In the field of orthopaedics improved regeneration of muscle would have direct 
benefits as enhanced patient outcome following surgery is gaining increasing 
prominence, yet to date this has not been investigated. While there may be a general 
application of potential muscle therapy techniques, for example to patients 
undergoing leg lengthening procedures, the largest single population who potentially 
stand to benefit are those suitable for total knee arthroplasty. In addition to the 
potential volume, knee arthroplasty is possibly the most relevant operation to 
consider due to the importance of the extensor mechanism, and specifically the 
quadriceps muscle group, in subsequent rehabilitation and eventual outcome. 
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A strong extensor mechanism is recognised as being paramount to the patients return 
to functional activities following surgery (Mizner, 2005b). There appears however, to 
be no consideration as to the mechanisms how and to what extent the muscle tissue 




1.2 Scope of thesis and research hypothesis 
 
This thesis is concerned with two poorly explored influences on post-operative 
muscle performance within the context of patient outcome following total knee 
arthroplasty; (1) the role of prosthetic design that confers a mechanical advantage to 
the quadriceps and (2) the role of the patient’s underlying regenerative capacity of 
the quadriceps.  
 
The aim of this thesis is to determine whether either the mechanical factor of 
prosthetic design or the physiological factor of regenerative capacity of the patient’s 
muscle influences the patient’s physical function following total knee arthroplasty. 
 
The primary hypothesis is that both mechanical and physiological variables will 
influence the ability of the patient to generate lower limb power post operatively, and 
thus benefit overall patient function. 
 
Three specific research questions address this hypothesis: 
 
1.    Does implant design that mechanically advantages the musculature of the 
extensor mechanism enhance muscle power and physical outcome following 
TKA? 
2.    Does the number and activation state of the quadriceps muscle satellite cells 
influence the recovery of extensor mechanism muscle power post-operatively? 
3.    To what extent is physical recovery expressed through standard patient outcome 
assessments following TKA, and how does the extensor mechanism power 






The background of total knee arthroplasty, factors that influence patient outcome and 
the methods of assessing this outcome following surgery are introduced in Chapter 2. 
The literature concerning single radius implant designs that theoretically enhance the 
function of the extensor mechanism is critiqued, as is that of the muscle satellite cell. 
The limited investigation of these cells in human populations is also highlighted. 
 
The clinical evaluation of a new implant based on this differing understanding of the 
kinematics of the knee is presented in Chapter 3. The new design is compared with 
that of a standard implant in a double blind randomised controlled trial to assess both 
overall patient outcome and specific extensor mechanism power output at 1 year. 
Respective recovery of function within that year is also assessed. 
 
Chapter 4 considers the differing levels of information conferred by different types 
of outcome assessment, to determine the association between patient reports of 
function and direct evaluation of this (including power output assessment).  A novel 
aspect is the consideration of the relationship between patient report of outcome and 
direct measurements at differing time points prior to and following TKA. Regression 
models are constructed for this relationship and a theoretical assessment framework 
to explain the interaction of these assessment methods presented. 
 
The influence of the muscle satellite cell is considered in Chapters 5 and 6. Biopsies 
of the quadriceps muscle are taken and immunohistochemical methods used to locate 
and count the cells. Data is analysed in the context of muscle power recovery 
following total knee arthroplasty. The relevance of intrinsic satellite cell number on 
subsequent post-operative muscle power is compared with the influence of pre-
operative power values. More precise molecular biology techniques used to 
determine the satellite cell content are developed in Chapter 6. These allow the 
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consideration of the state of activation of the satellite cell, which is further 
investigated as to the effect on patient lower limb power recovery following TKA.  
 
The conclusions of the thesis are presented in Chapter 7 in addition to suggested 
methods by which future research could be promoted. 
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2 Literature Review 
 
2.1 History and Development of Knee Arthroplasty 
 
The concepts of knee arthroplasty and prosthetic implants have changed dramatically 
over the last century. Whilst this change has been evolutionary in nature, a 
progression through three broad phases has defined changes in practice. Soft tissue 
arthroplasty initially dominated thinking before the advent of metal hinges; it was not 




In 1861 Ferguson reported the first successful soft tissue interposition knee 
arthroplasty. 5 years post-operatively the patient was described as having a ‘useful 
limb’, which established that interposition of soft tissues or foreign material into the 
knee joint could prevent ankylosis (Shetty et al, 2003a). Baer (1918) published a 
series of 28 cases of interpositional knee arthroplasties using pigs bladders tanned in 
potassium chloride, reporting 15 ‘good’ outcomes, though the exact definition of 
‘good outcome’ at that time must be considered different to that accepted today. 
Around the same time Putti (1920) reported good results interposing the Tensor 
Facia Lata into the knee. This interpositional technique was used until as recently as 
1958 with skin flaps (Brown et al, 1958). Problems such as soft tissue shortening, 
infection, inflammatory response and re-ankylosis were however associated with this 






Cobalt-chrome (Vitallium, Howmedica) was first used as a material in 1938, though 
gained prominence in the 1950s. It had excellent wear characteristics and was non-
corrosive, which constituted a major technological change and subsequently soft 
tissue interpositional arthroplasty dwindled in popularity. This development has led 
directly to today’s use of titanium alloy, stainless steel 316L and cobalt alloy F75 
(Shetty et al, 2003a).  
 
Tibial hemi-arthroplasty had been suggested as early as 1894, when Gluck described 
the use of an ivory cup with an intramedullary peg inserted into the tibia. The 
concept of tibial (and femoral) hemi-arthroplasty didn’t emerge as a technique until 
1950 using steel implants (Marquardt, 1950). Mackintosh (1966) refined this, using 
techniques not dissimilar to those employed today: correction of bony deformity and 
removal of minimal bone and ligaments. Metallic tibial blocks were not fixed but 
held by tension in the collateral ligaments; an early example of ligament balancing. 
Different sized blocks were used to correct for varus / valgus deformity (Shetty et al, 
2003a). Good results were reported with the elderly, but interestingly not the ‘active 
young’. Also of note is that most early surgery was in rheumatoid and not 
osteoarthritis patients, the degenerative process having not been properly identified at 
this time. 
 
Combining tibial and femoral components, joined by a steel rod to create a hinged 
prosthesis (Walldius, 1953) was the next major development in arthroplasty (Shetty 
et al, 2003b). These were introduced in an attempt to provide stability via the 
implant. Initially acrylic was employed then metal due to breakage of the acrylic 
(Walldius 1957 and 1960). This simple hinge allowed a theoretical 115 degrees of 
flexion. Jones (1969) reported a series of 80 Walldius replacements, commenting 
75% were pain free on weight bearing, and 85% exhibited over 60 degrees of 
flexion. These results were tempered by high failure rates due to aseptic loosening 
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and infection (requiring removal and arthrodesis) and that patient selection favoured 
those who were older with limited walking ability. Semi-constrained hinges were 
developed to allow tibial rotation; these also had high failure rates and were bulky 
and complex. Shetty et al (2003b) comment that a failure to understand that 
instability was actually due to the cartilage and bone loss and not the disruption of 
the collateral ligaments delayed the introduction of reliable joint replacements for a 




Gunston (1971) suggested the complexity of the knee joint could not be recreated by 
a simple hinge. Movement was not in a single axis (as the hinge) but constituted a 
roll and glide of the femur on the tibia: a multi instant centre of rotation. He also 
introduced the combination of metal, plastic and cement, performing articular surface 
replacements. Twenty of 22 procedures were reported as good at two years (Gunston, 
1971). This was important as it demonstrated that instability was due to cartilage and 
bone loss, as opposed to collateral ligament destruction (Shetty et al, 2003c), this 
minimalistic implant actually facilitating better physiological stability than the large 
hinges. 
 
Freeman and Swanson introduced a similar implant in 1972, and the tensor 
instrument in 1974 that is still used today for ligamentous gap balancing to control 
varus / valgus alignment (Todd et al, 1978). The Freeman prosthesis (the ICLH) was 
the first to be subjected to a large multi-centre trial. Gibbs et al (1979) reviewed 75 
prostheses and reported 80% success (defined as minimal or no pain, flexion in 
excess of 60 degrees and no major complications). Insall, Ranawat and Walker (later 
with Burnstein) developed their similar design of total condylar replacement and 
were the first to introduce the tri-compartmental replacement, the lineage of which is 
used today. The total condylar replacement (Insall et al, 1976) has set the standard of 





Most modern knee implants are based on the condylar design, and achieve excellent 
rates of survival (NIH consensus statement, 2003; Liow and Murray, 1997: Pradhan, 
2006). The American Academy of Orthopaedic Surgeons estimates that over 150 
different knee implants are currently available for use (AAOS, 2010). 
 
The BOA/BASK position statement on good practice in TKA (2010) states that the 
selection of knee prostheses for general use should be based on evidence published in 
peer reviewed journals with a clinical follow-up of at least 10 years and calculated 
survival curves (Liow and Murray, 1997) demonstrating 90% implant survivorship at 
10 years. In the absence of this, devices should be subject to ongoing surveillance 
and be part of properly controlled prospective trials (BOA/BASK, 2010). Published 
results of many knee implants, however, offer little help to the surgeon wishing to 
make an informed choice, as most outcome research is short term, non-comparative 
and doesn’t take into account variations in operating technique (BOA/BASK  2010). 
 
Jacobs et al, writing in a Cochrane Collaboration Review, comment that to improve 
on an already successful procedure it is the small details that require investigation 
(Jacobs et al 2007a). Many developments in implant design have been aimed at 
improving quality of life, and the duration of prosthetic survival (KAT trial group, 
2009), though there is little consensus as to whether some recent design changes 
genuinely affect patient outcome.  
 
Many factors influence the surgical and functional outcome of TKA, and choice of 
prosthesis may have an important influence (NIH, 2003). Most of the current 
developments in design have failed to produce substantive benefits in terms of 
patient outcome. An example of this is the effect of bearing design, where mobile 
designs have theoretical advantages compared to fixed systems but these have not 
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been established biomechanically or clinically (NIH position statement, 2003; 
Wylde, 2007; Huang, 2007).  
 
Mobile designs were introduced with the intention of reducing polyethylene wear 
and component loosening, as the mobility of the tibial surface allows both low 
contact stress and constraint forces (Sathasivam and Walker, 1994; McEwan et al, 
2005). Huang et al (2007) in a review article note equivalent survival rates of around 
95% at 10 years for both designs and equivalent patient outcome (Range of motion, 
patellofemoral complication rates, American Knee Society Score) in comparative 
studies. A Cochrane review (Jacobs et al, 2007b) described the overall quality of 
research methodology in this area as poor, as only one suitable randomised trial 
(Price et al, 2003) could be analysed. These authors demonstrate superior early 
results with mobile bearing components, however it is conceded that that the 
difference cannot be solely linked to the bearing surface as different prostheses types 
were used in the study. Since this review, two multi centre randomised trials (Wylde 
et al, 2007; KAT trial group, 2009) have found no early difference in outcome at to 
two years post-operation. 
 
Other current examples of design changes that have been made to improve outcome, 
but for which clinical evidence is lacking are metal backed tibial components (KAT 
trial group, 2009), patella resurfacing (Pakos et al, 2005; KAT trial group 2009), the 
role of high flexion implant designs (Nutton et al, 2008) and the retention/sacrifice of 
the posterior cruciate ligament (Jacobs et al, 2007a). The four bar linkage system 
explains that the anterior cruciate ligament is of key kinematic importance in the 
knee (O’Connor, 1989), and crucial to the functioning of the successful 
unicompartmental knee arthroplasty procedure. It does not have the same influence 




2.2 Knee Arthroplasty Outcome 
 
Success of total knee arthroplasty 
 
Whilst generally a very successful procedure, patient outcome following TKA is not 
universally positive, as a significant number of patients continue to experience pain 
and functional disability post surgery (Hawker, 2006).  
 
The American National Institute for Health notes that short-term outcomes were 
generally substantially improved following TKA across the spectrum of presenting 
disability (NIH position statement, 2003). Despite this, unimpaired function is rare 
post-operatively, and some degree of limitation should be expected. Although clearly 
a very effective procedure in the majority of cases, some patients receive no benefit 
(Wylde et al, 2007). Chronic pain is the major reason that people elect to undergo 
TKA, thus pain relief is a key outcome post-operatively. Wylde et al (2007) notes 
that the majority of literature suggests that TKA provides good pain relief, and that 
the majority of patients experience no (or very mild) pain, however a subsection 
experience moderate to severe levels.  
 
Technical factors (including surgical technique and alignment of the prosthesis) have 
been noted to influence both short and long-term outcomes, while factors related to a 
surgeon's case volume, and choice of prosthesis also have important influences (NIH, 
2003; Dennis et al, 2007). Peri-operative complications, post-operative rehabilitation 
and patient factors are also accepted as affecting outcome (Dennis et al, 2007). Not 
all differences in functional outcome can be accounted for by these surgical 
variables, those that remain are, as yet, medically unexplained (Wylde et al, 2007). 
Many risk factors for poorer outcome have been identified, and include socio-




Lingard et al (2004) in a multi-centre study of 860 patients highlight the role of pre-
operative status. While the poorest functioning patients pre-operatively make the 
largest proportional gains, they retain the lower spectrum of post-operative functional 
scores. Low pre-op physical and mental health scores are the strongest determinants 
of limitation to post-operative function at 1 and 2 years. Franklin et al (2010) also 
describe substantial variation in function post TKA, despite ‘excellence in surgical 
technique and consistent pain relief’. In a review of over 8000 patients, they also 
found pre-operative variables to be associated with poorer improvement in post-
operative function. Interestingly, they reported a bimodal distribution in post-
operative SF-12 physical component scores (noting a normal distribution pre-
operatively), thus suggesting two distinct groups of responders and non-responders. 
A higher chance of ‘less functional gain’ was reported for patients with a BMI over 
40, low mental health scores, increasing age and poor quadriceps strength. The BMI 
and poor quadriceps strength had the most impact, with more than a 2-1 odds ratio of 
poor functional gain post-op.  
 
In contrast, Bourne et al (2007) reported a consecutive series of 728 patients from a 
single centre, all with the same implant, thus controlling for many of the known 
surgical variables. Similar outcomes were described when change in outcome score 
from pre-op to post-op was assessed regardless of gender, age or obesity class. They 
suggested that this was a more appropriate analysis. A report from the Edinburgh 
unit, in a paper comparing outcome following hip and knee replacement, found that 
neither age nor gender are significant in predictive regression models of 1 year 
outcome (Hamilton et al. manuscript under review, after modifications requested by 
the editor, Appendix A). A consecutive series of 1244 knee replacements and 1410 
hip replacements from this centre were reported. Only two factors were predictive of 
change in Oxford Scores; the type of surgery (THA or TKA) and the pre-operative 
Oxford Score. This same study highlighted significant differences in physical 
outcome between arthroplasty groups. The knee arthroplasty group demonstrated 
worse levels of physical function and twice the rate of dissatisfaction (20% 
dissatisfied) 1 year post-operation. 
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Another potential variable is the trend to operate on younger patients with increased 
expectations of high levels of post-operative activity. Mont et al, (2008) report 
similar clinical and radiographic outcomes in groups of active and sedentary patients 
7 years post TKA. The active group undertook many of the activities suggested as 
suitable post TKA (swimming, cycling and doubles tennis), however around 20 
percent of this group were able to participate in higher stress sports (such as jogging, 
singles tennis, football and basketball). The contrast between the reports of high 
levels of function (Mont et al, 2008) and those of cohorts of poorly functioning 
TKAs (Hawker, 2006) suggests the potential for a vast discrepancy to exist between 
the upper and lower ability levels of patients following knee arthroplasty. These 
highly functioning individuals may be masking the poor responders when average 
population scores are reported; this is particularly relevant if change in score is not 
assessed. 
 
Assessment of outcome 
 
Orthopaedic interventions are assessed on their outcome, and outcome scores are 
now commonly used in the TKA research literature to compare prostheses, surgical 
techniques, post operative care and also in auditing departments and individual 
surgeons (Beard et al, 2010; Ashby et al, 2008). 
 
Survival curves are the standard long term evaluation of implant longevity, for which 
revision procedure is generally accepted as the end-point (BOA/BASK, 2010; Liow 
and Murray, 1997). This analysis is criticised as not adequately defining the failure 
of the implant, nor commenting on patient function prior to the diagnosis of failure 
(Price et al, 2010). Previously implant designs could be differentiated as to their 
respective merit by their failure rates. However the advent of modern implants and 
enhanced surgical procedures has devalued this assessment, as most achieve 




Assessment of outcome is shifting away from the dichotomous criteria of success or 
failure (Ashby et al, 2008). The combination of comparable implant survival, 
continual prosthetic design development, changing functional expectation post 
surgery and the understanding that some patients do not benefit from TKA has driven 
the need for reliable short term information as to the success of surgery. The use of 
patient reported outcome measures (PROMs) to assess functional outcome and 
quality of life following TKA is advocated as additional information (Bream et al 
2010; Beard et al, 2010; Price et al, 2010; Bream and Black 2009), and recently has 
been adopted as a requirement of all providers of elective arthroplasty surgery of 
NHS patients (DoH, 2008).  
 
Objective clinical assessment of outcome following TKA is routinely performed by 
the surgical team, though formal scoring systems that are assessor-based suffer 
observer bias, and have been criticised for this (Beard et al, 2010). Patients are 
suggested to offer a complimentary perspective to that of the clinician into the 
effectiveness of health care. Clinicians can make objective observations as to 
impairment and disability, but only patients can report on their quality of life (Black 
and Jenkinson, 2009). Advocates of PROMs say that they provide a remarkably 
sophisticated measure of whether a treatment has worked in the (important) sense of 
whether or not the patient feels better, and how much better (Timmins, 2009). 
 
Numerous scales exist to determine post-operative function (Beard et al, 2010; 
Riddle et al, 2008), though no gold standard tool for assessing outcome following 
joint arthroplasty has been developed (Davies, 2002). The current consensus 
statement from the British Orthopaedic Association and the British Association for 
Surgery of the Knee (2010) states that there is no agreed standardisation of outcome 
measures for TKA. Many trials report similar research questions but with differing 
outcome measures which makes it difficult or often impossible to compare the trials 
or carry out systematic reviews (Riddle et al, 2008; Davies, 2002). Beard et al (2010) 
note that many of these scoring systems do not meet the recommended quality 
criteria around validity, reliability and responsiveness; further complicating the issue. 
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Broadly PROMs questionnaires fall into three categories; generic health assessments, 
disease specific instruments and joint specific tools (Ashby et al, 2008). These reflect 
the suggestion of the OMERCAT group, that three core patient reported domains 
related to the symptomatic severity should be evaluated: pain, physical function and 
patient global assessment (Bellamy et al, 1997). A combination of assessment tools 




A disadvantage of patient report based scales for assessing post-operative function is 
that they measure the patient’s perception of their knee status and are thus subjective 
(Stratford and Kennedy, 2006). As a consequence they are thought to be influenced 
by pain (Terwee et al, 2006; Stratford and Kennedy, 2006), which results in a low 
functional content validity (Boonstraa et al, 2008). High levels of content validity are 
required to evaluate biomechanical aspects of function, and generally, performance 
based measures demonstrate this (Boonstraa et al, 2008; McCarthy and Oldham, 
2004). 
 
It has been suggested that self report questionnaires and performance measures may 
assess different aspects of physical function. Stratford and Kennedy (2006) suggest 
that in terms of expressing the difficulty patients have in moving around or looking 
after themselves, self-report measures provided information concerning the 
experience associated with doing the task, while performance measures confer 
information about the ability to do the task.  
 
The Outcomes Measures in Rheumatology Conference specified that patient report 
measures of functional outcome are recommended for all phase III clinical trials; 
whereas performance based measures of physical function are optional (Bellamy et 




PROMs measures are commonly used as they are comparatively cheap, effective at 
collecting large volumes of data, and do not require follow-up clinic visits to achieve 
this (Mizner et al, 2011 published ahead of print). Woods et al (2008) however 
justified the relevance of physical assessment tools as offering additional insights 
into clinical progression and prognosis. The suggested discrepancy between patient 
report questionnaire assessment of function and objective measure of patient 
performance (Beard et al, 2010; Stratford and Kennedy, 2006) suggests that both 
assessments should be used in tandem to provide the most complete assessment 
(Witvrouw et al, 2002). One assessment type should perhaps not be considered 
preferential to the other, as they provide distinct but complementary information. 
This is akin to the suggestion that generic and specific PROMs should be employed. 
The choice of assessment tools depends on a variety of factors relating to the aim of 
the study, level of detail of observation required, funding and the context of the study 
(Beard et al, 2010; Ashby et al, 2008). 
 
2.3 Muscle Power and Functional Outcome 
 
Green and Schurman (2008) comment that post-operative muscle strength is a critical 
part of the success of TKA, and further state that insufficient quadriceps strength is 
recognised as a relative contraindication for the procedure. Adequate function of the 
extensor mechanism is essential to allow participation in most activities of daily 
living (Noble et al, 2006; Silva et al, 2003), and knee extensor weakness has been 
reported to be closely associated with mobility limitations in the TKA population, 
particularly when evaluating functional tasks such as climbing stairs and transferring 
from a chair (Mizner et al, 2005c; Valtonen et al, 2009). Several studies have shown 
difficulties in both walking (Yoshida et al, 2007; Walsh et al, 1998) and stairs ascent 
(Walsh et al, 1998) post TKA compared to controls. Relatively little data however 
exist on knee strength post TKA and its relationship to patient characteristics and 




Power is better related to function than measures of absolute strength due to the role 
of velocity of movement in every day tasks (Bassey and Short, 1990). Several 
investigators note lower limb power deficits in excess of 20% compared to the non-
operated knee up to six months post TKA (Gapeyeva et al, 2007; Berman et al 1991; 
Mizner et al, 2005a; Lorentzen et al, 1999). This deficit would appear to continue 
over time, though the studies reporting this suffer from poor methodological design.  
 
Valtonen et al (2009) assessed the power output of 50 unilateral TKA patients at an 
average of 10 months post-op. They found mean knee flexion power deficits of 19% 
and extension power deficits of 23% compared to the un-operated limb. Silva et al 
(2003) demonstrate 30% deficits compared to healthy controls at 3 years post-op. 
Both investigations suffer from a lack of pre-operative data. There is only a single 
paper that reports longer term power data (Huang et al, 1996); they noted deficits in 
hamstring to quadriceps peak torque ratio of TKA patients compared to controls at 6-
13 years post-op. This paper reported the results of 50 replacement knees in 34 
patients and 16 control knees in 9 patients. Unfortunately, the reporting of multiple 
joints per individual, a lack of pre-operative data or stratification by subject 
characteristics, prevents comparison of absolute strength between patients and 
controls. Berman et al (1991), in contrast, noted a normalisation of flexion extension 
ratios, compared to the contralateral uninvolved limb by 2 years post TKA in a well 
conducted prospective study involving 68 patients. Interestingly the hamstring peak 
torque reached the levels of the uninvolved knee between 7 and 12 months post-op, 
while the quads mechanism continued to demonstrate slightly reduced peak torque at 
2 years post-op, suggesting specific limitations in the rehabilitation of this muscle 
group. 
 
Pre-op function (Lingard et al, 2004) and quadriceps muscle strength (Franklin et al, 
2010) have been suggested as the strongest predictors of post op function. Lamb and 
Frost (2003) assessed the predictors of recovery of mobility at 6 months post TKA in 
a series of 79 patients. Mobility was measured using timed tests of walking and stairs 
climbing. Pre-operative variables considered included age, gender, comorbidities, 
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flexion BMI and lower limb power. Pre-operative power most strongly predicted 
walking speed and stairs ascent speed at six months (BMI and pain were associated 
to a lesser extent; no other variables were significantly associated with either 
measure). Lamb and Frost (2003) is the only report to also assess recovery of 
mobility. Lower limb power was, by a large margin, the strongest predictor of 
change in walking speed and change in stairs ascent speed between pre-operative and 
6 month assessments (comorbidities and BMI the only other variables associated). 
Mizner et al (2005c) corroborate this, reporting pre-operative quadriceps strength, 
but not pain or range of motion to be significant predictors of post of function (stairs 
climbing or chair transfer) in a study of 40 arthroplasty patients at 1 year. 
 
The assertion that pre-operative flexion does not affect post-operative function is in 
keeping with the lack of benefit found with high flexion implant designs. Nutton et al 
(2008) in a well designed RCT investigated the role of an increased posterior femoral 
offset high flexion design modification compared to the standard implant that it was 
based on. No clinically relevant differences were found.  Interestingly both implant 
groups in this study used generally the same range of motion to complete daily 
functional tasks; however the range used by both implant groups was substantially 
below that of an aged matched control group of healthy individuals. 
 
The current literature indicates that the dominant factor in physical recovery post-
operatively relates to the extensor mechanism function; however muscle atrophy 
alone does not explain the variation found. Mizner et al (2005a) suggest that the 
recovery of function is related not simply to addressing muscle atrophy, but to the 
failure of voluntary muscle activation. They suggest that failure of voluntary 
activation contributes twice as much as atrophy to the loss of quadriceps strength in 
the early post-operative phase. Further that as much as 85% of the loss of quadriceps 
strength can be explained by these two factors. While an attractive idea, that 
resonates with clinical physiotherapy practice in terms of post-operative 
rehabilitation, these conclusions are based on a study of 20 patients. Disappointingly, 
 
 21 
these exciting pilot results published in 2005 have yet to be corroborated by a large 
clinical trial. 
 
2.4 Single Radius Implant Design 
 
Classic theory of the kinematic motion of the knee suggests that flexion and 
extension occur around a changing instant centre of rotation (Figure 2.1). This 
conceptual axis is located relatively anterior and proximal in extension moving 
posterior and distal in flexion. This theory underpins the traditional femoral 
component design of all multi radius implants (Mahoney et al, 2002).  
 
Figure 2.1 – Images showing the instant multi-centre of rotation implant design. The 
shifting centre of rotation is highlighted in both the Radiographic image (the Releaux 
method to show the ‘Instantaneous Centre of Rotation’ between two flexion angles) 
and the accompanying diagram which demonstrates the resultant implant design 




Images adapted from Stryker Orthopaedics instructional publications. 
 
 
More recently, the validity of the anatomical observations that are the basis of the 
shifting instant centre of rotation and underpin the multi-radius design have been 
challenged (Panjabi et al, 1982) and recent anatomical studies have led investigators 
to suggest that knee flexion / extension occurs around a single fixed axis in the femur 
 
 22 
(Hollister et al, 1993) that approximates to the transepicondylar axis (Churchill et al, 
1998).  
 
The single radius of curvature design of femoral component (Figure 2.2) is based on 
the premise that there is a single axis which is fixed on the femur, as opposed to the 
instantaneous shifting centre of traditional designs which have two or more radii of 
rotation within the functional range of motion of the knee (Hoshino, 1997). 
 
Figure 2.2 – Images showing the single axis of rotation implant design. Radiograph 
highlighting the single flexion / extension axis from 10 to 100 degrees of knee 





Images adapted from Stryker Orthopaedics instructional literature. 
 
 
This difference in axis of rotation establishes a major biomechanical difference in the 
implant design that results in a more posterior axis of rotation in the femoral 
condyles (D’lima et al, 2001; Churchill et al, 1998, Hoshino, 1997: Pinskerova et al, 
2000). A consequence of this is the moment arm of the knee extensor mechanism is 




Figure 2.3 - Diagrammatic representation of the hypothesised reduction in 
quadriceps muscle force generation required to extend the knee as a result of the 




Image adapted from Stryker Orthopaedics instructional literature. 
 
 
It has long been recognised that increasing the femoral offset of a total hip 
arthroplasty provides the abductor muscles with a longer moment arm which 
decreases the muscle force required to abduct the lower limb and lowers the joint 
reaction force. The same principle can be applied to knee arthroplasty, where a more 
posterior flexion / extension axis lengthens the knee extensor moment arm, 
decreasing the quadriceps muscle force required to extend the knee and reducing the 
joint reaction force (Mahoney et al, 2002). A failure to restore the normal knee 
extensor moment arm following TKA with the traditional multi radius design of 
implant has been reported (Huang et al, 1996, Singh and Schmalzried 1996), and the 
single axis concept provides a convenient explanation as to the reasons for this, and 
suggests a potential biomechanical benefit of designs based on the single axis theory.  
 
The extensor mechanism is the fundamental dynamic support of the knee during 
stance and locomotion (Gomez-Barrena et al, 2010). Adequate function of which is a 
prerequisite for participation in many activities of daily living (Silva et al, 2003), and 
crucial in promotion of positive clinical outcome and postoperative satisfaction 
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(Noble et al, 2006). Enhanced muscle recovery based on the single radius femoral 
components is claimed by the manufacturer (Stryker literature). A cadaver study 
suggests reduced patello-femoral joint forces with a single radius design (D’Lima et 
al 2001), but little is known about the consequential effects of single radius design on 




Wang et al (2006) investigated the effect of differing radii of curvature implant 
designs on the patient’s ability to stand from a seated position using a complex 
analysis of video motion tracking and isokinetic dynamometry with complementary 
(surface) electromyography. The authors note significant biomechanical differences 
in time to complete the performance task, kinematic values and patterns of electrical 
activation between TKA groups during the sit-to-stand motion. Specific differences 
in compensatory mechanisms (of trunk flexion angle and velocity) adopted to 
achieve the task were observed in the multi radius group that were absent in the 
single radius group. 
 
Previously Su et al (1998) have noted increased trunk flexion angle in patients 
following TKA compared to controls to compensate for extensor muscle weakness. 
A brief summary of the mechanism being that increased trunk angle reduces the 
extension moment across the hip joint, which subsequently reduces the knee 
extension moment, thus requiring less knee extensor muscle force.  
 
Wang et al (2006) report a tendency for increased trunk flexion velocity of 7 degrees 
per second in the multi radius group to generate the standing motion. Theoretically, if 
increased trunk flexion velocity is demonstrated, an increased deceleration of this 
motion must also occur. As the hip extensors pull the trunk backwards to reduce the 
forward momentum, at the same time a transfer of mechanical energy from the trunk 
to the thigh occurs which acts to rotate the thigh to a vertical position. (Riley et al, 
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1991), i.e. horizontal momentum of the trunk can be transferred into vertical 
momentum of the thigh. This compensatory strategy may reduce the knee extensor 
moment and resultant quadriceps activity needed to achieve the movement. 
Interestingly Wang et al found increased muscle activity (EMG analysis) in the multi 
radius group compared to the single radius group (1 way ANOVA p <0.05). 
 
While the results are suggestive of differing performance between single and multi 
radius design, there is some ambiguity with the data analysis and reporting. The 
study of Wang et al is a single assessment of 16 patients at least 18 months following 
TKA. The patients are described only as being from a group of well functioning 
TKAs in a single surgeon series. Eight single radius implants (Scorpio, Stryker 
orthopaedics) and eight multi radius implants (Series-7000, Stryker Orthopaedics or 
PFC, DePuy Orthopaedics – relative numbers are not stated) are reported. The single 
radius group is younger at 65 (+/-5) years than the multi radius group at 72 (+/-7) 
years, and assessed much earlier post-op, 29 (+/-11) months compared to 79 (+/- 25) 
months respectively.  
 
The statistical analysis is somewhat confusing. It is stated that 1-way ANOVAs were 
compared to 1-way analysis of covariance to assess the role of the age and post-
operative time. These covariates were found to affect the time of three variables: 
standing time, trunk flexion velocity and knee extension velocity. Despite 
conclusions being drawn on between group differences using these variables, the 
results reported are for the ANOVAs, not the analysis of covariance, that the authors 
state affects the significance of the outcome. The authors justified this in their 
conclusion by stating that the results are still significant when controlled for the 
covariates, however the details remain elusive and unreported, thus true differences 
can only be speculated upon. It is also unclear the extent to which these very specific 
differences in function are clinically relevant.  
 
Three further sets of authors have investigated the clinical outcome of single radius 
designs in terms of the extensor mechanism efficiency, though all suffer from issues 
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around their study design. Mahoney et al (2002) reported improved function of the 
extensor mechanism post TKA and faster restoration of flexion in association with 
design features that increase the length of the extensor moment arm. Analysis of a 
consecutive series of patients (from a single surgeon) was reported, with the stated 
aim to compare the last 100 multi radius TKAs (Series 7000 PPSK, Osteonics, NJ) 
performed with the first 100 single radius TKAs (Scorpio, Osteonics, NJ). 184 knees 
in 150 patients were subsequently reported without adequate discussion of the 
reduced numbers (83 multi radius knees in 74 patients and 101 single radius knees in 
76 patients). A further confounding issue is the inclusion of the 34 patients who had 
bilateral knee implants (9 in the multi radius group, 25 in the single radius) and no 
discussion as to how this affected the results, beyond commenting that bilateral 
patients were slower to rehabilitate. If this is the case, then the different proportion 
bilateral procedures in each group is clearly relevant. 
 
Evaluation consisted of multiple testing time points: pre-operatively and then follow-
up at 6 weeks and 3, 6, 12 and 24 months post-op. The outcome measures chosen 
were the American Knee Society Scoring System (KSS) and three simple 
dichotomous yes/no questions concerning the ability to rise from a chair without the 
use of the arms and the pain experienced during this activity. 
 
Despite ongoing attempts, the KSS has not been validated since its publication in 
1989 (Insall et al, 1989). Pragmatically the scoring system is a useful clinical tool as 
it aggregates weighted scores for pain, range of motion, stability, alignment, and 
functional ability and has been widely used as an objective measure. Lingard et al 
(2001) however found the KSS to display poor face validity and differing levels of 
responsiveness between the clinical and functional components of the score, the 
former being responsive, the latter not. A further limitation is that the physical 
examination score is subject to misrepresentations, as poor correlation among the 
items of the KSS clinical score makes it possible for two very different patients to 
receive the same score. Lingard et al cite the example of, a knee score of 80 points 
being given to a patient who has no pain, 0° to 25° of knee flexion, normal 
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alignment, and no instability, or to a patient who has mild or occasional pain on 
walking and stair-climbing, 0° to 130° of knee flexion, normal alignment, and no 
instability. Clearly, these patients had very different results post surgery. 
 
No difference in KSS was observed between groups in the Mahoney et al study. A 
larger proportion of the single radius group could rise form the chair unaided, and 
reported less pain at 6 weeks and 6 months post-op (p<0.001).  At 1 year, 74% of the 
multi radius patients could complete the test unaided compared to 89% in the single 
radius group, which was reported as being significant at p = 0.01. At 2 years, the 
proportions were 73% and 90% respectively, with the significance having jumped 
dramatically to p = 0.003, based on only a 2% change in the number of patients that 
could achieve this function. There is no description of the quality of movement 
throughout the test, or the time taken to achieve the goal. 
 
Despite the test consisting of an un-validated observation of an activity, Mahoney et 
al consider the chair rise test to be the more focused assessment of extensor 
mechanism function than their other outcome measure, as the KSS evaluates only 
walking and stair climbing and does not specify the location of pain experienced with 
these activities, thus conclusions of differing outcome between groups are drawn. 
The authors acknowledge that ideally allocation would be random and an 
independent assessor, blinded to implant type, should conduct the physical tests, but 
justify the comparability of their cohort as pre-operative demographic variables 
(gender, age and body mass) were not statistically different.   
 
Hall et al (2008) reported no difference in extensor mechanism function in a study 
that benefited from a randomised trial design. Conclusions were based on equivalent 
KSS and ability to rise from a chair with out the use of the arms as per the Mahoney 
study. Prospective allocation of 50 multi radius implants (PFC sigma, Johnson and 
Johnson) were compared with 50 single radius designs (Scorpio, Stryker 
Orthopaedics) at the same assessment time points as Mahoney et al (2002). No 
between group differences were observed at any assessment.  
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As with the Mahoney et al study, this trial suffers from poor outcome measures, most 
emphasis being placed on the ability or not to stand from a chair without the use of 
arm assistance. Prospective randomisation of implants enhances the validity of the 
results, however the trial is powered on the results of the previous Mahoney et al 
study with an assumed 15% difference between groups in ability to raise from the 
chair, and a beta of 80% at an alpha of p = 0.05 to detect this.  
 
The powering of this RCT is possibly inadequate, as it was based on the between 
group differences detected by the Mahoney et al study that suffered from numerous 
design issues as discussed. While the equivalent results of this study should not be 
ignored, it may be that the trial is not sensitive enough to test its hypothesis with the 
expected between group difference of 15% and accepted chance of a type II error of 
20%. 
 
Gomez-Barrena et al (2010) performed a retrospective case-controlled study with 60 
patients comparing 30 single radius implants (Scorpio, Stryker Orthopaedics) against 
30 multi radius devises (NexGen, Zimmer Inc). Outcome was assessed with KSS and 
number of physiotherapy sessions required for postoperative rehabilitation. Further 
analysis of muscle performance (isokinetic dynamometry) stability of the knee 
(dynamometric balance platform) and gait analysis was also reported. 
 
The single radius group demonstrated better KSS and fewer physiotherapy sessions 
were required to reach post-operative goals. They concluded that there was better 
active knee extension in the single radius and an enhanced flexion / extension ratio 
on isokinetic testing. The authors report quadriceps recovery to be a key aspect in 
knee and posture stabilisation. ‘Enough recovery’ was described as occurring in both 
groups, but better extensor recovery seen in the single radius group.  No differences 
were observed in the stability assessments conducted. Of the gait analysis, only the 
contralateral limb was found to perform differently between groups, which the 
authors suggest to be of importance and related to quadriceps recovery in the single 
radius group. Of note, no statistical correction was made for multiple testing. 
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Another interpretation of the data presented is that the contralateral leg differences 
reported do not reach an appropriate level of significance. 
 
Again procedural ambiguities in the study design confound the outcome reported. 
This was a single retrospective assessment of unilateral TKA patients at, broadly, 11 
months post-op for each group (that the ranges differ, 7-13 months in the single 
radius group and 9-14 months in the multi radius, is not addressed). Patient selection 
is stated to have been from the total 186 patients operated on in a 12 month period, 
and implant usage at the preference of the operating surgeon. Strict inclusion criteria 
results in only a third of these being eligible to take part, with convenient symmetry 
of 30 patients per group. The statistical power of the study is not discussed. 
 
The physical patient benefits suggested to result from the use of a femoral 
component with a single radius of curvature have not been thoroughly investigated. 
Studies have either focused on highly technical assessments on small numbers of 
patients with a single assessment post-op design and carry little clinical relevance 
(Wang), or consist of larger more clinical studies with prospective design, but 
simplistic outcome assessments of which the validity is dubious (Mahoney et al, 
2002; Hall et al, 2008). The power of these studies to detect differences is also 
questionable. Gomez-Barrena et al (2010) correctly comment that the theoretical 
advantages of the single radius design remain to be clinically proven. 
 
2.5 Muscle Regeneration 
 
As recently as 1990, in their specialist text book of muscle physiology, Jones and 
Round note that a widespread belief that skeletal muscle is not able to regenerate 




This intrinsic regenerative capacity was first demonstrated in 1964 by Studitsky who 
showed that a muscle that was removed, minced then returned to the original site was 
able to regenerate into a functional muscle. This capacity is attributable to the muscle 
satellite cell (Bischoff, 1975; Schultz, 1976; Snow, 1978; Hawke and Garry, 2001).  
 
Muscle satellite cells 
 
Initially described in the frog (Mauro, 1961; Katz, 1961), then subsequently in 
humans (Laguens, 1963), these cells are named according to their location 
anatomically, on the surface of the myofibre, between the plasmalemma and basal 
lamina (Figure 2.4). The muscle satellite cell is an undifferentiated myogenic 
precursor that is activated and proliferates following injury to repair the damaged 
muscle fibre (Mauro, 1961).  
 
Mature skeletal muscle is a relatively stable tissue, thus the homeostatic demand on 
satellite cells is comparatively low and the majority are quiescent pending activation 
(Schultz et al, 1978; Hawke and Garry, 2001). These cells are primarily responsible 





Figure 2.4 - Satellite cell anatomical location, occupying a sublaminar position in 
adult skeletal muscle. In the uninjured muscle fibre, the satellite cell is quiescent, 
however when injured, they increase their cytoplasmic content and develop 
cytoplasmic processes that allow for chemotaxis of the satellite cell along the 
myofiber to the site of damage. The satellite cells can be distinguished from the 
myonuclei as it lies beneath the basal lamina but above the plasmalemma. 




Diagram taken from Hawke T and Garry D. Myogenic satellite cells: physiology to molecular 
biology. J Appl Physiol 2001;91-2:534-51. 
 
 
In normal muscle, satellite cells respond to regenerative cues such as injury or 
exercise, by proliferating to form myoblasts, which divide a limited number of times 
before terminally differentiating and fusing to form multinucleated myotubes 
(Morgan and Partridge, 2003; Wagers and Conboy, 2005) to provide new myonuclei 
for the homeostasis, hypertrophy or repair of the muscle fibres (Figure 2.5). These 
cells also self-renew in order to maintain a viable stem-cell pool that is able to 




Figure 2.5 - Satellite cell response to myotrauma. Upon activation some of the 
satellite cells will re-establish a quiescent satellite cell pool through a process of self-
renewal. Others will migrate to the damaged area and, depending on severity of 
injury, fuse to the existing myofiber or align and fuse to produce a new myofiber. In 
the regenerated myofiber, the newly fused satellite cell nuclei is located centrally, 






Diagram taken from Hawke T and Garry D. Myogenic satellite cells: physiology to molecular 
biology J Appl Physiol 2001 91:534-551. 
 
 
Contribution to muscle hypertrophy 
 
Boldrin et al (2010) in a review note that satellite cells become activated and increase 
in number in response to exercise. It has been demonstrated in the rodent model that 
satellite cells are required for hypertrophy of overloaded skeletal muscles (Snijders et 
al, 2009). Studies of ‘unloading-induced’ muscle atrophy, also demonstrate that 
satellite cells initially become activated (Ferreira et al. 2006), but eventually decrease 
in number (Hawke and Garry, 2001). 
 
Human studies suggest that satellite cells of both young and old individuals respond 
similarly to exercise, increasing in number and activation status (Crameri et al, 2004; 
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Kadi et al, 2005; Verdijk et al, 2009) and contributing to muscle hypertrophy (Kadi 
et al. 1999; Kadi and Thornell 2000). 
 
Regulation of satellite cell activity 
 
The regulation of satellite cell proliferation and differentiation is not completely 
understood. There is general consensus that satellite cells are marked by the 
expression of the Pax7 gene and that this is primarily important in the cell activation 
process (Zammit, 2008; Buckingham, 2007; Seale, 2000). Activated cells express 
myogenic regulatory factors in a similar manner to muscle precursor cells during 
early muscle development (Morgan and Partridge, 2003). These myogenic 
transcription factors play a further role in the regulation of the differentiation process 
(Relaix, 2005). Current thought is that Pax7 regulates the entry of the satellite cells 
into the myogenic programme via the activation of the myogenic determination 
genes, MyoD and Myf5 (Buckingham, 2007). 
 
Boldrin et al (2010) in a recent review suggest a working model of satellite cell 
activation and progression through the myogenic program. Quiescent satellite cells 
express Pax7 and Myf5. Upon activation, they up-regulate MyoD and divide to 
produce a pool of muscle precursor cells (MPC). Satellite cell progeny then follow 
one of two fates. They either down-regulate MyoD and self-renew to provide a new 
satellite cell, or alternatively, differentiate by down-regulating Pax7, Myf5, and 
MyoD and expressing MRF4 and myogenin, eventually fusing either to form new 




Figure 2.6 - Model of satellite cell activation and progression through the myogenic 
program. Quiescent satellite cells express Pax7 and the myogenic regulatory factor 
(MRF) Myf5. Upon activation, they divide to produce a pool of muscle precursor 
cells. The cell progeny then follow one of two fates, self-renewal to give rise to 





Diagram taken from Boldrin L, Muntoni F, and Morgan J. Are Human and Mouse Satellite 




There is much optimism that manipulation of satellite cells may result in therapies to 
treat muscular dystrophies and perhaps sarcopenia. Collins et al (2005) working in 
the mouse, transplanted single intact myofibres (containing approximately 7 satellite 
cells) into ablated muscle of immuno-compromised hosts. The grafted fibres were 
demonstrated to produce over 100 new myofibres, containing an estimated 25000 – 
30000 differentiated myonuclei. These donor derived satellite cells persisted in the 
skeletal muscle for several weeks and could be reactivated and expanded in response 




It has been recently demonstrated that transplanting aged satellite cells into young 
hosts restores their regenerative capacity. Hall et al (2010) have shown (again in a 
murine model) that transplantation of myofibres with associated satellite cells, 
coupled with induced muscle injury, elicits lifelong enhancement in muscle mass, 
stem cell number and force generation in the host animal. When compared to the 
uninjured contralateral limb, a 50% increase in mass and a 170% increase in size was 
recorded that persisted for the lifetime of the mouse. Unfortunately, transplanted 
satellite cells have a limited capacity for migration, and are only able to regenerate 
muscle in the region of the delivery site (Relaix et al, 2005). As such systemic 
treatments or even the treatment of an entire muscle in this way is currently not 
possible.  
 
Hall et al. (2010) speculate that an alternative therapeutic approach to enhance the 
regenerative capacity of the endogenous cell population may be possible by 
modifying the signalling pathways to mimic the environment of the transplanted 
satellite cells. While this idea is attractive, as the approach may provide therapeutic 
benefit in the absence of cell transplantation, there are many issues to resolve before 
any such therapies can be trialled. Hall et al. acknowledge that the underlying 
cellular mechanisms involved are not fully understood and that minimal work has 
been carried out with human tissue. Of further note, previous animal studies in stem 
cell and muscle transplantation have resulted in minimal physiological improvements 




Much of the research into satellite cell activation and proliferation has been 
conducted in the murine model, with only a handful of authors conducting human 
studies. Boldrin et al (2010) comment that the lack of specific satellite cell markers 
in the human has led to equivocal, and sometimes contradictory, reports on their 
presence and number in human muscle sections. 
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In the few human studies that have been conducted, satellite cells have generally 
been identified with immunohistochemical antibody staining. Leu19, which 
recognizes CD56 (or neural cell adhesion molecule, NCAM) (Schubert et al, 1989), 
being the most common antigen. NCAM expression is not satellite cell specific 
(Schubert et al, 1989; Mechtersheimer et al, 1992), but has been extensively used for 
identification of satellite cells in human muscle (Schubert et al, 1989; Illa et al, 1992; 
Kadi et al, 1999; Kadi et al, 2006; Kadi and Thornell, 2000; Charifi et al, 2003; 
Mackey et al, 2007). 
 
Although Pax7 is considered essential for the specification of satellite cells, it has 
been suggested that Pax7 staining does not account for all human satellite cells 
(Boldrin et al, 2010). This suggests that the use of Pax7 staining as a marker for 
satellite cells could, lead to an underestimation of total cell count. Previous authors 
however (Reimann et al, 2004; Verdijk et al, 2007) have demonstrated 96% of 
NCAM-positive satellite cells were also Pax7 positive, the remaining cells suggested 
as being either activated or differentiating, suggesting Pax7 to be a reliable marker. 
Authors now generally either use multiple antibody markers or a single marker in 
combination with the anatomical location to confirm the positive stain (Lindstrom 
and Thornell, 2009). 
 
Human muscle regeneration and the aging process 
 
A progressive loss of muscle mass and function, accompanies aging (Jones and 
Round, 1990; Kadi and Ponsot, 2010; Grounds, 1998), resulting in a decreased 
ability to generate power and force due to loss and change of contractile properties of 
the motor units in muscle (Lexell, 1995). Typical loss of muscle mass and strength 
between the ages of 25 and 80 has been estimated at between 33 and 50% (Lexell, 
1993; Brooks and Faulkner, 1994). This loss of strength is directly associated with 
limitation in mobility and physical performance (Whipple et al, 1987). This in turn is 
associated with a high incidence of injury, and a loss of quality of life (Ryall et al, 
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2008). With increasing age, there is also a decline in the ability of skeletal muscle to 
regenerate (Kadi and Ponset, 2010; Grounds, 1998; Lexell, 1995).  
 
As noted there is little experimental data on human satellite cells. The few studies 
that have been conducted though provide reasonable evidence that satellite cell 
content in skeletal muscle reduces with age (Renault et al, 2002; Kadi et al, 2004; 
Verdijk et al, 2007). Early work with electron microscopy (to determine the position 
of the satellite cell between basal lamina and sarcolemma of the muscle fibre) 
suggested no difference in satellite cell numbers in samples of vastus lateralis, 
reporting equivalent numbers in young and elderly men and women (Hikida et al, 
1998; Roth et al, 2001). More recent investigations however, with 
immunohistochemistry and light microscopy suggest a reduction in cell number. 
Boldrin et al (2010) describe the use of electron microscopy for quantification as 
technically demanding and not suited to studying large portions of muscle, as the 
number of fibres that can be assessed is much lower than with 
immunohistochemistry. Electron microscopy does allow a detailed morphological 
analysis of the myonuclei and satellite cells, however the reported number of fibres 
assessed per individual is around 4 times less than with the immunohistochemistry 
method.   
 
In contrast to the early investigations, Renault et al (2002) report fewer satellite cells 
in an older compared to young cohort. Biopsies were obtained from the masseter and 
biceps brachii muscles in 6 young (age range 20-28 years) and 6 old (58-83, years) 
subjects. Satellite cells were identified by an IHC staining protocol using NCAM and 
cell location. They further evaluated regenerative history of the individuals by 
measuring telomere length. 
 
Telomeres are repeated DNA sequences located at the end of all chromosomes. They 
are small sections of non-coding DNA sequences, and play an important role in 
recombination function (Haber and Thorburn, 1984). During DNA replication, DNA 
polymerase is unable to copy the terminal segment of each DNA strand, which 
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results in shortening of the chromosomes at each round of cell division (Harley et al, 
1990). In somatic cells, telomere length decreases regularly with cell division. In 
skeletal muscle, since nuclei are added to muscle fibres at various times during fibre 
regeneration, the mean telomere length reflects this heterogeneity, while the 
minimum length reflects the most recent nuclei incorporated, thus the length of 
telomeric DNA has been proposed as a good indicator of regenerative history 
(Renault et al, 2002). Using this approach Decary et al (1997) showed a small 
decrease in minimum telomere length (11 base pairs per year) in human quadriceps 
samples between 9 months and 86 years of age, whereas a comparatively large 
decrease (187 base pairs per year) was detected in children with muscular dystrophy 
(Decary et al, 2000). 
 
Renault et al (2002) did not find any significant difference in telomere length in 
either the masseter or biceps between the old and young groups. The number of 
satellite cells reduced with age, while the number of myonuclei remained constant. 
They comment that these results suggest that a decrease in regenerative potential (as 
demonstrated by a decrease in the satellite cell number) is not accompanied by an 
excessive turnover of myonuclei, as the length of telomere fragments remained 
constant. 
 
A decrease in the number of muscle fibres has been reported in the older population 
(Larson, 1978; Lexell 1988). This would suggest a loss of myonuclei and satellite 
cells, and would not explain the selective loss of satellite cells found in the study by 
Renault et al (2002). Renault et al thus speculates as to a deficit in the restoration of 
the ‘pool’ of satellite cells that return to quiescence following activation and division 
(Figure 2.5), and further that this decrease is probably related to continual low level 
turn over of satellite cells with aging and repair – which would progressively exhaust 
the proliferative capacity of some of these cells. 
 
Kadi et al (2004) reported significant difference between young and old groups in a 
much larger cohort using immunohistochemistry staining for NCAM / CD56 and 
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position under the basal lamina. Biopsies of tibialis anterior were obtained from 15 
young male and 16 young female (age range 20-32 years) and 13 old male and 14 
female (age range 70-83 years) in subjects free from musculoskeletal complaints. 
The total number of myonuclei was found to increase with aging, however 
significantly reduced numbers of satellite cells per muscle fibre (approximately 40%) 
were observed in the older population, no gender effect was observed.  
 
Verdijk et al (2007) found a specific satellite cell reduction in type II muscle fibres in 
the elderly. They obtained biopsies bilaterally from the vastus lateralis of 8 young 
(age 20 +/-1 years) and 8 elderly (age 76+/- 1 years) men, and assessed by an 
immunohistochemistry protocol for Pax7 and corroborated this count in a subset of 
tissue with a separate stain for NCAM / CD56. Previously Kadi et al (1995) had 
reported that no difference was found in satellite cell number between fibre types in 
the young subjects. The Verdijk study corroborated this finding, however noted a 
44% lower content of satellite cells in type II fibres compared to the type I fibres in 
the elderly group.  The satellite cell content in the type II fibres of the older group 
was also significantly lower when compared to the type II fibres of the young group. 
Verdijk et al suggest that this fibre type specific decline in satellite cell content might 
represent an important factor in the aetiology of sarcopenia. 
 
Together these studies suggest that satellite cell number is reduced with aging, 
although it should be noted that the combined number of subjects in the 3 studies was 
only 45 young and 41 older individuals and that the biopsy site incorporated a variety 
of individual muscle groups. 
 
Verdijk et al (2007) concede that the potential causes and clinical relevance of these 
changes in muscle satellite cell content with aging can only be speculated upon. It is 
also difficult to draw a direct causal link between satellite cell loss and age related 
muscle atrophy from this data. It is to be expected that progressive exhaustion of the 
satellite cell pool with advancing age should impair muscle regeneration; however 
mouse studies suggest that the inability of aged muscle to regenerate is due to an 
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inhibitory effect of the local environment on regenerative capacity (Conboy et al, 
2005; Carlson and Faulkner, 1989). It is also possible that other factors, such as 
nervous system degeneration are relevant. This neurogenic process, associated with 
aging, has been reported to lead to a reduction in muscle mass (Dutta and Hadley, 
1995).  Interestingly, it has also been demonstrated that chronic denervation is 
associated with a reduction in local muscle satellite cell content (Rodrigues and 
Schmalbruch, 1995). 
 
Another factor that may complicate the relationship between age and cell number is 
the effect of physical training. The activity levels and training state of individuals, 
irrespective of age, can affect satellite cell numbers (Chafri et al, 2003). As such, the 
cell numbers reported in the aging studies may reflect age related declines, or may be 
associated with activity levels that commonly reduce with advancing age. 
 
Long term strength training has been shown to increase satellite cell numbers. In a 
study with high-level powerlifters, trapezius muscle satellite cell content was 70% 
higher than that of control subjects. Further studies investigating the short term 
response of satellite cells to exercise have demonstrated increases in both young 
(Kadi and Thornell, 2000) and elderly (Mackey et al, 2007; Chafri et al, 2003; Roth 
et al, 2001) populations. Chafri et al (2003) found a 29% increase in the number of 
satellite cells in elderly men in response to a cycle ergometer exercise program while 
Mackey et al (2007) reported an increase following a 12 week resistance exercise 
programme in elderly. 
 
The regenerative response of skeletal muscle following exercise has been well 
reviewed by Grounds (1998) who described different levels of muscle damage that 
determine the cellular response. In ‘sub-lethal’ damage that was insufficient to 
provoke regeneration (examples of which were eccentric exercise with disruption of 
myofibrilar structure - particularly the z-bands), the response was macrophage 
activity and inflammatory response without associated myofibre necrosis and 
regeneration. In this situation, there was no need for satellite cell replication and 
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delivery of new myoblasts. The classic regeneration response of necrosis and 
regeneration follows more substantial damage, usually after intense or unaccustomed 
exercise. In this situation, the damaged myofibre is sealed off by new sarcolemma 
formation, and then an influx of inflammatory cells follows prior to satellite cell 




While the influence of the muscle satellite cell has been considered with reference to 
microvascular free flap reconstruction for salvage of limbs following complex 
fractures and soft tissue trauma (Kauhanen et al, 2003), surprisingly, there has been 
no investigation of the role of the satellite cell in an orthopaedic population, and no 
consideration as to its influence in post-operative recovery. Specifically, any link 
between the regenerative potential of skeletal muscle, intrinsic satellite cell number 
and post-operative recovery has been neither investigated nor established in a knee 
arthroplasty population. This population is particularly relevant due to the substantial 
influence of the quadriceps on post-operative outcome (Greene and Schurman, 2008; 
Aspden, 2008). 
 
Below normal muscular performance has been observed in both rheumatoid arthritis 
and osteoarthritis populations (Beals et al, 1985; Tiselius, 1969), and in particular 
specific weakness in the quadriceps group was noted (Nordesjo et al, 1983). The 
association of strength loss with osteoarthritis is traditionally thought to be that of 
disuse atrophy, secondary to joint pain. The muscle weakness can lead to joint 
instability which can contribute to mechanical overload of the joint (Aspden, 2008). 
This association has however now been questioned, and it has been suggested that 
muscle motor and sensory dysfunction may actually be a causative factor in knee 




Asmussen and Heeboll-Nielson (1962) and then Larson (1978) showed the age 
related decline in muscle strength to be most conspicuous in the proximal muscles of 
the lower limbs, while the musculature of the back and hand grip muscles were less 
affected. If one assumes the quadriceps and hamstrings to broadly consist of type II, 
phasic muscles and the hand grip and back muscles more of a mixed fibre type, this 
may suggest a relevance of the specific fibre type atrophy previously outlined. It may 
also though reflect a specific detraining of the lower limbs compared to the upper 
body musculature through decreased weight bearing activity. However this is 
difficult to ascertain clinically. 
 
Barton and Morris (2003) in a review of strategies to counter muscle atrophy note 
two conceptual types of atrophy – acute and chronic. Acute atrophy is generally 
associated with disuse and chronic atrophy with aging and sarcopenia. While there 
are some similarities (reduced muscle mass and fibre size) there is also an important 
difference, in that fibre properties tend to shift toward faster fibres in acute (disuse) 
atrophy, whereas in chronic (ageing) atrophy a decrease of both in total fibre number 
and selective atrophy of the fastest, most powerful fibres is prevalent (Lexell, 1993). 
Applying this general classification to the knee arthroplasty population is difficult, as 
they are likely to demonstrate a mixed picture of both chronic and acute atrophy, 
though it reasonable that a reduction in both fibre number and specifically of type II 
fibres can be expected in many cases. 
 
Those undergoing TKA are likely to have substantial associated muscle atrophy. 
How this affects recovery following knee replacement is unclear. Mizner et al 
(2005a) have demonstrated that the early/acute phase of recovery following knee 
arthroplasty may well be related to the voluntary activation of muscle. In this early 
post-operative phase both pain and muscle spasms complicate the picture. The time 
course of the inflammatory response and of muscle regeneration would suggest that 




Following TKA, many patients are able to rehabilitate to enhance physical function 
and return to their desired level of activity, which may include gentle sports such as 
bowls, golf and doubles tennis (AAOS, 2010; BOA/BASK, 2010). Others find it 
difficult to regain post-operative function which is known to be linked to pre-
operative quadriceps strength (Faulkner et al, 2010; Mizner et al, 2005b, Lingard et 
al, 2004; Lamb and Frost, 2003) though the mechanisms that modulate the 





3 The Influence of Single Radius Femoral Component 




TKA is an established and successful procedure (NIH position statement, 2003), 
however although the majority of patients do well, others report a variable outcome 
and moderate rates of dissatisfaction have been reported (Wright et al, 2004; 
Robertson et al, 2000). Jacobs et al consider that technical developments may 
potentially improve this procedure, which is already successful (Jacobs, et al, 2007a), 
but while many such developments in implant design have been aimed at improving 
quality of life, there is little consensus as to whether these design changes affect 
patient outcome (BOA/BASK position statement, 2010). 
 
The single radius design is one such concept that has yet to be proven to be of benefit 
to patients. The Triathlon prosthesis is a new implant developed with a single 
radius of curvature femoral component that is suggested to benefit patient recovery 
and subsequent function through enhanced reproduction of normal femoral 
kinematics and a longer moment arm for the extensor mechanism (resulting in a 
decreased requirement for muscle work to extend the knee). 
 
Adequate extensor mechanism function is considered a prerequisite for participation 
in many activities of daily living and in promoting a positive clinical outcome (Noble 
et al, 2006; Silva et al, 2003). Quadriceps weakness is often present in patients 
receiving a TKA and has a substantial impact on movement patterns and 
performance during functional tasks (Mizner et al, 2005c). Previous studies (Gomez-
Barrera et al, 2010; Hall et al, 2008; Wang et al, 2006; Mahoney et al, 2002) have 
assessed the use of single radius of curvature designs, though not with the Triathlon 
prosthesis specifically and reported conflicting results as to patient benefits. As has 
been previously discussed (in Chapter 2), these studies all suffer from a range of 
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limitations including poor trial design and lack of statistical power to determine 
differences between the implant groups investigated. 
 
Clear guidance is currently lacking as to the methodology required to determine post-
operative outcome following TKA. As previously discussed (Chapter 2), the most 
thorough analysis will likely incorporate both patient reported outcome measures and 
direct functional testing. In this case direct functional testing is essential to 
specifically assess the extent of the influence of the enhanced moment arm of the 
extensor mechanism on subsequent muscle function. 
 
The aims of this chapter were (1) to assess whether the difference in implant design 
influenced overall patient functional outcome, and (2) whether the design change in 
axis of rotation that lengthens the moment arm of the extensor mechanism 
specifically influenced the function of the extensor mechanism and the ability to 
generate muscle power.  
 
To determine if any differences in patient outcome can be attributed to the differing 
implant design, a randomised controlled trial was designed comparing the single 
radius Triathlon TKA against a traditional multi radius design, the Kinemax TKA 
(both Stryker Orthopaedics, Mahwah, New Jersey). The Kinemax implant is an 
example of the traditional condylar femoral component design (Pradhan et al, 2006) 
and has demonstrated a good track record of success (Pradhan et al, 2006; Wright et 
al, 2004; Back et al, 2001).  
 
Due to the lack of clarity as to best appropriate post-operative outcome, a multi-
modal trial design was established to reflect the various components of patient 
outcome. The primary outcome measure selected was the Oxford Knee Score as it 
has been developed specifically to measure the outcomes of knee replacements, is 
widely employed in orthopaedic research as a primary outcome measure, and has 
been shown to perform very well compared with alternative
 
tools (KAT trial group, 
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2009; Garrat et al, 2004; Dunbar et al, 2000). A raft of secondary outcome measures 
encompassing pain and functional testing were also incorporated to the trial design to 
evaluate these aspects of patient outcome in a comprehensive manner (Beard et al, 
2010; Stratford and Kennedy, 2006; Davies, 2002). Specific assessment of the power 
output of the extensor mechanism was included to the trial design as one of these 




Study design and ethical approval 
 
A prospective, double blind, randomised control trial was conducted to investigate 
the effect single radius of curvature femoral component implant design on 
subsequent patient outcome following knee replacement surgery.  
 
The trial was powered based on the ability to show a difference of 3 points on the 
Oxford Knee Score, the value currently accepted to reflect a clinically meaningful 
difference (Murray et al. 2007). The minimally clinically important difference 
(MCID) is the smallest change in score which patients perceive as meaningful, and 
which would cause clinicians to change management (Fayers and Machin, 2000). 
MCID values have not yet been calculated for the Oxford Knee Score, however 
Murray et al (2007) comment that pending this, approximation can be derived by 
calculating half the standard deviation (SD) of change in score. The SD of change in 
OKS is typically reported as between 6 and 10 points, and thus the MCID is likely to 
lie between 3 and 5 points. Some studies however have reported lower scores, and 
thus the real difference may actually be less than this. Clinically, the 3 point 
difference is approximated as the meaningful value and is widely used to power 
clinical studies. A power calculation was conducted with an alpha of 0.05 and beta of 
0.8, which resulted in 102 patients per arm required to account for a total drop out of 
10% at 1 year.  
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Local ethical approval was granted for the study by Lothian Research Ethics 




Patients were recruited from the planned operating lists of six consultant orthopaedic 
surgeons in the arthroplasty service at the Royal Infirmary of Edinburgh. All six have 
substantial experience of using both implants, and were content to use either for the 
duration of the trial. 
 
Suitable patients were approached at the time of pre-operative assessment, 
approximately 2 weeks prior to surgery, and were recruited to the trial through 
informed consent. Once recruited, the lead surgeon allocated the patient either 
implant using a computer randomisation program. Both the patient and researcher 
were blinded to the allocation, and remained so throughout the trial period. A colour 
code was used to represent the respective implant types, and was used to instruct the 
subsequent surgical teams as to which implant trays should be prepared for the 
procedure.  
 
A pragmatic trial design was adopted that best reflects the wider clinical population, 
and specific recruitment criteria applied. Inclusion criteria for participation was that 
patients were suffering from osteoarthritis of a severity that was suitable for joint 
arthroplasty, but were otherwise healthy (i.e. not suffering form any co-morbidities 
that would affect their post operative recovery or subsequent performance, such as 
cardiovascular or neurological disease).  
 
Previous joint replacement (in other major joints) was accepted, as was osteoarthritis 
in the contralateral knee or either hip, provided that it was not of a severity that 
would be considered for surgery and / or did not impact the patient’s functional 
performance. Additional criteria was that the planned procedure was ‘routine’ 
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primary total knee arthroplasty, i.e. the first surgical procedure on the osteoarthritic 
joint, performed with standard versions of the trial implants, without the addition of 
any augments to address compromised bone stock. Finally patients had to be 





Both implants were inserted utilising the same technique and standard 
instrumentation for each system; using intra-medullary referencing for the femur and 
extra-medullary jigging for the tibia. Patello-femoral resurfacing as part of TKA is 
not routinely practiced at the arthroplasty unit at the Royal Infirmary of Edinburgh, 
and no patients recruited to this study underwent patello-femoral resurfacing.  
Components were cemented in all cases. Implant alignment was specifically set with 
femoral rotation of 3 deg of external rotation using posterior referencing and rotation 
confirmed by assessing the transepicondylar axis and Whitesides line. 
 
Follow-up and patient withdrawal 
 
212 patients were recruited to the study, although 24 were subsequently withdrawn 
and a further five patients experienced complications that prevented them completing 
the 12 month assessment protocol. As a result 183 patients completed the full study 
protocol (reference trial flow chart). 
 
Of the withdrawn patients, six procedures were cancelled or delayed beyond the trial 
recruitment period due to pre-operative medical complications. A further two 
procedures were transferred to ‘non-trial’ consultants as a part of a waiting list 
initiative. Due to their specific practice, these surgeons were not happy to use the 
trial implants, and opted instead to use another. One patient died during the follow-
up period (unrelated to the surgery), another patient acquired a deep infection on the 
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ward post-operatively that led immediately to a 2-stage revision procedure, one 
patient experienced a peroneal nerve complication during surgery that prevented 
functional testing post-op, and a further patient subsequently revealed that she 
suffered from chronic pains in multiple joints. This was not divulged at the 
recruitment stage, and would have excluded her from participating in the trial.  
Despite previously consenting to the trial protocol with full information of the post-
operative procedures, 12 patients requested post-operatively that they be followed up 
by clinical teams at their local satellite hospital which meant that they did not attend 
attending the Royal Infirmary orthopaedic research facility; these patients were 
withdrawn.   
 
Of the 5 later complications, two patients were diagnosed with deep infections and 
had revision procedures. One had a post-operative flare-up of previously 
undiagnosed rheumatoid arthritis that required management with disease modifying 
drug therapy. One developed a progressive foot neuropathy that prevented functional 
assessment, and one could not be contacted for final follow-up at 12 months. 
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Assessed for eligibility (n = 237) 
Gave informed consent, underwent pre-operative assessments and 
randomised to implant group (n = 212)  
Kinemax (n = 97) 
 
Triathlon (n = 107) 
Did not receive TKA as allocated 
(n = 1) 
 
● Surgery cancelled (n = 1) 
Loss to follow up (n = 6) 
 
● Request local follow up (n = 3) 
● Deep infection (n = 1) 
● Other (n = 1) 
Excluded (n = 25) 
 
● Did not meet criteria (n = 13) 
● Refused to participate (n = 12) 
Loss to follow up (n = 15) 
 
● Request local follow-up (n = 9) 
● Deceased (n = 1) 
● Deep infection (n = 2) 
● Other (n = 3) 
Analysed (n = 82) Analysed (n = 101) 
Kinemax (n = 104) 
 
Triathlon (n = 108) 
 
Did not receive TKA as allocated 
(n = 7) 
 
● Non-trial surgeon (n = 2) 





Patients were assessed pre-operatively, then post-operatively at routine outpatient 
clinical reviews at 6 weeks, 26 weeks and 52 weeks following surgery in a local 
clinical testing facility at the Royal Infirmary of Edinburgh. A comprehensive 
physical outcome testing protocol was used to evaluate patient function. This 
comprised the Oxford Knee Score, range of motion, pain score, timed test of 
activities of daily living and lower limb power output. All tests were carried out by 
the same researcher in the same manner. 
 
Oxford Knee Score 
 
The importance of a joint-specific tool lies in the ability to isolate the function of a 
single joint from the overall functional picture. The Oxford Scores are well validated 
as sensitive tools that are accepted by patients’ and surgeons to gauge pain and 
functional outcomes (Dawson et al, 1998; Murray et al, 2007; Garrat et al, 2004). 
The Oxford Knee Score (OKS) has undergone one of the most thorough assessments 
of reliability and validity of all the tools used to assess outcome following TKA 
(Davies et al, 2002) and it use recommended (Davies et al, 2002; Dunbar et al, 2001). 
 
The OKS consists of 12 equally weighted questions addressing pain and functional 
activity, each scoring form 1 – 5. Best possible scores are 12 and worst 60. Specific 
attempt was made during the construction of the OKS to minimise the influence of 
comorbidities (Murray et al, 2007).  
 
As relative change in OKS is considered a more valid assessment of outcome than 
the absolute OKS (Murray et al, 2007; Price et al, 2010), the change in score value is 




Range of motion 
 
Active measures of flexion and extension were determined at all assessments by the 
same assessor using universal goniometry. A high level of accuracy has been 
previously demonstrated assessing knee range of motion with this instrument in the 
clinical setting (Watkins et al, 1991) and specifically in patients following TKA 
(Jakobsen et al, 2010).  
 
The twelve-inch universal goniometer was chosen due to high intratester reliability 
(Brosseau et al, 1997). Brosseau et al (2001) noted high levels of intra-rater 
reliability for repeated goniometric measurements of knee range of motion in patients 
with restricted movement (ICC for flexion 0.997, and for extension 0.975) when 
evaluated against gold standard radiographs. Inter-tester reliability was found to be 
less accurate, and it has been recommended that the same assessor conduct all 




The aggregated locomotor function (ALF) score is a simple measure of observed 
locomotor function using timed tests of walking, stairs ascent/decent and chair 
transfers. It has been previously demonstrated to be valid, reliable and responsive, 
and proposed as a tool with which to assess physical function and to quantify 
treatment response (McCarthy and Oldham, 2004). These three measures have 
extensively been used individually as outcome assessments, but it has been suggested 
that a composite aggregated time provides a better objective assessment of the 
patients overall functional capabilities (Hurley and Scott, 1998).   
 
The test was conducted in the manner suggested by McCarthy and Oldham (2004). 
Specifically, patients were asked to walk over a flat eight metre course, ascend and 
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then descend a rehabilitation style platform consisting of seven fixed steps (four of 
15cm and three of 20cm) using banisters if required and additionally walk two 
metres to a chair (with seat height of 0.46m), sit down, then immediately stand up 
and return to the start.  
 
In all tests patients were instructed to move at their own preferred ‘comfortable’ 
pace. A mean of three repetitions of the walking and transferring assessments and 
four repetitions of the stairs assessment were recorded. The four attempts of the stairs 
assessment were to balance the differing step heights. By traversing the steps in both 
directions, the patients ascend and descend the different height steps twice 
(McCarthy and Oldham, 2004). Time was recorded in seconds using a handheld 
stopwatch (Zeon, UK); the same assessor conducted each assessment, preventing 
intra-tester reliability issues around the use of the stopwatch. 
 
Lower limb power output 
 
Specific assessment of the recovery of muscle power was assessed by use of a Leg 
Extensor Power Rig (Queens Medical Centre, Nottingham, NG7 2UH) which has 
been well validated for use with this population group (Lamb and Frost 2003; 
Robertson et al, 1998; Bassey et al, 1992). The Leg Extensor Power (LEP) Rig 
consisted of a seat and footplate connected through a lever and chain to a flywheel 
(Figure 3.1). Application of force accelerated the flywheel from rest, and output was 
recorded as maximal wattage (W) generated.  
 
The test procedure followed that suggested by Robertson et al (1998) where the 
patient was seated in an upright position with arms folded, so as not to contribute to 
power generation. The distance between the pedal and seat was dependant on the 
length of the individual’s lower limb. Seat position for the test was determined by 
positioning the patient in comfortable extension of the knee in conjunction with full 
depression of the foot pedal. The subject was instructed to move the pedal by 
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pushing the leg into extension with maximal effort. A command of ‘push as hard and 
as fast as you can’ was given prior to each effort as per the manufacturers 
instructions. Where continued progressive improvement in power output was 
observed, a maximum of 10 attempts was conducted. A minimum rest period of 20 
seconds between attempts was enforced. Those not able to complete the test were 
assigned a score of zero as advocated by Lamb and Frost (2003). After each attempt, 
the force produced was recorded. The highest recorded output was used for analysis 
as suggested by Barker and Simpson (2004).  
  
Figure 3.1 - Diagrammatic representation of the patient seated on the leg extensor 




Adapted from: Bassey. E, Short A. A new method for measuring power output in a single leg 
extension: feasibility, reliability and validity 1990, Eur j Appl Physiol 60: 385-390 
 
 
Power output was also recorded for the patient’s contralateral leg to establish 
approximate ‘normal’ levels of output for that individual. Values were recorded at 
the 12 month assessment period to aid consistency and to standardise any influence 




Global knee pain severity (not activity specific pain) was assessed using an 11 point 
(0-10) numerical rating scale (NRS), where 0 represents no pain and 10 the worst 
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possible pain. The validity (Jensen and Karolyn 2001; Van Koff et al, 2000) and 
sensitivity (Williamson and Hogarth, 2005) of the NRS has been well documented, it 
is easy to administer and score and can also be used with a greater variety of subjects 
than other pain scales (Bellamy, 1993; Van Koff et al, 2000). 
 
It has been suggested that using multiple measurements of pain status as opposed to a 
single value of ‘current pain’ may provide more realistic and meaningful 
measurements of pain intensity (Jensen et al, 1996). Separate assessments were made 
of ‘worst pain’ and ‘perceived mean daily pain’ as has been specifically 
recommended for use in OA clinical trials (Perrot et al, 2010). Patients were asked to 
state the severity of the worst and the average pain they experienced over the 
previous week. The validity of pain recall has been previously demonstrated over this 





Data was collated and analysed using SPSS version 17. Microsoft Office Excel 2003 
and Minitab release 15 were further utilized to present data for superior graphical 
quality. All available data was included in the analysis to limit any effect of loss to 
follow up (Murray et al 1997). 
 
The RCT was powered to determine between group differences in the OKS at 12 
months, thus all outcome variables were assessed initially with Two-Way Repeated 
Measures ANOVAs to investigate the overall change between pre-op and twelve 
months assessment, and also the effect of implant group on the overall change, as 





Specific differences in outcome between the groups were assessed separately at the 4 
assessment time points to investigate the changing outcome in the year following 
surgery. Independent samples t-tests or Mann-Whitney U tests (depending on the 
underlying distribution of the data) were used to assess between group differences at 
the four assessment points. Differences between the four assessments were assessed 
with Paired Samples t-tests or Wilcoxon Signed Ranks tests for repeated measures, 
depending on the normality of the underlying data. Multiple testing may lead to a 
type 1 error, thus the Bonferroni correction was applied to the level of accepted 





Despite random allocation to ensure equal distribution of implant type, the 
withdrawn patients were unevenly split between groups, resulting in 101 Triathlon 
implants and 82 Kinemax implants being available for analysis (see trial flow chart).  
 
The male to female ratio was equivalent between groups. The Triathlon group 
contained 37 male (36.6%) and 64 female (63.4%) patients, the Kinemax group 34 
male (41.5%) and 48 female (58.5%) patients (Figure 3.2). The mean age of the trial 



































Table 3.1 – Mean age of patients at time of surgery by implant group. 
 
 
Implant group mean (+/-SD) Range 
   
Triathlon 68.9 (9.11) 46 – 92 




Oxford Knee Score 
 
RCT results: 1 year outcome 
 
The treatment effect of the TKA caused a left shift of the data post operatively, 
resulting in a non-Gaussian distribution when assessed at individual time points post-
operatively. The repeated measures ANOVA however considered the change in score 
between the assessments, and this ‘change data’ was normally distributed. The mean 
change in OKS (difference between pre-op and 12 month assessment periods) was 





A two-way repeated measures ANOVA was performed to assess overall change in 
outcome between pre-operative and 12 month assessment periods and the influence 
of implant groups. There was a significant main effect of the TKA surgery reflected 
in a pre-operative to 12 month change in the Oxford Knee Score F (1, 172) = 709.5 p 
= <0.001. Further there was a significant interaction of the implant used and the 
change in Oxford Knee Score F (1, 172) = 4.28 p = 0.04 (Figure 3.3 and Appendix C 
for statistical output). 
 
Figure 3.3 - Graphical illustration of the repeated measures ANOVA for OKS. The 
overall change and trajectory of change in both groups is highlighted. Although the 
overall change is similar, the triathlon group demonstrates greater overall change in 




Longitudinal change across the 4 time points 
 
Specific analysis of the four assessment points highlighted the similar overall pattern 
of reduction in Oxford Knee Score (Table 3.2 and Figure 3.4). The change in score at 





Table 3.2 – Oxford Knee Score  
 
 Triathlon Kinemax 
   
Pre-op 42.5 (35.25, 47.75) 41.0 (34, 47) 
6 weeks 32.0 (26, 38) 31.0 (26, 40) 
6 months 23.0 (18.5, 31) 23.0 (18.75, 30) 
12 months 20.0 (15, 26) 21.5 (17, 27.5) 
   
Data presented as medians (+/- IQR) 
 
 
Figure 3.4 - Boxplot of Oxford Knee Score, highlighting the similar pattern of 


















Boxplot of Median Oxford Score
 
 
X denotes the median result and * an outlying data point. 
 
 
Wilcoxon Signed Rank tests demonstrated statistically significant differences in 
Oxford Score between all assessment periods for both implant groups, p = <0.001 
(Appendix C for statistical output), highlighting a step wise improvement in score 
over the first year post-operatively.   
 
Mann-Whitney U-tests of between group differences at the four assessment periods 
highlight that while the overall change in score was significantly different between 
 
 60 
groups, at no specific assessment point were the implant groups significantly 
different to each other (Table 3.3 and appendix C for statistical output). This again 
highlighted the similar pattern of improvement in patient reported score between 
groups. 
 
Table 3.3 – Between group differences at specific assessments 
 
 Z statistic Significance 
   
Pre-op -0.80 p = 0.42 
6 weeks -0.17 p = 0.86 
6 months -0.12 p = 0.90 
12 months -2.18 p = 0.03 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. No results reach 
required level of significance. 
 
 
Range of motion – Flexion 
 
RCT results: 1 year outcome 
 
The data was normally distributed at all time points. The mean change in flexion 
(difference between pre-op and 12 month assessment periods) was 5.15 (+/- 12.37) 
degrees for the Triathlon group, and 0.65 (+/- 14.57) degrees for the Kinemax group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKR surgery on the recorded flexion, F (1, 180) 
= 5.08, p = 0.025. There was also a significant interaction of the implant group and 
the change in flexion, F (1, 180) = 8.418, p = 0.004 (Figure 3.5 and Appendix C for 




Figure 3.5 - Graphical illustration of the repeated measures ANOVA for flexion, 
highlighting the differing trajectory of change in the implant groups. The Triathlon 
group achieves improvement in flexion following surgery, however this was only of 
the order of 5 degrees, while the Kinemax group broadly achieves pre-operative 





Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessments highlighted a similar 
overall pattern of change in flexion (Table 3.4 and Figure 3.6). Both groups 
presented with a mean pre-operative flexion of around 105 degrees, which reduced at 
first post-operative assessment, then recovered at later assessments. The differing 
amount of recovery of flexion between implant groups was also apparent, the 
Triathlon group achieving a flexion greater than pre-operative levels at 6 months, 
which subsequently improved further, the Kinemax group never regaining the pre-




Table 3.4 – Flexion at assessment point.  
 
 Triathlon Kinemax 
   
  Pre-op 104.9 (14.8) 104.5 (14.5) 
6 weeks 97.9 (13.3) 94.5 (13.0) 
6 months 106.4(11.8) 101.5 (12.6) 
12 months 110.1 (10.8) 103.9 (12.0) 
   
 
Data presented as degrees of flexion mean +/- (SD) 
 
 
Figure 3.6 - Change in flexion over the assessment period. Graph demonstrates the 
striking similarity of the change in flexion in both groups, and the superior results 
achieved by the Triathlon group. 
 























Data plotted at assessment time points highlighting the proportional change in flexion over 
the year. Error bars represent the SEM. 
 
 
Paired samples t-tests demonstrated statistically significant differences in flexion 
between all assessment periods for both implant groups, p = <0.001 (Appendix C for 




Independent samples t-tests of between group differences at the four assessment 
periods highlighted statistically significant differences between implant groups at 6 
months and 12 months, the Triathlon group achieving greater flexion than the 
Kinemax group (Table 3.5 and also Appendix C for statistical output). 
 
Table 3.5 – Flexion difference between groups at assessments 
 
 Mean difference (95% CI) Significance 
   
Pre-op 0.33 (-3.98, 4.63) p = 0.88 
6 weeks 3.88 (-0.53, 7.29) p = 0.09 
6 months 4.87 (1.22, 8.52) p = 0.009 
12 months 6.19 (2.84, 9.57) p = <0.001 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 
indicates a significant result. 
 
 
Range of motion – Extension 
 
RCT results: 1 year outcome 
 
The data was normally distributed at all time points. The mean change in extension 
(difference between pre-op and 12 month assessment periods) was -2.75 (+/- 5.09) 
degrees for the Triathlon group, and -2.11 (+/- 5.42) degrees for the Kinemax group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKR surgery on the recorded extension, F (1, 
180) = 38.7, p = <0.001. There was no significant interaction between the implant 
group and the change in extension, F (1, 180) = 0.67, p = 0.414 (Figure 3.7 and 




Figure 3.7 - Graphical illustration of the repeated measures ANOVA for extension. 
The reduction in mean flexion and similar trajectory of change in both groups is 




Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessment points highlighted the 
similar overall pattern of change in extension; both groups record a small mean 
limitation in extension that gradually reduced at subsequent assessments (Table 3.6 
and Figure 3.8). 
 
Table 3.6 – Extension at assessment point 
 
 Triathlon Kinemax 
   
Pre-op 3.05 (5.24) 3.27 (5.70) 
6 weeks 2.03 (3.97) 1.95 (4.03) 
6 months 0.83 (2.07) 0.99 (2.61) 
12 months 0.30 (1.21) 1.16 (3.32) 
   
 
Data presented as degrees of extension from neutral mean (+/- SD) 
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Figure 3.8 - Change in extension over the assessment period. Graph demonstrates 
the similar early change in extension in both groups to 6 months, then the further 


































Data plotted at assessment time points highlighting the proportional change in extension 
over the year. Error bars represent the SEM. 
 
Paired samples t-tests demonstrate significant change in extension between 6 weeks 
and 6 months for both implants. The Triathlon group demonstrated further significant 
reduction between 6 and 12 months, whereas the Kinemax group extension plateaus 
(Table 3.7, Figure 3.8 and also Appendix C for statistical output).  
 
Table 3.7 – Extension change between assessments 
 
 Implant Mean (95% CI) Significance 
    
Pre-op – 6 weeks Triathlon 1.13 (-0.05, 2.30) P = 0.06 
 Kinemax 1.29 (0.09, 2.48) p = 0.035 
    
6 weeks – 6 months Triathlon 1.22 (-0.06, 1.82) p = <0.001 
 Kinemax 1.09 (0.40, 1.78) p = 0.002 
    
6 months – 12 months Triathlon 0.54 (0.23, 0.84) p = 0.001 
 Kinemax 0.09 (-0.27, 0.45) p = 0.062 
    
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 
indicated a significant result. 
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Independent samples t-tests of between group differences at the four assessment 
periods highlighted that no differences exist pre-op, at 6 week or 6 month 
assessments, however the Triathlon group demonstrated a significantly improved 
mean extension compared to the Kinemax group at 12 months (Table 3.8, Figure 3.8 
and also Appendix C for statistical output).  
 
Table 3.8 – Extension difference between groups at assessments 
 
 Mean difference (95% CI) Significance 
   
Pre-op -0.22 (-184, 1.40) p = 0.79 
6 weeks 0.08 (-1.11, 1.28) p = 0.894 
6 months -0.16 (-0.87, 0.56) p = 0.667 
12 months -0.22 (-0.63, -0.10) p = 0.017 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 
indicates a significant result. 
 
Timed functional assessment 
 
RCT results: 1 year outcome 
 
The data was normally distributed at all time points. The mean change in timed 
functional assessment score (difference between pre-op and 12 month assessment 
periods) was -10.67 (+/- 12.01) seconds for the Triathlon group, and -8.67 (+/- 10.93) 
seconds for the Kinemax group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKR surgery on the timed functional assessment, 
F (1, 181) = 127.0, p = <0.001. There was no significant interaction of the implant 
group and the timed assessments, F (1, 180) = 1.37, p = 0.243 (Figure 3.9 and also 




Figure 3.9 - Graphical illustration of the repeated measures ANOVA for timed 
functional assessment. The overall reduction following surgery and the similar 
trajectory of change in both groups is highlighted. See Figure 3.10 for errors at 





Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessment points highlighted the 
similar overall pattern of change in timed assessment. Both groups demonstrated a 
similar improvement in combined functional assessment in the year post surgery 
(Table 3.9 and Figure 3.10). 
 
Table 3.9 – Timed function score at assessment point 
 
 Triathlon Kinemax 
   
Pre-op 36.18 (3.06) 34.4 (2.67) 
6 weeks 31.59 (2.37) 31.7 (2.41) 
6 months 26.6 (1.55) 26.49 (1.67) 
12 months 25.5 (1.33) 25.73 (1.37) 
   
 
Data in seconds, presented as mean (+/- SD) 
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Figure 3.10 - Graph demonstrates the similar change in functional score in both 
groups. Data plotted at assessment time points highlighting the proportional change 
in extension over the year. 
 




































Error bars represent the SEM. 
 
Paired samples t-tests demonstrated significant changes in timed functional 
assessment between all time points for the Triathlon group. Significant 
improvements in the Kinemax group were only observed between 6 weeks and 6 
months (Table 3.10, Figure 3.10 and also Appendix C for statistical output).  
 
Table 3.10 – Timed function change between assessments 
 
 Implant Mean (95% CI) Significance 
    
Pre-op – 6 weeks Triathlon 4.64 (2.27, 7.01) p = <0.001 
 Kinemax 2.82 (0.57, 5.06) P = 0.015 
    
6 weeks – 6 months Triathlon 4.93 (3.59, 6.26) p = <0.001 
 Kinemax 5.50 (3.74, 7.26) p = <0.001 
    
6 months – 12 months Triathlon 1.10 (0.31, 1.89) p = 0.007 
 Kinemax 0.04 (-0.06, 1.74) p = 0.068 
    
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 
indicates a significant result. 
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Despite the significant changes notes above, independent samples t-tests of between 
group differences at the four assessment periods demonstrate that no differences exist 
between the groups at any time point (Table 3.11, Figure 3.10 and also Appendix C 
for statistical output).  
 
Table 3.11 – Timed function score difference between groups at assessment 
 
 Mean difference (95% CI) Significance 
   
Pre-op 1.78 (2.30, 5.86) p = 0.39 
6 weeks -0.10 (-3.50, 3.31) p = 0.96 
6 months 0.92 (-2.19, -2.42) p = 0.92 
12 months 0.81 (-2.16, 1.70) p = 0.81 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. No results reach 
required level of significance. 
 
Lower Limb Power Output 
 
RCT results: 1 year outcome 
 
The data was normally distributed at all time points. The mean change in maximal 
lower limb power output (difference between pre-op and 12 month assessment 
periods) was 45.02 (+/- 29.33) Watts for the Triathlon group, and 30.47 (+/- 35.86) 
Watts for the Kinemax group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKR surgery on the lower limb power output, F 
(1, 177) = 239.98, p = <0.001. There was also a significant interaction of the implant 
group and the recorded power output, F (1, 177) = 8.91, p = 0.003 (Figure 3.11 and 
also Appendix C for statistical output).  
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Figure 3.11 - Graphical illustration of the repeated measures ANOVA for lower limb 
power output. The overall increase in power following surgery is highlighted, and 
also the differing trajectory of change between the groups. See Figure 3.12 for 





Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessment points highlights the 
similar overall pattern of change in power output over the 1 year testing period, but 
also the early (6 week) and late (12 month) differences between the two implant 
groups (Table 3.12 and Figure 3.12). 
 
Table 3.12 – Power Output at assessment points 
 
 Triathlon Kinemax 
   
Pre-op 42.20 (37.81) 47.11 (44.30) 
6 weeks 54.86 (38.48) 50.11 (32.53) 
6 months 75.14 (40.57) 74.17 (44.44) 
12 months 87.84 (48.11) 77.78 (46.01) 
   
 
Power output in Watts, data presented as mean (+/- SD) 
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Figure 3.12 - Graph demonstrates the similar overall change in power output (W) 
over time, but also the divergence between groups at 6 weeks and 12 months 
assessments. 
 




















Error bars represent the SEM. 
 
 
Paired samples t-tests demonstrate significant change in power output between all 
time points for the Triathlon group, whereas significant improvements in the 
Kinemax group were observed between 6 weeks and 6 months only (Table 3.13, 
Figure 3.12 and also Appendix C for statistical output).  
 
Table 3.13 – Power output change between assessments 
 
 Implant Mean (95%  CI) Significance 
    
Pre-op – 6 weeks Triathlon -11.47 (-16.03, -6.91) p = <0.001 
 Kinemax -1.86 (-8.68, 4.96) p = 0.589 
    
6 weeks – 6 months Triathlon -20.07 (-24.29, -15.85) p = <0.001 
 Kinemax -25.47 (-31.54, -19.40) p = <0.001 
    
6 months – 12 months Triathlon -12.70 (-17.03, -8.37) p = <0.001 
 Kinemax -4.51 (-10.03, 1.01)  p = 0.108 
    
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 




Independent samples t-tests of between group differences at the four assessment 
periods highlight that while the trend was for greater improvement in the Triathlon 
cohort, no statistically significant differences existed between the absolute power 
output of the groups at any individual time point (Figure 3.12 and Table 3.14 and 
also Appendix C for statistical output).  
 
Table 3.14 – Power output difference between groups at assessments 
 
 Mean difference (95% CI) Significance 
   
Pre-op -4.91 (-17.24, 7.42) p = 0.43 
6 weeks 4.75 (-5.76, 15.25) p = 0.37 
6 months 0.97 (-11.77, 13.71) p = 0.88 
12 months 10.06 (-3.72, 23.84) p = 0.15 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. No results reach 
required level of significance. 
 
 
Proportional lower limb power output 
 
RCT results: 1 year outcome 
 
The maximal wattage achieved by the patients at each time point was compared to 
the output of the contralateral limb (at 12 months) as an internal control. This data 
was normally distributed at all time points. The mean change in proportional lower 
limb power output (difference between pre-op and 12 month assessment periods) was 
66.13 (+/- 44.22) for the Triathlon group, and 42.89 (+/- 47.76) for the Kinemax 
group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKA on the proportional lower limb power 
output, F (1, 177) = 249.09, p = <0.001. There was also a significant interaction of 
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the implant group and the proportional power output, F (1, 177) = 11.33, p = 0.001 
(Figure 3.13 and also Appendix C for statistical output).  
 
Figure 3.13 - Graphical illustration of the repeated measures ANOVA for 
proportional lower limb power output. The overall increase in power as a proportion 
of the contralateral limb following TKA is highlighted. The differing trajectory of the 
two groups is also apparent, the Triathlon group achieving greater relative 




Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessment points highlights the 
similar overall pattern of change in power output (as a percentage of the contralateral 
limb) over the 1 year testing period, and also the superior improvement of the 




Table 3.15 – Proportional power output at assessment points 
 
 Triathlon Kinemax 
   
Pre-op 50.41(32.04) 50.47 (36.67) 
6 weeks 68.83 (33.30) 58.20 (27.74) 
6 months 102.3 (50.13) 88.93 (30.04) 
12 months 116.38 (35.57) 92.95 (35.44) 
   
 
Data presented as mean (+/- SD) 
 
 
Figure 3.14 - Graph of change in power output, demonstrates the similar overall 
pattern of change in power output over time, but also the greater proportional 
increase for the Triathlon group. 
 















































Error bars represent the SEM. 
 
 
Paired samples t-tests demonstrate significant change in proportional power output 
between all time points for the Triathlon group, whereas significant improvements in 
the Kinemax group were observed between 6 weeks and 6 months only (Table 3.16, 




Table 4.16 – Proportional power output change between assessments 
 
 Implant Mean (95% CI) Significance 
    
Pre-op – 6 weeks Triathlon 17.07 (24.56, -9.57) p = <0.001 
 Kinemax 6.93 (15.41, -1.55) p = 0.108 
    
6 weeks – 6 months Triathlon 34.76 (43.77, 25.76) p = <0.001 
 Kinemax 30.87 (37.36, 24.38) p = <0.001 
    
6 months – 12 months Triathlon 14.08 (22.42, -5.73) p = 0.001 
 Kinemax 6.03 (12.36, -0.29) p = 0.061 
    
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 
indicates a significant result 
 
Independent samples t-tests of between group differences at the four assessment 
periods highlight that while the trend was for greater improvement in the Triathlon 
cohort at all assessments, only at the 12 month time point were the results 
statistically different between groups. The results at 6 weeks and 6 months were 
independently significant at p = 0.05, however did not reach the required significance 
when the Bonferroni correction for multiple testing was applied (Figure 3.14 and 
Table 3.17 and also Appendix C for statistical output). 
 
Table 3.17 – Proportional power output difference between groups at assessments 
 
 Mean difference (95% CI) Significance 
   
Pre-op -0.06 (24.56, -9.57) p = 0.99 
6 weeks 10.63 (1.42, 19.85) p = 0.024 
6 months 13.37 (1.42, 25.33) p = 0.029 
12 months 23.42 (12.98, 33.86) P = <0.001 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 





Reported average pain score 
 
RCT results: 1 year outcome 
 
The data was skewed to the left at 6 and 12 months post surgery. The repeated 
measures ANOVA considered the change in score between the assessments, and this 
‘change data’ was normally distributed. The mean change in average pain score 
(difference between pre-op and 12 month assessment) was 4.41 (+/- 1.89) points for 
the Triathlon group, and 4.38 (+/- 2.18) for the Kinemax group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKA on the report of average pain, F (1, 181) = 
849.9, p = <0.001. There was no significant interaction of the implant group and the 
report of average pain, F (1, 181) = 0.009, p = 0.926 (Figure 3.15 and also Appendix 




Figure 3.15 - Graphical illustration of the repeated measures ANOVA for average 
pain score. The overall reduction on pain score following surgery is highlighted, and 




























































Change in average pain between pre-op and 12 months
 
 
Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessment points highlights the 
similar overall pattern of change of reported average pain between the groups across 
the study timeframe (Table 3 18 and Figure 3.16). 
 
Table 3.18 – Average pain score at assessment point 
 
 Triathlon Kinemax 
   
Pre-op 5.0 (4.0, 6.0) 5.0 (5.0, 7.0) 
6 weeks 2.0 (1.0, 4.0) 3.0 (2.0, 3.0) 
6 months 1.0 (0.0, 2.0) 2.0 (0.0, 3.0) 
12 months 0.0 (0.0, 1.0) 0.0 (0.0, 2.0) 
   
 





Figure 3.16 - Boxplot highlighting the similar pattern of reduction of average pain 
score across the assessment period. The Triathlon group appear to report less pain 
























Boxplot of Average Pain Score
 
 
X denotes the median result and * an outlying data point. 
 
 
Wilcoxon Signed Rank tests demonstrated statistically significant differences in 
average pain score between all assessment periods for both implant groups, p = 
<0.003 (Table 3.19 and also Appendix C for statistical output), highlighting a step 
wise improvement in score over the first year post-operatively. 
 
Table 3.19 - Average pain score change between assessments 
 
 Implant Z statistic Significance 
    
Pre-op – 6 weeks Triathlon -7.51 P = <0.000 
 Kinemax -6.12 P = <0.000 
    
6 weeks – 6 months Triathlon -6.11 P = <0.000 
 Kinemax -5.53 P = <0.000 
    
6 months – 12 months Triathlon -3.80 P = <0.000 
 Kinemax -2.95 p = 0.003 
    
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 




Mann-Whitney U-tests of between group differences at the four assessment periods 
confirmed that while the Triathlon scores appeared generally lower, at no specific 
assessment point were the reports of average pain significantly different between the 
implant groups (Table 3.20 and Appendix C for statistical output). 
 
Table 3.20 – Average pain score difference between groups at assessments 
 
 Z statistic Significance 
   
Pre-op -1.30 p = 0.19 
6 weeks -1.54 P = 0.125 
6 months -1.37 p = 0.17 
12 months -1.74 p = 0.82 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. No results reach 
required level of significance. 
 
Reported maximal pain score 
 
RCT results: 1 year outcome 
 
The data was skewed to the left at 6 and 12 months post surgery. The repeated 
measures ANOVA considered the change in score between the assessments, and this 
‘change data’ was normally distributed. The mean change in maximal pain score 
(difference between pre-op and 12 month assessment) was 6.39 (+/- 2.46) points for 
the Triathlon group, and 5.34 (+/- 2.71) points for the Kinemax group. 
 
A two-way repeated measures ANOVA was performed to assess the overall change 
between pre-op and 12 month assessment, and any influence of implant group. There 
was a significant main effect of the TKA on maximal pain score, F (1, 181) = 1981.5, 
p = <0.001. There was also significant interaction of the implant group and the 
reported maximal pain, F (1, 181) = 7.44, p = 0.001 (Figure 3.17 and also Appendix 
C for statistical output).  
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Figure 3.17 - Graphical illustration of the repeated measures ANOVA for maximal 
pain. The overall reduction in pain score is apparent, and also the similar but 
significantly different trajectory of change between the groups. See 3.18 for ranges 





























































Longitudinal change across the 4 time points 
 
Specific analysis of the change at the four different assessment points highlights the 
similar overall pattern of change of reported maximal pain between the groups across 
the study timeframe (Table 3.21 and Figure 3.18). 
 
Table 3.21 – Maximal pain score at assessment point 
 
 Triathlon Kinemax 
   
Pre-op 8.00 (8.00, 9.00) 9.00 (7.00, 9.00) 
6 weeks 5.00 (3.00, 7.25) 6.00 (4.00, 8.00) 
6 months 2.00 (0.00, 5.00) 3.00 (0.00, 5.00) 
12 months 1.00 (0.00, 3.00) 2.50 (0.00, 5.00) 
   
 





Figure 3.18 - Boxplot highlighting the broadly similar pattern of reduction of maximal 
pain score across the assessment period, and the reduced score of the Triathlon 
























Boxplot of Maximal Pain Score
 
 
X denotes the median result and * an outlying data point. 
 
 
Wilcoxon Signed Rank tests demonstrated statistically significant differences in 
average pain score between all assessment periods for both implant groups (p = 
<0.001), except between 6 and 12 months in the Kinemax group (Table 3.22, Figure 
3.18 and also Appendix C for statistical output). 
 
Table 3.22 – Maximal pain score change between assessments 
 
 Implant Z statistic Significance 
    
Pre-op – 6 weeks Triathlon -7.56 <0.001 
 Kinemax -6.72 <0.001 
    
6 weeks – 6 months Triathlon -6.76 <0.001 
 Kinemax -6.22 <0.001 
    
6 months – 12 months Triathlon -3.88 <0.001 
 Kinemax -1.92 0.06 
    
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. Red highlighting 





Mann-Whitney U-tests of between group differences at the four assessment periods 
highlighted a similar change over the study time frame. While the overall change 
between groups differed (ANOVA), at no specific assessment point was there a 
significant difference between implant groups. Independently assessed, the Triathlon 
group demonstrated a lower maximal pain score at 12 months compared to the 
Kinemax group (Table 3.23, Figure 3.18 and Appendix C for statistical output), 
however due to multiple testing, this difference cannot be said to be significant. 
 
Table 3.23 – Maximal pain score difference between groups at assessments 
 
 Z statistic Significance 
   
Pre-op 0.00 1.00 
6 weeks -1.28 0.20 
6 months -0.58 0.57 
12 months -2.89 0.04 
   
 
Significance accepted at p= 0.0125 when Bonferroni correction applied. No results reach 





It was hypothesised that single radius of curvature femoral component designs would 
improve patient outcomes following TKA through enhanced kinematics and superior 
extensor mechanism / quadriceps function. In this study, two questions were 
addressed; whether the implant design affected (1) overall patient outcome, and (2) 
specific muscle power output of the extensor mechanism. These were assessed by a 
comprehensive physical assessment protocol incorporating patient reported outcome 
and functional assessments in addition to a specific power output analysis.  
 
Substantial treatment effects as a result of undergoing TKA were observed across the 
range of outcome assessments, the patients reporting much reduced pain and 
demonstrating enhanced functional ability 1 year post-operation. Differences were 
also observed between the implant groups across this time frame in OKS, maximal 
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pain report, flexion, extension and lower limb power output, the single radius 
Triathlon implant group achieving superior results in all cases. 
 
The initial question of overall patient outcome was assessed by the comprehensive 
outcome assessment regime employed. The primary outcome of the RCT was change 
in Oxford Knee Score (between pre-operative and 12 month values), This was found 
to be significantly different between the groups (p = 0.04, Figure 3.3), the difference 
also reaching the accepted level of clinical significance of around 3 points (Murray et 
al, 2007). Of interest was that no specific differences between groups were observed 
in the time course of change over the year, nor were the groups significantly different 
at any specific time point, suggesting relative parity between groups across the post-
operative time frame, in all but overall change in score. 
 
Patient reports of pain are reported not to correlate well to nociception, the activation 
of sensory transduction in receptors that convey information about potential tissue 
damage. Von Koff et al (2000) describe pain severity as a global construct measured 
by both pain intensity and interference with activities. Pain intensity is a quantitative 
estimate of the perception of pain, or more simply, how much a person hurts. Pain 
affect is more complex than intensity and involves emotional arousal and changes in 
‘action readiness’ caused by the sensory experience of pain. It is this arousal that 
leads to interference in daily activities.  
 
A simple measure of pain intensity that could be measured clinically was considered 
the best way of assessing the change in the patient’s pain between assessment 
periods, and the numerical rating scale the most suitable of these tools. Assessment 
was made of both ‘worst’ and ‘average’ pain as is recommended (Perrot et al, 2010). 
The assessments of function (OKS and ALF) taken as part of the trial reflect the pain 
affect element through its noted link to interference with daily activity. The OKS was 
particularly likely to provide analysis of this aspect as around half of its questions 
relate to pain limited function. 
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A suggested criticism of numerical rating scale scoring is that these scales may not 
have ratio qualities (Price et al, 1994). While this does not affect the validity, 
reliability or sensitivity of the scale, when evaluating the change in reported 
perceived pain, percentage reductions cannot be calculated as the scoring intervals 
may not be consistent. It has been recognised recently however that parametric 
statistical techniques (specifically the analysis of variance used in this analysis) are 
appropriate and valid when used with data that do not represent equal interval values 
if the number of categories on the scale in question is five or more (Philip, 1990; Van 
Koff et al, 2000). 
 
The substantial reductions in pain reported in each group were broadly similar. There 
were no between group differences observed in average pain reported between pre-
operative and 12 month post-operative assessments (ANOVA, Figure 3.15), though a 
significant difference emerged in report of maximal pain (ANOVA, Figure 3.17). 
Much of this difference can be attributed to the continued reduction in pain score in 
the Triathlon group between 6 and 12 months, where the corresponding Kinemax 
group score plateaus (Figure 3.18).  
 
The between group difference in maximal pain reported (between pre-operative and 
12 month assessment) is 1 point on the 0-10 scale. Whether this represented a 
clinically meaningful difference is difficult to interpret as it is debated whether or not 
the scale can be interpreted as interval or ratio level data. This perhaps then 
represents a ten percent difference between the groups in terms of change in maximal 
pain reported over the year, and corresponds to the superior OKS of the Triathlon 
group. Despite this, it must be noted that the median change in pain demonstrated 
over the four assessment periods (Figure 3.18) suggests no between group effect, nor 
is there a between group difference in either assessment of average pain report 
(Figures 3.15 and 3.16), suggesting little clinical relevance to this statistical finding 




No differences are apparent between groups in timed assessment of function. The 
groups follow the same pattern of recovery of function post-operatively (Figure 3.10) 
demonstrating essentially identical change in time measured on the ALF score. Both 
groups demonstrate achievement of a high level of post-operative function. It may be 
that the ALF test is not sensitive enough to detect changes in well functioning groups 
and that a basement effect is limiting analysis. There is a limit to how fast these three 
activities can be performed when mobilising in a ‘normal manner’, as the patient is 
instructed at the onset of the test. The average times achieved of around 25 seconds 
for the composite assessment at 1 year are comparable to control data obtained for 
healthy volunteers (internal data, not displayed). Of interest is the change from pre-
operative time to initial 6 week post-op assessment, where the Triathlon group 
demonstrates a larger improvement. This early change is independently significant, 
though not when assessed as part of the overall change (Table 3.11). It may be that at 
this specific time point in the recovery process that the Triathlon group achieved 
enhanced functional timed outcome, but that this comparative improvement was lost 
by subsequent assessments. 
 
Range of motion was significantly improved in both groups by the TKA, and 
significant between group differences were observed in both flexion and extension 
(Figures 3.5 and 3.7). Recovery of flexion followed the same pattern for each group, 
but at all post-operative assessments, the Triathlon group demonstrated significantly 
greater flexion than the Kinemax (Table 3.5, Figure 3.6). Mean extension followed 
the same pattern of recovery until 6 month assessment, where the values found in the 
Kinemax group plateau and the Triathlon group continued to improve (Figure 3.8, 
Table 3.7). It is unlikely that the difference found in extension represents a clinically 
significant finding as it represents an average value of less than 1 degree of motion, 
which is below the sensitivity of the measurement tool used. 
 
The second question, relating specifically to the power output of the extensor 
mechanism is perhaps the most interesting aspect of this study, as the between group 
differences found in lower limb power output were specifically predicted by the 
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implant design that incorporated a lengthened moment arm of the extensor 
mechanism. Substantial improvement was observed in both groups reflecting post-
operative muscle recovery. There was also substantial difference between the groups, 
the Triathlon group demonstrating significantly enhanced change over the test period 
both assessed as maximal power output, and as a proportion of the contralateral limb 
(Figures 3.11 and 3.13).  
 
The results expressed as a percentage of the opposite limb is the most meaningful 
analysis, as this acts as an internal control to quantify the power recovery. Here the 
same pattern of recovery was demonstrated by each group across the 4 assessment 
points; however the Triathlon group showed a trend of enhanced results at every 
assessment (Figure 3.14). Statistical significance was reached at p<0.03 at both 6 
weeks and 6 months assessment, which does not reach the required value due to the 
correction for multiple testing (Table 3.17). The large differences in individual 
patient power output results in large confidence intervals for the mean value, which 
play a dominant role in the lack of between group significance detected in this study. 
It is likely that increased volume of data would address this discrepancy. Differences 
at 12 months were highly significant (p<0.001), the Triathlon group actually 
demonstrating superior power output compared to the contralateral limb, in contrast 
to many authors (Valtonen et al, 2009, Gapeyeva et al, 2007; Mizner et al, 2005c; 
Berman et al, 1991) who report typical power output being 20 percent below the 
opposite limb up to 12 months post-op. 
 
Substantial differences in lower limb power and flexion were observed between the 
implant groups. A three point change in the OKS and small difference in maximal 
pain reported were also apparent. Interestingly, this did not seem to substantially 
affect the ability of the patients to perform timed functional tasks. That range of 
motion did not affect function supports the results of Nutton et al (2008) who 
demonstrated that high flexion implants do not to make any difference to functional 
ranges of flexion. Power output though is known to relate strongly to functional 
ability, particularly to tests of walking and climbing the stairs (Lamb and Frost, 
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2003, Mizner et al, 2005c). It is therefore interesting that the differences apparent in 
power output did not translate to the ALF timed assessments. This supports the 
theory that a basement effect was reached in this assessment, and that a well 
performing total population limits the analysis of this particular assessment. 
 
Strengths and limitations 
 
This is the only assessment of post-operative function directly comparing single and 
multi-radius implants that has both the statistical power and range of assessment 
tools to assess patient functional outcome comprehensively. Further, this is the only 
report to assess the functional outcome of the Triathlon prosthesis in such a manner. 
A particular strength is the double blind and randomised conditions of the trial.  
 
Covariates were not specifically addressed as the randomised nature of the trial limits 
any such effect. The trial is of a pragmatic design to best reflect the typical 
presentation of knee arthroplasty patients pre-operatively. While the inclusion of 
patients with other joints that suffer from osteoarthritis or have had previous 
arthroplasty may theoretically affect subsequent function, the exclusion criteria was 
set to prevent recruiting patients whom it was felt suffered functional limitation due 
to these other joints, and again the randomised nature of the trial limited any specific 
effect on the between group differences. The overall function of both groups can be 
reported as excellent, and it is unlikely that any such influences affected the mean 
post-operative function of either group. 
 
All surgical and post-operative factors were kept identical as far as possible. Routine 
surgical procedures and post-operative care were not affected by recruitment to the 
trial, and the researcher performed all post-operative clinical assessments adhering to 
local clinical protocol blinded to the underlying prosthesis. Other implant factors that 
are thought to impact outcome such as bearing surface and cruciate retaining design 
were also identical. 
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The lack of clarity as to which outcome measures should be employed to investigate 
research of this nature in clinical populations demanded a pragmatic and 
comprehensive trial design, thus a blinded randomised controlled trial was chosen. A 
particular problem when designing this study was the lack of information as to the 
relative importance, and indeed relationship between, patient report measures of 
outcome and performance measures of outcome. The data collected in this study will 
be analysed to allow comment on these issues (and is presented in Chapter 4). Had 
this information been available prior to the development of this trial, it may have 
driven the specific design and outcome measures employed. The absence promoted 
the most pragmatic trial design that would confer information through various 
assessments as the most appropriate methodology to assess the question of power 
output, and also put that information into context within the wider sphere of patient 
outcome. This has been achieved, and information is now available to further assess 
the relationship between different types of outcome assessment tools. 
 
Alternative trial designs, such as a cohort study, utilising additional specific testing 
of the quadriceps muscle group by means of perhaps isokinetic dynamometry and 
imaging modalities (to assess the muscle cross-sectional area) could also be 
employed to investigate the specific differences pertaining to the extensor 
mechanism muscle function. It was not possible to include such intensive analysis 
tools within the context of the study that was performed, due to the multi-modal 
assessment protocol that was required. Additionally clinical time constraints and the 
size of the population assessed limited such detailed evaluation. An additional cohort 
study may provide advantageous supplementary information by which to assess the 
specific issue of the muscle function facilitated by these differing implant designs. 
 
Conducting a cohort study of a specific population group with a restrictive inclusion 
criteria may hypothetically have reduced the standard deviation of the power output 
scores, aiding interpretation of the between group results. In terms of the hierarchy of 
evidence however, the RCT is a superior methodology to the cohort study as it 
minimises the chance of bias through the randomisation process. This limits the 
 
 89 
chance of (previously unknown) confounding variables differing between the groups. 
From a statistical perspective, the randomised nature of the trial conducted justifies 
the pragmatic inclusion criteria. The baseline power data was found to be comparable 
in each arm of the trial, and was strikingly similar when assessed against the internal 
control of the contralateral limb. This strengthens the conclusions of this chapter 
regarding the influence of the implant design on the subsequent power output. 
 
The Kinemax total knee replacement is an older implant of 2
nd
 generation design, 
while the Triathlon total knee replacement is of 4
th
 generation lineage. The major 
difference that distinguishes these implants is that they are based on alternative ideas 
regarding the underlying kinematics of the knee. Further differences do however 
exist between these implants that could in principle also affect subsequent patient 
outcome. Additional design changes incorporated into the Triathlon implant that 
differ form the Kinemax include a ‘sided’ patello-femoral grove, decreased size but 
increased angle of anterior flange (reducing the patello-femoral bulk of the 
prosthesis) and a shortened posterior condylar offset (These changes are visualised 
for clarity in Appendix I). The changes to the anterior aspect of the implant may 
influence such factors as anterior knee pain, and the posterior condylar offset the 
flexion achieved (Nutton et al, 2008). A third arm comparing another, more modern, 
multi-radius implant that incorporates some of these additional design changes would 
have been beneficial to address the extent to which these additional factors 
influenced the overall patient outcome.  
 
It was necessary to compare the new Triathlon implant with an established current 
implant that demonstrated 10 year survival to benchmark the new design in 
accordance with best practice (BOA / BASK, 2010). The Kinemax knee 
replacement was a good example of a successful ‘condylar’ multi-radius implant 
(Wright et al, 2004; Back et al, 2001), further Pradhan et al (2006) note similar 
survival curves and generally good 10 year performance of all the condylar devises 




In conclusion, this double blind randomised controlled trial demonstrated functional 
differences in overall patient outcome based on the implant used at time of surgery. 
The modern implant design allowed enhanced patient function as observed by the 
change in OKS and an additional raft of outcome assessment tools.  
 
The most striking difference detected between the implant groups was in the lower 
limb power output of the patients, a factor specifically predicted by the axis of 
rotation related design changes through an enhanced moment arm of the extensor 
mechanism. Support can be lent to the single radius design improving quadriceps 
function post-operatively through mechanically reducing the work the quadriceps 
muscle need perform to extend the knee. The wider effect of this difference in 
quadriceps power and further relationship between patient reported outcome and 
direct assessment of outcome is developed in the following chapter. 
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4 The Role of Patient Report and Performance Assessment 




Assessment of outcome has shifted away from the dichotomous criteria of success or 
failure and towards the use of quantifiable outcome measures. The use of patient 
reported outcome measures (PROMs) to assess functional outcome and quality of life 
following TKA has now been adopted as a requirement of all providers of elective 
arthroplasty surgery of NHS patients (DoH, 2008). Advocates of these patient 
reported tools suggest that they provide a sophisticated measure of whether a 
treatment has worked in terms of how much better a patient feels (Timmins, 2008). 
Terwee et al (2006) define a performance measure as one in which the individual is 
asked to perform an activity that is evaluated in a standardised manner using 
predefined criteria such as time taken. Self report assessments are ones in which 
individuals are asked to report their perceived level of functioning during daily 
activities described in standardised questions. 
 
Recently a small number of authors have suggested that PROMs alone are not 
sufficient to assess patient outcome. Mizner et al (2011, published ahead of print) 
argue that patient report measures fail to capture the actual changes in functional 
performance after TKA. Performance assessments are additionally required to obtain 
the full picture of the patient’s physical function (Stratford and Kennedy, 2006). The 
benefits and limitations of each type of assessment have been discussed in Chapter 2, 
though it is specifically suggested that the patient report measures have low construct 
validity, and that this is perhaps due to an influence of pain (Terwee et al, 2006; 
Stratford et al 2006). Despite this, Bream et al (2009) claim that patients are the ‘gold 
standard’ judges of symptoms and quality of life, and that PROMs thus provide an 




Scant analysis has been conducted directly comparing patient report and performance 
data, and only one recent study (Mizner et al, 2011, published ahead of print) has 
assessed how this relationship changes over time following TKA. The Mizner et al 
paper reports poor concurrent validity between the assessment types and that patient 
report measures overstate the functional ability of the patient, particularly in the 
acute post-operative phase. These authors compared the responsiveness of the two 
types of outcome assessment over time, but did not investigate the relationship 
between assessments at individual time points. 
 
Beard et al (2010) pragmatically note that the choice of outcome assessment tool will 
depend on a variety of factors relating to the aim of the assessment, its context and 
the level of detail required. It remains somewhat unclear as to the most appropriate 
method of examining function following TKA, and how to interpret the results. The 
association between patient report and performance data has not been previously 
investigated in sufficiently large volume to answer these questions.  
 
A large volume of performance data was presented in the previous chapter, 
prospectively collected in tandem with the patient reported Oxford Knee Score. The 
separate performance measures and pain assessments are examined against the 
patients’ report of pain and function via the OKS with the aim of assessing the 
association between the two types of measurement at the different time points.  
 
It is hypothesised that correlation will be apparent between the OKS and the 
additional pain and performance measures and further that the variation in OKS 






The patient outcome data recorded as part of the RCT presented in the previous 
chapter was assessed to determine the relationship between patient report outcome 
measures and direct assessment of patient physical performance. This data was 
recorded for patients listed for TKA pre-operatively and at 6 weeks, 6 months and 12 
months post-operatively.  
 
The Oxford Knee Score is a widely employed patient derived outcome questionnaire 
(KAT trial group, 2009; Davies, 2002). It consists of 12 equally weighted questions 
addressing pain and functional activity, each scoring form 1 – 5. Best possible scores 
are 12 and worst 60. It is a joint specific instrument that was developed to assess the 
outcome of knees in randomised trials and has undergone rigorous assessment of 
reliability, validity and responsiveness. Specific attempt was made during the 
construction of the OKS to minimise the influence of comorbidities (Murray et al, 
2007).  
 
The additional physical performance assessments were the Aggregated Locomotor 
Function test, lower limb power output (Leg Extensor Power Rig) and goniometric 
assessment of knee flexion. For the pain component, both the 11 point (0-10) 
numerical rating scales for average and maximal pain experienced were assessed. 
The individual assessment tools have been described previously (Methods section, 
Chapter 3).  
 
The additional pain and physical outcome assessments were compared against the 
patient report of these parameters (OKS) to determine the extent of the variance of 





Data was analysed using the Minitab (release 15) software. Differences in outcome at 
each assessment between the outcome measures were assessed with paired samples t-
tests.  
 
Correlation of performance variables with the OKS was assessed, and regression 
analysis performed on those that formed significant associations. Multiple linear 
regression analysis was employed using a stepwise model building technique to 
screen out predictors not associated with the response. Significance was accepted at p 
= 0.05. The adjusted R
2
 value (adjusted for the number of predictors in the model) 
and Mallows Cp statistic (to assess how well the model fits the data) are reported to 




Data for 183 cases were available for analysis. Mean age of the patients was 68.4 
(9.03) years, the gender split was 71 male (38.8%) to 112 female patients (61.2%). 
Table 4.1 displays the mean score for each of the outcome assessments at each time 
point. 
 
Table 4.1 – Mean outcome scores for all assessment time periods 
 
 Pre-op 6 weeks 6 months 12 months 
     
OKS 40.87 (7.519) 32.58 (8.99) 24.97 (8.24) 22.17 (7.90) 
Flexion 104.70 (14.62) 96.39 (13.22) 104.27 (12.35) 107.30 (11.76) 
ALF 35.38 (14.24) 31.64 (11.51) 26.55 (7.77) 25.61 (6.60) 
Power 44.40 (40.79) 52.72 (35.91) 74.72 (42.18) 83.33 (47.32) 
Pain (Max) 8.27 (1.46) 5.34 (2.53) 3.00 (2.70) 2.35 (2.57) 
Pain (Ave) 5.37 (1.54) 2.97 (2.01) 1.52 (1.80) 0.98 (1.53) 
 
 
Mean (SD) scores are displayed for all variables. OKS = Oxford Knee Score, ALF = 
Aggregated Locomotor Function score (seconds), Power output (watts), Maximal and 
Average Pain scores (0-10 NRS). 
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All variables, changed significantly between each assessment time point (paired 
samples t-test, p = < 0.001 in all cases). This change was almost universally positive 
in nature, the only exception being a reduction in flexion from pre-operative to 6 
week post-operative assessment. 
 
Relationship of OKS with pain and functional measures over time 
 
Correlation coefficients are displayed in table 4.2 for the relationship between 
Oxford Knee Score and the functional parameters at all assessments. Highly 
significant correlations (p = <0.001) were found between the OKS and all other 
assessments. Generally, high levels of correlation (r = 0.6 - 0.7) were seen between 
the OKS and pain reports post operatively, though these were less well associated 
pre-operatively (r = 0.4). Functional parameters (ALF and power output) were 
modestly associated (r = 0.4) with OKS, and measure of knee flexion the least well 
correlated variable (r = 0.3).  
 
Table 4.2 – Correlation of OKS with pain and performance variables 
 
 Pre-op 6 weeks 6 months 12 months 
     
OKS and ALF 0.31 0.41 0.54 0.49 
OKS and Power 0.39 0.37 0.37 0.39 
OKS and Flexion 0.36 0.27 0.25 0.25 
OKS and Average Pain 0.44 0.60 0.63 0.70 
OKS and Maximal Pain 0.35 0.60 0.61 0.65 
 
 
Individual correlation coefficient r values are displayed for each variable at each assessment 
time point, p = <0.001 in all cases 
 
 
Pre-operatively, both pain and function (ALF) assessments were less well correlated 
to OKS than they are post operatively. The relationship with power remain stable 
both pre and post-operatively. Post-operative correlation between the OKS and both 
power and pain was relatively stable across the assessments, suggesting a similar 
magnitude of improvement in both the OKS and these measures over this time period 
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(Figure 4.1 and 4.2). Correlations with ALF score however improve over time 
(Figure 4.3).  
 
Figure 4.1 - Relationship between Oxford Knee Score and pain report. Figure 
demonstrates the linear relationship between maximal pain report and the OKS at all 
4 assessments. The top figure displays the regression on the underlying scatter plot 
of the data, the bottom figure the individual regression lines for clarity. The gradient 
of the regression lines are comparable at each post-operative assessment, though 



























































Figure 4.2 - Relationship between Oxford Knee score and power output. Figure 
demonstrates the linear relationship between maximal lower limb power output and 
the OKS at all 4 assessments. The top figure displays the regression on the 
underlying scatter plot of the data, the bottom figure the individual regression lines 




























































Figure 4.3 - Relationship between Oxford Knee Score and functional assessment. 
Figure demonstrates the linear relationship between functional assessment (ALF) 
time and the OKS at all 4 assessments. The top figure displays the regression on 
the underlying scatter plot of the data, the bottom figure the individual regression 
lines for clarity. The gradient of the regression lines is similar at 6 and 12 months 
post-operatively, but notably different at the other assessments, highlighting the 
























































Regression of OKS and ALF at 4 assessment points
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Pain was less well correlated with the functional assessments (ALF and power 
output) than it is with the OKS, these correlations are displayed in table 4.3. Pain 
correlated consistently poorly with both ALF and Power assessments at all 
assessments (r = 0.15 - 0.30). The power and ALF scores were modestly correlated (r 
= 0.5) and this relationship remains stable throughout the assessments. The separate 
measures of pain correlate highly in the first three assessments (r = 0.8) though 
modestly at 12 month follow-up. Comparative decrease in both maximal and average 
pain was seen at earlier assessments (Table 4.1). The treatment effect of the TKA 
results that many patients report no pain at 12 months. This affected the resultant 
correlation between pain assessments. Despite high degree of correlation between 
average and maximal pain report, the maximal report of pain does not correlate with 
either power or ALF assessment pre-operatively, though average report of pain does 
so poorly. 
 
Table 4.3 – Correlation of pain and performance variables 
 
 Pre-op 6 weeks 6 months 12 months 
     
ALF and Average Pain 0.17 (p=0.02) 0.27 0.27 0.25 
ALF and Maximal Pain 0.03 (p=0.63) 0.26 0.25 0.25 
     
Power and Average Pain 0.30 0.30 0.21 0.21 
Power and Maximal Pain 0.06 (p=0.47) 0.30 0.15 (p=0.05) 0.19 
     
ALF and Power 0.49 0.55 0.48 0.48 
     
Average and Maximal Pain 0.76 0.83 0.75 0.49 
 
 
Correlation coefficient r value is displayed, p = <0.001 unless stated. Non significant results 
highlighted in bold type. 
 
 
Multiple linear regression demonstrated that the results of the pain and functional 
assessments explain much of the variance in OKS post-operatively. Functional 
measures, pain assessment and demographic variables were assessed as to their 
relevance to the OKS outcome; the results are displayed in table 4.4. Only pain 




Stepwise regression modelling was performed to screen out predictors not associated 
with the response variable (OKS) based on the criteria of alpha (to enter or remove 
from the model) of 0.05. Results are displayed in Table 4.4. 
  
Table 4.4 – Multiple linear regression analysis for OKS at each assessment 
 
 Pre-op 6 weeks 6 months 12 months 
     
Flexion 0.069ns 0.057ns 0.671ns 0.273ns 
ALF <0.000 0.005 <0.000 <0.000 
Max Pain 0.017 0.005 0.001 <0.000 
Ave pain 0.006 0.001 0.055 <0.004 
Power 0.022 0.020 0.015 0.003 
Gender 0.225ns 0.071ns 0.228ns 0.210ns 
Age 0.184ns 0.027 0.004 0.254ns 
     
Stepwise model     
     
Adjusted r
2
 34.8 44.0 56.9 62.3 
Mallows Cp 8.3 10.7 7.3 6.4 
     
 
Multi-variant regression analysis for OKS at each time point, p-value reported for individual 
factors, significance accepted at p = 0.05, non significant results noted (ns). Stepwise 
regression models were constructed. Regression coefficients are displayed for these at each 
time point. Full data output displayed in Appendix D. 
 
 
At 12 months, the regression model included maximal pain, ALF, average pain and 
power output (explaining 62.3% of the variation in OKS). At 6 months, the model 
consisted maximal pain, ALF, age and power output (explaining 56.9%). At 6 weeks 
the model consisted of maximal pain, ALF and average pain (explaining 44.0%). 
Preoperatively the model consisted average pain, ALF, maximal pain and flexion 
(explaining 34.8%). See Appendix D for statistical data output.  
 
Of all the assessments conducted, pain appeared to be the dominant factor in the 
variation of the OKS at every assessment. Table 4.5 displays the contribution of the 
factors that best explained the variation in OKS; pain report (maximal and average), 
ALF score and power output. The regression best explained the variation in OKS at 
all time points, however the report of pain demonstrates values only slightly less than 
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those of the multiple response analysis, again highlighting its stronger association 
with the OKS compared to the functional assessments.  
 
Table 4.5 – Comparison of regression model with pain and function values 
 
 Regression model Pain reports ALF score Power output 
     
Pre-op 34.8 20.4 17.9 14.4 
6 weeks 44.0 40.0 15.9 13.4 
6 months 56.9 41.4 29.2 13.2 





 values are displayed for both multiple and simple regressions to allow direct 
comparison. 
 
Pre-operative predictors of 1 year patient outcome 
 
Multiple linear regression analysis and then stepwise regression modelling was 
performed (alpha to enter or remove from the model of 0.05) to assess the pre-
operative predictors of post operative OKS. Results are displayed in table 4.6, see 
Appendix D for statistical data output. 
 
The pre-operative assessments are poor predictors of post-operative patient reported 
outcome. Table 4.6 highlights this poor relationship. Only pre-operative OKS was 
significantly related to post-operative values at any time point. This score predicted 




Table 4.6 – Pre-operative predictors of post-operative OKS 
 
Pre-op predictor 6 weeks 6 months 12 months 
    
Flexion 0.528ns 0.469ns 0.563ns 
OKS <0.001 <0.001 0.028 
ALF 0.043 0.134ns 0.533ns 
Power 0.703ns 0.533ns 0.341ns 
Pain (Max) 0.827ns 0.962ns 0.457ns 
Pain (Ave) 0.807ns 0.134ns 0.220ns 
Gender 0.725ns 0.509ns 0.162ns 
Age 0.423ns 0.162ns 0.536ns 
    
Stepwise model    
    
R-Sq (adjusted) 20.4 17.1 8.2 
Mallows Cp 0.3 1.1 2.6 
    
 
Multiple regression for 12 month OKS using pre-operative variables. p-values reported for 
individual factors, significance accepted at p = 0.05, non significant results noted (ns). 
Stepwise regression models were constructed. Regression coefficients are displayed for 





Recently the relationship between direct assessment of function and patient reported 
function has been questioned, with some authors claiming PROMs are inadequate to 
assess function, and that performance data is required to supplement them. Little 
prospective patient report and performance data has been concurrently collected with 
which to draw conclusions as to the relationship between the two types of 
assessment. No previous study has used multiple linear regression analysis to 
compare patient report and performance data at multiple time points. 
 
This study analysed 183 datasets pre-operatively and at a further 3 assessments in the 
year following TKA. The highly validated and well utilised OKS that assesses 
patients’ pain and function was compared with direct measurements of these 
attributes. In addition to the composite ALF timed test of function, specific power 




As expected, significant correlations were found between the Oxford Knee Score and 
separate specific assessments of pain and functional outcome. Additionally highly 
significant correlations between OKS and both lower limb power output and knee 
flexion were also observed (Table 4.2).  
 
The relationship between OKS and separate pain and functional measures over the 
assessment period is displayed in the Figures 4.1, and 4.3. The good relationship 
between patient report of pain (NRS) and patient report of joint specific pain and 
function (via the Oxford Knee Score) remains similar throughout the assessment 
period, though the correlation is weaker pre-operatively (Figure 4.1). The changing 
relationship between timed assessment of function and OKS is displayed in figure 
4.3. This correlation between functional assessment and report of function improved 
over the rehabilitative period, and coincides with substantial reductions in reported 
pain post-operatively (Table 4.1).  
 
It has been suggested that pain interferes with patient report of function and these 
results provide support for this assessment. Stratford and Kennedy (2006) examined 
the association between performance rated assessments of pain, functional tests and 
the WOMAC self report of pain and physical function in 85 patients suffering from 
osteoarthritis. Interestingly, they found pain to be the strongest determinant of the 
WOMAC function sub-score, and change in pain the strongest determinant of change 
in functional score. They used this data to suggest that patients report their 
experience of performing an activity, while the ability to perform the activity is 
assessed by the performance measure.  
 
The data presented in this chapter provided support for this theory. Pain scores were 
particularly well associated with the OKS while timed functional ability was 
modestly associated. Pain is poorly correlated with composite functional activity 
time achieved (r = 0.25, Table 4.3). This was unexpected as pain is known to limit 
physical function, particularly in the case of osteoarthritis of the knee. While a 
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significant association is apparent, the proportion of variation explained is only of the 
order of 6%. 
 
It is notable that as the effect of pain is reduced in the year following surgery, the 
association between ALF and OKS improves. The theory of pain levels affecting 
reported level of functional ability fits well with the improving relationship of 
reported function and direct assessment of that function as the pain level experienced 
reduces post-operatively.  
 
It has been well documented that range of motion does not affect functional outcome 
(Nutton et al, 2008), and thus unsurprising that this was confirmed here. That the 
maximal lower limb power output did not interact strongly with either OKS or 
reports of pain is however interesting. Previous authors have demonstrated the link 
between pre-operative strength and post-operative function (Faulkner et al, 2010; 
Mizner et al, 2005b; Lingard et al, 2004; Lamb and Frost, 2003). The association 
between power and function is confirmed in this study, through modest correlation 
with both ALF score (r = 0.5) and OKS (r = 0.4) at all assessment points (Table 4.2 
and 4.3). The striking stability of both these relationships at all 4 assessment times 
confirms the link between power and function, but also highlights the differing 
relationship found between the objective timed functional assessment (ALF) and the 
OKS.  
 
Surprisingly, pain does not seem to influence the maximal power output achieved as 
poor correlation of these variables was found (Table 4.3). Further, maximal pain 
levels reported pre-operatively had no interaction with the ability to generate force. 
The power output is an objective test that results in ratio level data. This therefore 
suggests that any error in measurement is likely to be attributable to the patients’ 
report of pain. It is very difficult to rate the level of pain one is experiencing 
objectively as it is linked to prior experience of pain, attitude towards pain and 
coping strategies developed to deal with it. It must be assumed that patients try to 
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report this pain as best they can and that it is the complexity of the constituents of the 
pain experience that clouds the report. 
 
Pre-operative patient report of maximal pain did not correlate with either power or 
ALF score. This may reflect an inaccurate report of this constituent of pain intensity 
and behaviour. At the same time point, report of average pain does correlate with 
both physical measures albeit poorly. Interestingly average and maximal pain reports 
were found to correlate highly to each other pre-operatively. It may be that these 
differences found highlight the differing components of pre-operative pain reported 
by the two separate measures. This lends support for a more rigorous assessment of 
patient pain report than can be achieved by a single average of overall pain. 
 
Change over time 
 
The results demonstrate (with the notable exception of range of knee flexion) that all 
aspects assessed significantly improved from pre-operative values by the initial six 
week assessment, and then subsequently improved further by six months and again 
by one year assessments (Table 4.1). This is in direct contrast to the only other study 
that has assessed how the PROMs / physical performance relationship changes over 
time (Mizner et al, 2011 published ahead of print).  
 
Mizner et al (2011, published ahead of print) assessed the relationship between 
patient report of function (via SF36 questionnaire) and various performance 
measures in 100 patients prior to TKA and at one and twelve months post-operation. 
They report that physical measures provided a more comprehensive perspective of 
recovery after TKA as the patient report measures did not reflect the acute worsening 
of scores seen in the performance measures at four week assessment. Patients in this 
study actually reported improvements on the SF36 questionnaire where deficits were 




Mizner et al. use this information to criticise the ‘over-estimation’ of patient report 
data in the acute post-operative phase. It may be that the two week difference n 
assessment time between this study and that of Mizner et al. is highly important in 
the recovery following TKA. The Mizner group are the same authors that vigorously 
promote the idea of failure in voluntary activation of the quadriceps muscle in the 
early post-operative phase accounting for much of the poor functional performance 
post-operatively. This, and potentially a difference in the post-surgical pain 
experienced, having reduced further in the extra two weeks post-operatively may 
help explain why the results presented here differ so markedly.  
 
Stratford and Kenndey (2006) note that correlations of the value r = 0.4 to 0.6 
between performance and self report assessments have been used to argue that a 
common attribute is being assessed. Correlations however can only assess whether a 
relationship exists between two variables, only regression analysis assesses the extent 
to which variation in the response variable is explained by variation in the predictor 
variables. Regression analysis of the larger of these suggested correlations would 
result in R
2
 values of around 0.36, i.e. that one variable explains’ around a third of 
the variation in the other, and not that a common attribute is being assessed.  
 
The regression analysis performed with this data demonstrates that the pain 
component accounts for the largest proportion of variation in the OKS. Multiple 
regression models were created using the stepwise modelling approach with the 
addition of the ALF score, though few other variables were relevant (Table 4.4 and 
Appendix D). 
 
Around 60% of the variation in OKS was explained by assessment of pain and 
performance variables at six and twelve months. The poor pre-op relationship of 
around 35% variation further highlights the inconsistent relationship between the 
patient reported data and that directly assessed, possibly due again to the pain 
influence (highest levels are reported pre-operatively, Table 4.1) as suggested.  
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Even the best regression equations derived fail to explain around 40% of the 
variation in OKS post-op. Many other factors are known to influence post-operative 
outcome, in this case gender did not, age did at the early assessments, specific co-
morbidities or influences of other joints were not assessed, though all data is drawn 
from the RCT reported in the previous chapter that had inclusion criteria relating to 
reasonable physical function and will have diluted any such effect. Further the 
factors relating to the centre and surgeon volume are not likely to be relevant in this 
case as all operations were conducted at the Royal Infirmary of Edinburgh by 
experienced consultants, and technically performed in the same manner as part of the 
randomised trial. 
 
The pre-operative functional and pain measures were unable to explain any of the 
variance in post-operative OKS at any time point. Only pre-operative OKS displayed 
any effect in predicting post-op score. Interestingly, the relationship was strongest at 
early assessment and diluted with time post-operatively (Table 4.6). This was an 
unexpected finding and somewhat at odds with the accepted understanding that pre-
operative function should be considered as a co-variable in analysis of change in 
function. It highlights the widely varying levels of patient outcome and the 
complexity of trying to analyse this. 
 
Difference in patient report and direct assessment of outcome is important, as it has 
been suggested that patient reported assessment can be used instead of direct 
assessment (Bellamy et al, 1997). It has previously been suggested that while both 
are acceptable outcome assessments, they are complementary (not equivalent), and 
should be reported as such (Hamilton et al. conference abstracts, Appendix B). It was 
previously reported in a study of 100 patients that patient reported outcomes 
correlate well to each other and to pain, but not to specific functional assessments 
following knee arthroplasty. Oxford Knee Score and the Physical Component Score 
(PCS) of the SF-12 questionnaire were found to correlate highly (r = 0.74, p = 0.001) 
at both six and twelve months post-op. Comparative correlations to the ALF timed 
score and power output were found to be poor – modest (r = 0.2 - 0.4) for both OKS 
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and SF-12 PCS (Hamilton et al. Orthopaedic Research Society 2010 extended 
abstract, Appendix B).  
 
A theoretical assessment framework can be drawn that helps explain some of the 
differences between the assessment types (Figure 4.4). This framework is loosely 
based on the WHO classification of impairment, disability and handicap. The 
arthroplasty (in this case TKA) can be assessed at various levels in the body: at the 
level of the implant, the limb, or in the person as a whole. Different assessments are 
required to ascertain information about each level. Performance data generally 
assesses function of the limb, while patient reported information reflects the issues 
(related to their pathology, pain, further symptoms or surgery) perceived by the 
individual about their functioning in society. 
 
It is notable that the strong association between PROMs and pain report highlighted 
previously occur at the same level of this model, whereas the weaker associations 
between performance data and self report are comparing across levels, this may help 




Figure 4.4 - Clinical assessment framework. Figure displays a theoretical 
hierarchical model that demonstrates the differing levels of information assessed by 





The most effective way to consider this model is to take the example of a poorly 
functioning TKA.  Clinically, information is sought about the functioning of the 
implant specifically via radiographs. Consideration is then given to component 
positioning or perhaps loosening. At the same time a clinical examination is 
performed to ascertain the functional limitations of the limb, and the patient’s report 
of their pain and functional difficulties discussed to determine the most appropriate 
further treatment options.  
 
This example also highlights the hierarchical nature of the model, where appropriate 
level of assessment is required to determine problems that relate to that level. A 
poorly functioning implant (perhaps due to malalignment) may influence the limb, 
manifested in poor range of motion and walking ability, and further affect the 













Clinical assessment framework 
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via pain. Whilst the dysfunction can be screened by any level of assessment, only 
radiographs will ascertain the actual underlying issue. This may reflect the 
relationship between PROMS and performance data, where physical dysfunction of 
the quadriceps can be inferred by the PROMS but only confirmed by direct 
assessment. This may explain why the substantial differences observed in lower limb 
power in the previous chapter did not result in large differences in patient reported 
score, and confirms that the specific analysis of the power output employed in the 
previous chapter was required to assess this specific parameter.  
 
Confounding variables such as mental health issues (depression, anxiety) that are 
known to relate to the outcome of TKA will have largest influence at the level of the 
person. The results presented here, and those of Mizner et al (2011) and Stratford and 
Kennedy (2006) suggest that the role of pain is also most influential at this level of 
the suggested model.  
 
In conclusion, this was the most comprehensive analysis of a large sample of TKA 
patients to assess the relationship between physical performance and the patient’s 
report of that performance prior to and following surgery. Further, it is the first 
analysis to present regression models at all assessment points to reflect how the 
relationship between these two types of assessment changed over time.  The patient’s 
report of their function and direct assessment of that function became more closely 
associated over time following surgery. Pain was found to be the dominant factor 
that explained the variation in the OKS, and the improved relationship between 
performance and report of performance improved as the report of pain diminished. 
The hierarchical clinical assessment model presented suggests a link between direct 
functional assessment and patient reported function. This conceptual framework 
helps explain the link between lower limb power output and overall patient function. 
 
 111 
5 Influence of the Musculature on TKR Outcome: 




It has previously been demonstrated that the individuals’ lower limb power affects 
their physical functioning following total knee arthroplasty (Lamb and Frost, 2003). 
Clinically, it is thought that pre-operative physical function and lower limb power are 
relevant to the patients’ post-operative physical outcome, as correlation of these 
measures has been demonstrated (Faulkner et al, 2010; Lingard et al, 2004). 
 
Thirty percent (30%) strength deficits compared to aged matched controls have been 
demonstrated in TKA patients (Silva et al, 2003). Measurements of muscle atrophy 
has not been able to explain this discrepancy, Mizner et al (2005a) found only a third 
of strength deficits in the early post operative phase could be accounted for by 
reduction in muscle mass. Longer term deficits are as yet unexplained. No 
consideration has been given to the ‘regenerative potential’ of the musculature to 
explain post-operative power output following knee replacement. 
 
Muscle satellite cells are undifferentiated myogenic precursors that sit in quiescence 
below the muscle sarcolemma. In normal muscle, satellite cells respond to 
regenerative cues such as injury or exercise, by proliferating to form myoblasts, 
which divide a limited number of times before terminally differentiating and fusing 
to form multinucleated myotubes (Hawke and Garry, 2001; Morgan and Partridge, 
2003; Wagers and Conboy, 2005; Zammit et al, 2006) to provide new myonuclei for 
the homeostasis, hypertrophy or repair of the muscle fibres (Figure 2.5). Any 
situation that requires either the repair of existing myofibres or the creation of new 
myofibres such as the rehabilitation process following TKA relies on the ability of 
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the muscle satellite cell to generate new myoblasts, as has been previously discussed 
(Chapter 2).  
 
It has been suggested that the number of satellite cells in an individual is variable and 
factors such as aging (Renault et al, 2002; Kadi et al, 2004; Verdjik et al, 2007) and 
level of exercise (Chafri et al 2003; Mackey et al, 2007; Kadi et al, 2010) can affect 
this number. However human studies to date have involved only small numbers of 
healthy subjects. The relative number of cells in a typical osteoarthritic or knee 
arthroplasty population is unknown, and no study has considered the effect of the 
muscle satellite cell on post operative recovery following knee arthroplasty, or any 
other orthopaedic procedure. 
 
It was hypothesised that; (1) variation would exist in the number of satellite cells in a 
cohort of total knee arthroplsty patients, that (2) differing levels of recovery of 
muscle strength following surgery would be apparent, and that (3) this recovery 






Patients were recruited from the operating list of a single consultant surgeon. 
Inclusion criteria for participation was that patients were suffering from unilateral 
osteoarthritis of a severity that was suitable for joint arthroplasty, but were otherwise 
healthy (i.e., not suffering form any comorbidities that would affect their post 
operative recovery or subsequent physical performance, such as cardiovascular or 
neurological disease). Further that the planned procedure was ‘routine’ primary total 
knee arthroplasty, i.e. the first surgical procedure on the osteoarthritic joint, 
performed with standard implants, without the addition of any augments. Local 
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approval was granted for the study by Lothian Research Ethics Committee and NHS 
Lothian Research and Development Management.  
 
Suitable patients were approached at the time of pre-operative assessment, 
approximately 2 weeks prior to surgery, and were recruited through informed 
consent. 18 patients were recruited to the study, although 2 were subsequently 
withdrawn due to surgical complications. Thus 16 patients completed the study 
protocol. 
 
Of the withdrawn patients, one acquired a deep infection in the early post-operative 
phase, the other was found at the time of surgery to have significant synovitis and a 
subsequent post-operative flare-up of previously undiagnosed rheumatoid arthritis. 
Both patients were unable to undertake the post-operative power assessments. 
 
Power output assessment 
 
Specific assessment of the recovery of muscle strength in the cohort was assessed by 
use of a Leg Extensor Power Rig (Queens Medical Centre, Nottingham, NG7 2UH) 
which has been well validated for use with this population group (Lamb and Frost, 
2003; Bassey et al, 1990; Robertson et al, 1998). The Leg Extensor Power Rig has 
been described previously (Chapter 3). The test procedure followed that suggested by 
Robertson (1998) as was adhered to and detailed in Chapter 3. Application of force 
accelerated the flywheel from rest, and output was recorded as both maximal wattage 
(W) generated and relative power to body weight ratio (%) of a single leg extension. 
Those not able to complete the test were assigned a score of zero as advocated by 
Lamb and Frost (2003). After each attempt, the force produced was recorded. The 
highest recorded output was used for analysis as suggested by Barker and Simpson 
(2004). Body weight (Kg) was measured prior to leg power testing separately at each 
time point using a calibrated set of Seca 761 Approved Medical Mechanical Floor 
Scales (Class IIII). 
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Baseline power output was assessed at pre-operative assessment, then post-
operatively at routine outpatient clinical review at 6 weeks and 26 weeks post 




The muscle sample was obtained from distal quadriceps by the same surgeon during 
the knee arthroplasty via the consultant’s routine incision for this procedure. The 
biopsy technique was standardised and the sample of tissue was harvested approx 5 
cm proximal to the superior pole of the patella, dependant on the tissue quality of the 
individual. Samples were immediately fixed (in the operating theatre) in 10% neutral 
buffered formalin (4% formaldehyde in phosphate buffered saline) then kept in a 
fridge for 24 hours. Subsequently the samples were immersed in 70% ethanol before 




7 μm sections were cut on a microtome; multiple sections were cut from all samples. 
Mayer’s haematoxylin and eosin (H&E) staining was performed to ensure the muscle 
tissue quality was satisfactory using a standard local protocol (Appendix E). 
 
Satellite cells were identified by an immunofluorescence microscopy protocol using 
a primary mouse antibody for Pax7 and goat anti-mouse fluorescently labelled 
secondary. Counterstaining with DAPI (4’, 6-diamidino-2-phenylindole), a 
fluorescent stain that binds to DNA, established the position of the nuclear material 
within the cell. 
 
Induction of Pax7 is the mechanism by which pluripotent stem cells within the 
muscle tissue specify into the myogenic precursor satellite cells (Seale et al, 2000; 
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Hawke and Garry 2001; Buckingham, 2007). Pax7 has been reported to be present in 
all adult muscle satellite cells, and is a robust marker of these. As discussed in 
Chapter 2 there is some debate as to the relative benefits of using antibodies against 
Pax7 or NCAM. Both markers were trialled, but because Pax7 achieved a far greater 
staining efficiency, this marker was used for the quantification of satellite cells in the 
present study. 
 
The wax embedded slides underwent a local standard de-waxing protocol, using 
xylene and graded ethanol baths (Appendix E), then antigen retrieval, using sodium 
citrate (Appendix E). Sections were then loaded onto sequenza plates for 
immunofluorescence staining.  
 
Slides were washed in PBS (without calcium and magnesium) before adding 3 drops 
Protein Block (AMS biotechnology Abingdon, Oxon, OX14 4RX cat DPB-125) 
solution for 30 minutes at room temperature. Primary mouse anti-human Pax-7 
antibodies were diluted (1:150), to appropriate concentration in the protein block 
solution and 250l was added to each slide for 1 hour at room temperature. The 
slides were washed three times in PBS, and Alexa Fluor (Invitrogen) goat anti-mouse 
488 (red) 1:500 secondary antibodies were added for 30 minutes at room temperature 
in the dark. A further 4 washes in PBS were done before dehydrating the slides in 
100% ethanol and drying. The slides were then mounted with Vectashield hardest 
mounting medium with DAPI for fluorescence (Vector laboratories, Burlingame, CA 
94010, cat H-1500). 
 
A control experiment was run in parallel with all sections that followed the exact 
protocol, but did not include primary antibodies for each section to ensure antibody 
specific staining. 
 
Images of the sections were captured on a Zeiss Axioscope II MOT compound 
microscope under a 20x objective equipped with a Hamamatsu Camera Controller 
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(ORCA-ER) and OpenLab 4.0 image analysis software (ImproVision, Coventry, 
UK). Fluorescent images were then merged using Photoshop (Adobe®). Positive 
identification of satellite cells was determined by immunofluorescent staining in 
association with nuclear material, and by position under the basal lamina. 
Three separate areas of each section were imaged and counted separately. In each 
image, the number of muscle fibres, satellite cells and myonuclei were counted, the 
average count of the section was used for analysis. The counting of cells on each 
image was repeated three times to ensure consistency. The cell positive staining 
index (PSI) was calculated (no of satellite cells/total no of myonuclei x 100). The 
count was made by a single individual (the author) blinded to the patient identity 




Statistical analysis was carried out with the Minitab (release 15) software. All data 
was assessed visually for normality. Differences in power outcome scores across the 
3 assessment time points were assessed by paired sample t-tests. Strength of 
correlation between power output and satellite cell number was assessed with the 
Pearson product moment correlation coefficient and simple regression analysis 
performed to quantify this association. Multiple linear regression analysis was further 
employed using a stepwise model building technique screen out predictors not 






One sample was unfortunately damaged in the dewaxing process and all further 
staining attempts were unsuccessful. All of the remaining 17 samples were found to 
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contain viable muscle tissue (Figure 5.2). The control experiment, using only 
secondary antibodies, resulted in no staining thus demonstrating that there was no 
non-specific staining. 
 
Figure 5.1 - Examples of typical H&E staining of study tissue sections. Normal 
muscle architecture demonstrated in all samples. Haematoxylin stains the nuclei 






Positive cells were identified on the basis of positive immunofluorescent staining in 
association with nuclear material, and confirmed by their position under the basal 
lamina. In cases where the final image confirmed the presence of Pax-7 and DAPI, 
but the location under the sarcolemma was in question, the specific 
immunofluorescence image for Pax-7 (i.e. not combined with the image highlighting 
the DAPI stain) was viewed. On this image the muscle architecture was clearer; 
positive cells superficial to the basal lamina were not counted. Analyses of these two 
images enable classification. An example is portrayed in Figure 5.2, where the final 
image (B) suggested the presence of a satellite cell towards the upper right corner of 
the image (green fluorescence around the blue nuclear stain), but the location was not 
consistent with the overall architecture of the muscle myonuclei. Analysis of the 
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‘green channel’ revealed the position of this cell to be superficial to the basal lamina. 
This was not therefore counted as a satellite cell. 
 
Figure 5.2 - Multiple images of the section to confirm cell location. 
















A = ‘green’ Pax-7 immunofluorescence stain, B = merged and adjusted image (Pax-7 and 
DAPI stains) 
 
Numbers of identified satellite cells 
 
Variation of satellite cell number was observed within the patient population (Figure 
5.3 and Table 5.1). The positive staining index (PSI) of muscle satellite cells was 
calculated by assessing three separate areas of each individual section. Mean values 
per individual patient/section are reported in Table 5.1. The satellite cell data was 
normally distributed, with a mean PSI of 7.62 (95% confidence interval of mean 
6.30, 8.94) satellite cells per sample. Variation was found in the cell numbers (PSI 





Figure 5.3 – Immunofluorescence image of muscle satellite cells. Examples of 
typical staining profiles obtained. Separate samples demonstrating differing 




Satellite cells are identified with an antibody against Pax7 (green), further myonuclei with 
DAPI (blue).  
 
 
Table 5.1 - Satellite cell count  
 
Sample Cell count Myonuclei Fibres PSI 
     
2 5.34 105 23 5.09 
3 13 108.34 16.67 11.99 
4 9.67 104.67 17.67 9.24 
5 8.4 101.67 16.34 8.26 
6 12.25 123.34 11.5 9.93 
7 9.25 104.5 20.25 8.85 
8 8 82.67 14 9.68 
9 8.67 104.34 15 8.31 
10 4 130.34 18.25 3.07 
11 10.67 94 44.67 11.35 
12 7.34 104.34 16.67 7.04 
13 5 107.67 28.67 4.64 
14 11 98.25 21.75 11.20 
15 5.67 136.24 24.34 4.16 
16 5.67 100.34 38.67 5.65 
17 9.5 135 14.5 7.04 
18 10.67 158.67 43.34 6.73 
     
 
Average count of 3 imaged regions per muscle section/individual patient. Samples re-coded 
for blinding purposes, Sample 1 represents the destroyed sample and is not displayed. 
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Correlation of satellite cell number with patient age 
 
Patient age in the cohort was normally distributed, with a mean age of 73.5 (95% CI 
of mean 69.3, 77.9) years. The variation in satellite cell number formed a modest 
linear association with the age of the patient (r = -0.37, p = 0.14), see Figure 5.4, 
where the biopsies of the younger patients tended to contain greater numbers of 
satellite cells than the older patients. 
 
Figure 5.4 - Association of patient age and satellite cell number. Linear relationship 


































All data was normally distributed. Wide variation in power output between 
individual patients was observed, see table 5.2. Mean maximal power output of the 
cohort was 48.2 (SE of mean 12.6) W at pre-op, 60.2 (9.98) W at 6 weeks post-op 
and 82.4 (11.2) W at assessment 26 weeks post-op. This reflected a power output to 
body weight ratio of 53.7 (14.3) % at pre-op assessment, 75.0 (12) % at 6 week 




The large standard errors of the mean reported reflect the large individual variation in 
maximal power output amongst the patient group. 
 
Table 5.2 – Mean individual power output at assessments  
 
Sample 
Output at assessment 
 
Change between assessments 
 
Pre-op 6 weeks 26 weeks Pre-op - 6 week 6 - 26 weeks 























2 18 0.2 72 1 74 1 54 0.8 2 0 
3 116 1.1 104 1 134 1.2 -12 -0.1 18 0.2 
4 33 0.3 69 0.7 103 1 36 0.4 24 0.3 
5 73 0.8 60 0.8 103 1.3 -13 0 43 0.5 
6 1 0 35 0.4 55 1 34 0.4 20 0.6 
7 2 0 8 0.1 36 0.4 6 0.1 28 0.3 
8 Data unavailable 
9 137 1.8 148 2 189 2.4 11 0.2 41 0.4 
10 97 0.6 86 0.8 84 0.7 -9 0.2 -2 -0.1 
11 59 1.1 46 0.7 65 1.2 -13 -0.4 20 0.5 
12 38 0.5 70 1.1 72 1.1 32 0.6 2 0 
13 4 0.1 20 0.3 28 0.4 16 0 8 0.1 
14 13 0.2 65 0.9 92 1.2 52 0.2 33 0.3 
15 3 0 1 0 38 0.6 -2 0 11 0.3 
16 Data unavailable 
























W = maximal power output, measured in watts, %BW = maximal power output expressed as 
power to patient body weight ratio. 
 
Change in power output between assessments 
 
Substantial difference between individuals was noted. Improvement of maximal 
power output varied between 0 and 70 W, which reflected a change of -30% – 80% 
in power to body weight ratio. 
 
Improvement in power output was generally observed between assessment points. 
Mean improvement was 12.12 W between pre-op and 6 week assessment, though 
this difference was not statistically significant, paired samples t-test, 95% CI for 
mean difference: -1.37, 25.37 p = 0.075. Again, the wide variation in individual 
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results accounted for the large confidence intervals of the mean difference. Figure 
5.5 shows a boxplot of the difference in mean power output between pre-op and 6 
week assessments. This demonstrates the wide spread of data, and the resultant wide 
95% confidence intervals, that narrowly incorporate the zero value. 
 









(with Ho and 95% t-confidence interval for the mean)
 
 
Ho = null hypothesis of no difference existing between mean values at pre-op and 6 week 




Mean improvement in maximal power output between 6 and 26 weeks was 19.68 W. 
This difference was statistically significant, 95% CI for mean difference: 14.43, 
30.07 p = <0.000. 
 
The improvement in maximal power output reflected an improvement of power-body 
weight ratio of 21% between pre-op and 6 weeks. This difference was statistically 
significant 95% CI for mean difference: 0.03, 0.39 p = 0.025. A further 27% mean 
improvement in power to body weight ratio was found between 6 and 26 week 
assessments, which was also statistically significant 95% CI for mean difference: 




Correlation of satellite cell content and power output 
 
Good correlation was noted between the patients satellite cell number and 
improvement in power output between 6 weeks and 26 weeks, both in maximal 
power output (r = 0.57, p = 0.023) and power-body weight ratio (r = 0.64, p = 0.008) 
(Table 5.3, Figures 5.6 and 5.7). 
 









Power %BW Power %BW Power %BW 
 
r = 0.13 
p = 0.62 
 
 
r = -0.26 
p = 0.33 
 
r = 0.21 
 p = 0.44 
 
r = 0.21  
p = 0.44 
 
r = 0.34 
p = 0.2 
 
r = 0.41 
 p = 0.12 
 
Change in Power Output 
 
Pre-op – 6 wks 
 
6 – 26 weeks 
 
Pre-op – 26weeks 
Power %BW Power %BW Power %BW 
 




r = -0.23 
p = 0.36 
 
 
r = 0.57 
 p = 0.02 
 
 
r = 0.64 
p = 0.01 
 
 
r = 0.32 
p = 0.23 
 
 
r = 0.16 
p = 0.55 
 
 
Correlation coefficients of cell number and lower limb power output at the various time points 
for both power at that assessment, and change in power between assessments. Significant 





Figure 5.6 - Linear relationship found between positive staining index of satellite 
cells in muscle tissue samples and the subsequent change in individual maximal 
































Figure 5.7 - Linear relationship found between satellite cell positive staining index 
and individual change in power-bodyweight ratio, strong correlation between the 




































Uni-variant regression analysis demonstrated that 27 % of improved maximal power 
output between 6 and 26 weeks could be attributed to the variation in the number of 
underlying satellite cells (R
2
 adjusted = 27.0%). Further, 37% of the variation in the 
improvement of power to body weight ratio could be attributed to the satellite cell 
pool (R
2
 adjusted = 36.6 %). Full analysis is displayed in Appendix F. 
 
Poor correlation was found between both pre-op power output and improvement in 
power output (r = 0.32, p = 0.23) and pre-op power-body weight ratio and 
improvement in power-bodyweight ratio (r = 0.19, p = 0.47). Uni-variant regression 
demonstrated that pre-op scores account for very small amounts of the change in 
maximal power output post-op (R
2
 adjusted = 3.5%) and were not indicative of 
improved power-bodyweight ratio. Full analysis is displayed in Appendix F. 
 
Stepwise regression modelling was performed (alpha to enter or remove p = 0.05) to 
assess the relative contribution of each factor to the change in power output. The 
only factor associated with change in post-operative power output (both maximal 
watts and proportion of body-weight) was the number of satellite cells found at time 




This is the first study to assess the influence of the underlying regenerative potential 
of the muscle tissue of the extensor mechanism group on post-operative power 
output following total knee arthroplasty. A third of the variation of change in power 
output could be attributed to the intrinsic number of muscle satellite cells in the 
quadriceps muscle at the time of surgery. This result was substantial, and can put into 
context by the associated result that only 3.5% of the variation in change in post-
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operative power could be accounted for by the commonly used clinical measure of 
pre-operative power score. Further regression modelling in this cohort found that, of 
the two factors, only the satellite cell number was predictive of the post-operative 
change in power output (Appendix F). 
 
As described in Chapter 2, the muscle satellite cell is responsible for the generation 
of myoblasts that fuse to repair or to form new muscle fibres (Figure 2.5). The 
rehabilitative process following TKA typically results in training effects and 
hypertrophy of the quadriceps muscle that influence post-operative outcome (Greene 
and Schurman, 2008; Mizner et al 2005a). This process is driven by the 
differentiation of satellite cells through the myogenic program as previously outlined. 
. 
Pain (attributable to OA) is the prime indication for undergoing knee arthroplasty, 
and reduction of this pain the major goal of surgery. It is likely that pre-operative 
pain prevents accurate measurement of power output at this time, by limiting the 
patients’ ability to generate maximal force through a pain inhibition process. In 
keeping with this no correlation was observed with the satellite cell number and the 
change of pre-operative power to either 6 or 26 weeks. Much of the surgical pain had 
abated by the 6 weeks review, and the individuals were all able to mobilise without 
the use of aids that would have been necessary in the early post-operative phase.  
 
Improvement in muscle power output has been demonstrated by 6 months post TKA 
(Lamb and Frost, 2003). This current study corroborated that report demonstrating an 
improved mean muscle power between assessments. A mean difference of 12W was 
found between pre-op and 6 week review, then a further mean difference of 20W 
between 6 and 26 weeks. Apart from the underlying osteoarthritic knee, the patients 
were otherwise healthy, thus no other comorbidies were present which would have 




Magnitude of power output is inherently associated with the individual’s underlying 
muscle mass, as every muscle fibre can be thought of as an independent force 
generating unit (Jones and Round, 1990). For this reason, measurement of the 
improvement in power was assessed both in terms of absolute power and ratio of 
power relative to bodyweight. The power to bodyweight figure takes into account the 
general size of the individual, and is therefore the more relevant of the two measures 
in assessing change expressed in the population. It has been demonstrated that 
muscle power correlates more strongly than muscle strength to physical function, as 
power involves both force production and contraction velocity, which better reflects 
daily tasks that are force and speed dependant (Evans, 2000, Bassey and Short 1990, 
Bean et al, 2003). Interestingly, of the results presented here it is the power-
bodyweight ratio that demonstrates the strongest correlation with the satellite cell 
count (r = 0.64, Figure 5.7). The number of satellite cells also accounts for the largest 





Mizner et al (2005a) reported a reduction of quadriceps strength in the first 3-4 
weeks post-operatively compared to pre-operative levels in a small knee arthroplasty 





atrophy explained 85% of the loss of quadriceps strength (p
 
< 0.001). Multiple linear 
regression analysis further revealed that
 
failure of voluntary activation contributed 
around twice as
 
much as atrophy. This failure of neuromuscular activation in the 
early post-operative phase is an attractive explanation of the poor levels of 
quadriceps strength and power reported in the first month post-operatively, however 
does not well explain the reported prolonged power and strength deficits compared to 
healthy controls (Silva et al, 2003; Huang et al, 1996). 
 
No correlation was found in this study between satellite cell number and power 
output at the 6 weeks assessment (broadly around the same time point as the Mizner 
study). It is possible that the neuromuscular function deficits are important in the 
immediate post-operative period, whereas improvement in power output beyond this 
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early stage may be more closely associated with regenerative potential and satellite 
cell content. The difference in detected power levels between this study and those 
reported by the Misner group suggest either that the majority of reduction of the 
surgical pain that follows knee arthroplasty occurs between 4 and 6 weeks, or that the 
influence of a failure of voluntary activation is moderated by the 6 weeks 
assessment.  
 
It is notable that the previously reported decrease in cell number with advancing age 
was detected despite the relatively limited age range typical of a primary knee 
arthroplasty population. The modest strength of the correlation is indicative of this 
limited age range, and may be strengthened with increased data. This is also the first 
study to report variation in the individuals’ satellite cell numbers in an osteoarthritic 
population. This variation was expected and corroborates those reports of the wider 
population (Kadi et al, 2004; Renault et al, 2002; Verdjik et al, 2007). The process of 
osteoarthritis is not known to affect the number of individual satellite cells; however 
patients with osteoarthritis are likely to exercise less. Chafri et al (2003) have 
demonstrated a preservation of the satellite cell pool in elderly subjects that engaged 
in regular exercise. This may suggest that a typical osteoarthritic group may present 
with a comparatively reduced cell number due to the poor levels of activity generally 
associated with the disease. Individual variation depended on activity levels, and this 
was found in this cohort.  
 
The detection of Pax7 in the muscle section is indicative of satellite cells, as Pax7 is 
specific to muscle satellite cells. It is present in all adult myogenic precursor cells 
due to its role in specifying the differentiation of pluripotent stem cells (Seale, 2000). 
Previous human samples in healthy populations (Kadi et al, 2006, Chafri et al, 2003, 
Lindstrom and Thornell, 2009) have successfully used NCAM as an additional 
satellite cell marker. Staining with an NCAM marker was also attempted in this 
study, though the Pax7 marker was used to quantify the satellite cells due to a far 
greater staining efficiency. NCAM is a cell surface marker, and it may be that the 
embedding and retrieval from paraffin wax caused damage that the cytoplasmic Pax7 
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marker was not subjected to. It is notable that the other human studies (Kadi et al, 
2004 and 2006, Chafri et al, 2003, Lindstrom and Thornell, 2009) used frozen 
samples with this cell marker which would not have been subject to this procedural 
issue. The specific positive identification criteria of further association with the 
DAPI stained nuclear material, and also physical location under the basal lamina 
helped reduce the possibilities of false positive detection.  
 
In conclusion, pre-operative lower limb power (and thus by correlation function) was 
found to be less predictive of physical muscle power recovery post TKA than the 
number of satellite cells within the quadriceps muscle. Ten times the variation of 
change in power output post operatively was linked to the underlying number of 
muscle satellite cells in the individual compared to a measure of pre-operative power 




6 Influence of the Musculature on TKR Outcome: Satellite 




The results presented in the previous chapter suggested that the inherent number of 
satellite cells in the quadriceps muscle may substantially influence the patient’s post-
operative lower limb power output, and thus function, following knee arthroplasty. 
These results were obtained on thin longitudinal sections of the sample tissue which 
may not be representative of the content of the whole muscle. 
 
To explore this further real time reverse transcription polymerase chain reaction (RT-
PCR) analysis was used as the whole biopsy sample could be assessed to determine 
the quantity of specific genetic material. It enables both detection and quantification 
(as a relative amount) of specific gene expression in a sample. 
 
The PCR technique was devised in 1985 and has revolutionised molecular biology, 
as the recombinant DNA methods previously employed took weeks to clone a 
segment of DNA, whereas with PCR billions of copies can be made in a few hours. 
A further benefit to previous methods is the use of primers to determine the specific 
gene sequence to be amplified, thus isolation of the desired segment from the whole 
sample is not required (Campbell, 1996).  
 
The technique uses a solution of double-stranded DNA containing the nucleotide 
sequence that is to be targeted for copying. The enzyme DNA polymerase is added as 
a catalyst, along with a supply of all four nucleotides (to assemble the new DNA) 
and specific primers. These primers are chemically synthesised with sequences that 
are complimentary to the ends of the targeted segment of DNA, and are required for 
the DNA polymerase enzyme to initiate the DNA synthesis.  
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The actual process involves heating the DNA to separate the strands, then cooling to 
allow the primers to attach to (via hydrogen bonding) to the ends of the target 
sequence. The DNA polymerase extends the primers by adding nucleotides, using the 
longer DNA strands as a template. Further heating begins the next cycle of strand 
separation, primer binding and DNA synthesis (Campbell, 1996). 
 
Double stranded DNA is required for PCR, though it is single stranded specific 
mRNA that is extracted form the tissue samples. Normal transcription in the cell 
nucleus involves the synthesis of mRNA from DNA, the mRNA going on to 
synthesize proteins in the cell cytoplasm. Reverse transcription is the reverse of this 
process where a DNA copy (cDNA) is produced by the enzyme reverse transcriptase 
(a viral enzyme that uses an RNA strand as a template for the synthesis of a 
complementary DNA strand) forming a cDNA/mRNA hybrid helix that can be used 
for PCR (Albertz et al, 1994).  
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Figure 6.1 - Diagram detailing the process of reverse transcription, where cDNA is 




Taken from: Albertz B, Bery D, Lewis J, Raff M, Roberts K, Watson J. Molecular Biology of 
The Cell, Fourth Edition, 1994, Garland Publishing Inc, New York. 
 
 
Measurement of DNA amplification during PCR is in real time, i.e., the amplified 
product is measured during each PCR cycle. As PCR amplification is an exponential 
reaction, a straight line relationship between the amount of DNA and cycle number is 
apparent when plotted on a logarithmic scale (Figure 6.2 A). In the standard output 
plot of PCR data (Figure 6.2 B), the early doublings are not apparent at the scale 
used. A threshold is set at which the sample expresses beyond any background 
levels, and the cycle at which the sample crosses the threshold is called the cycle 
threshold, Ct. The quantity of DNA theoretically doubles every cycle during the 




Figure 6.2 – Explanation of the typical PCR output graph demonstrating the typical 
PCR output graph and logarithmic relationship.  
 
 
  A 
 
  B 
 
 
Figure adapted from Applied Biosystems promotional literature 
 
 
Measurement of DNA is in relation to a housekeeping gene measured in the same 
sample to normalise for possible variation in the amount of DNA between samples. 
This normalization permits accurate comparison of expression of the gene of interest 
between different samples, provided that the expression of the housekeeping gene 
used in the normalization is very similar across all the samples (Nailis et al, 2006; 
Nolan et al, 2006). 
 
The use of this technique also allows for the investigation of the expression of genes 
relevant to different stages of the cell cycle. It is hypothesised that the number of 
activated satellite cells should correlate more strongly with power output than the 




Secondary research questions were to: (a) corroborate the results of the previous 
study, using immunofluorescence staining protocols, and explore variation in the 
individual expression of Pax-7 and thereby satellite cell content. (b) correlate muscle 
satellite cell content to the ability of the patient to improve power output post knee 




Patient recruitment and power output analysis 
 
Patient recruitment was from the operating list of the same surgeon, as per the 
preceding study. Inclusion criteria were identical, briefly, that the patients were 
undergoing a planned primary total knee replacement for osteoarthritis and were free 
of co-morbidities that would affect their subsequent ability to generate lower limb 
power. Local approval was granted for the study by Lothian Research Ethics 
Committee and NHS Lothian Research and Development Management.  
 
Suitable patients were approached at the time of pre-operative assessment, 
approximately 2 weeks prior to surgery, and were recruited through informed 
consent. 11 patients were recruited to the study. 
 
Specific assessment of the recovery of muscle strength in our cohort was assessed by 
Leg Extensor Power-Rig (in the manner previously described) and output reported 
both by maximal wattage (W) generated, and in relative power to bodyweight ratio. 
Baseline power output was assessed at pre-operative assessment, then post-
operatively at routine outpatient clinical review at 6 weeks and 26 weeks post 






The muscle sample was obtained from distal quadriceps by the same surgeon during 
the knee arthroplasty via the standard incision for this procedure. Sampling was 
standardised, as per the previous experiment, aiming to biopsy the quadriceps 5 cm 
superior to the patella, dependant on the tissue quality of the individual. Samples 
were immediately snap frozen in liquid nitrogen (in the anti-room of the operating 
theatre) then subsequently transferred to -80C storage. 
 
A control biopsy of quadriceps muscle (required for the RT-PCR analysis) was 
obtained from a young patient undergoing limb length correctional surgery. Attempts 
were made by the surgeon to biopsy from the quadriceps group as close as possible 
to the biopsy site in the knee arthroplasty group. This was also immediately snap 
frozen in liquid nitrogen and processed as per the arthroplasty samples. The sample 




Frozen samples were transferred to -20C for 24 hours before being sectioned. Four 
7m thick tissue sections per sample were cut on a Leica 1850 cryotome for 
immunofluorescence analysis. The remainder of the samples were immersed in 
RNAlater ice (Ambion) to preserve the RNA and kept at -80C prior to for RT-PCR 
analysis. 
 
Immunofluorescence for Pax7 
 
An antigen against the satellite cell marker Pax7 was use as per the previous 
experiment. Frozen sections were fixed in cold acetone for 5 minutes and left to air 
dry before loading onto sequenza plates. Slides were washed in PBS (w/o) before 
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adding 3 drops of Protein Block (AMS biotechnology Europe ltd) solution for 30 
minutes at room temperature. Primary antibodies were diluted, to appropriate 
concentration in the protein block solution and 250l was added to each slide for 1 
hour at room temperature. The slides were washed three times in PBS and Alexa 
Fluor (Invitrogen) secondary antibodies added for 30 minutes at room temperature in 
the dark. A further 4 washes in PBS were completed before adding 250l of 1g/ml 
DAPI, which was followed by 2 washes with water. The slides were then dehydrated 
in 100% ethanol and dried before the slides were mounted with coverslips in 
Vectashield Hard Set mounting medium for fluorescence (Vector).   
 
A control experiment was run in parallel with all sections that followed the exact 





Prior to RNA extraction, the samples were thawed at -20 degrees for 24 hrs. Tissue 
was chopped finely with a scalpel blade, and then RNA extraction was performed 
using nucleospin columns (Macheray Nagel) which bind to the nucleic acid (specific 
protocol Appendix G). Quantification of the RNA yielded was performed on a 
nanodrop spectrophotometer. The amount of mRNA detected per sample is 








RNA (µg) Amount of RNA (µl) needed to 
make 0.3µg of cDNA 
Additional H20 
(µl) 
    
Control 0.044 6.8 3.2 
1 0.003 10 0 
2 0.086 3.5 6.5 
3 0.056 5.4 4.6 
4 0.045 6.7 3.3 
5 0.072 4.2 5.8 
6 0.003 10 0 
7 0.088 3.4 6.6 
8 0.11 2.7 7.3 
9 0.038 7.9 2.1 
10 0.057 5.3 4.7 
11 0.049 6.1 3.9 
    
 
 
The cDNA reverse transcription kit requires a 10µl volume of mRNA containing 
equal amounts of mRNA per sample. The lowest amount of mRNA detected sets the 
amount per sample. In this experiment, sample 7 contained the lowest concentration 
of mRNA (0.3µg), thus the other samples were diluted to this concentration (see 
table 6.1) yielding a solution of 10µl of mRNA at concentration of 0.3µg per µl. the 
reverse transcriptase kit (AB) adds a further 10 µl of a master mix containing dNTPs, 
buffer, random primers, RNase inhibitor, reverse transcriptase and water (Appendix 
G, high capacity cDNA reverse transcription protocol). cDNA is thus made at a 
concentration of 0.3µg per µl which is then used for RT-PCR analysis. 
 
Quantitative Real Time – PCR analysis 
 
The SYBR green method of quantification was used. SYBR green is a fluorescent 
dye that binds double-stranded DNA, and upon excitation emits light. Thus, as a 
PCR product accumulates, fluorescence increases. The qPCR reads the level of 
SYBR green bound to each cycle. The cycle number SYBR green is detected above 
the background threshold determines how abundant the gene is. This is compared 
with a house keeping gene to determine how much of the gene in question is 





Specific intron spanning primers were designed for the satellite cell markers Pax7, 
NCAM and CD-34 by technical staff in the ELIGI lab at the Queens Medical 
Research Institute, Edinburgh University and made externally by Eurogentec. 
  
Satellite cell markers 
 
Pax7 is considered to be a robust marker for satellite cells as discussed previously 
(Seale et al, 2000), NCAM is a marker of activated satellite cells (Lindstrom and 
Thornell, 2009), and CD34 (a cell surface glycoprotein which functions as a cell-cell 
adhesion factor) which  has been proposed as a marker of quiescent cells 
(Beauchamp et al, 2000). 
 
The commonly used 18s (ribosomal RNA) primer was included as the housekeeping 
gene, (RT-PCR 18S control kit Eurogentec). 
 
Quantitative PCR  
 
To quantify gene expression in human muscle tissue, each reaction contained 1g 
cDNA from each patient/sample. Per sample (each well of 96 well plate) 10ul of 
Syber Green (iTaq SYBR Green Supermix with rox, BioRad) was added along with 
7ul of water, 1ul of forward primer, 1ul of reverse primer (Eurogentech) and run in 
duplicate on a 7500 Fast Real-time PCR machine (Applied Biosystems). The 
following PCR cycling conditions were used for amplification: 50deg 2 min, 95deg 
10 min, then 40 cycles of 95deg 15 sec and 60deg 1 min. Dissociation step of 95 deg 
for 15 sec, 60deg for 1 min and 95deg for 15 sec were performed for primer 
specificity, to reduce the chance of false positive results.  
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Enough volume of cDNA was extracted from the mRNA in the samples to allow two 
separate runs of PCR. All four markers were included in the two individual plates (in 
duplicate) for all 12 samples. Average values were calculates for the plates, and then 




Statistical analysis was carried out with the Minitab (release 15) software. All data 
was assessed visually for normality. Differences in power outcome scores across the 
three assessment time points were assessed by paired sample t-tests. Strength of 
correlation between power output and satellite cell number was assessed with the 
Pearson product moment correlation coefficient and regression analysis performed to 
quantify this association. Multiple linear regression analysis was further employed 
using a stepwise model building technique screen out predictors not associated with 






Unfortunately it was retrospectively determined that temperature regulator of the 
cryotome was malfunctioning at the time of sectioning. This has caused the samples 
to thaw during the cutting process, which has resulted in poor sample integrity 
(Figure 6.3). All sections were cut from the samples at the same time, thus all slides, 




Figure 6.3 - H &E and Immunofluorescent staining, highlighting destruction of 
muscle architecture. Examples of typical H&E staining (A) and immunofluorescence 
staining (B) of study tissue sections. Abnormal muscle architecture with disruption of 
myofibres demonstrated in all samples. Image A: Haematoxylin stains the nuclei 
blue and eosin the collagen fibres pink. Image B: DAPI nuclear staining (Blue) and 
Pax-7 fluorescent stain (bright green). It was not possible to confirm the location of 





Images taken with a Zeiss Axioscope II MOT compound microscope under a 20x objective 
equipped with a Hamamatsu Camera Controller (ORCA-ER). 
 
 
The immunofluorescent staining protocol stains the tissue satisfactorily although the 
muscle architecture has been destroyed as a result of the thawing at time of 
sectioning. An accurate count of the satellite cells that satisfies the previous criteria 




Ct values were calculated for the expression of the three genes within each sample 
(using 18S as a reference gene, see figure X).  ΔCt values (difference between cycle 
number of housekeeping gene and gene in question) were calculated for the three 
satellite cell markers (Figure 6.4 and Table 6.2). 
 
As expected the expression of Pax7 (generic marker) was detected before the NCAM 




the Pax7 expression three full PCR cycles prior to the NCAM expression indicated 
that there was eight times as much Pax7 as there was NCAM in the samples. The 
CD34 marker of the inactive cells was expressed approximately two cycles ahead of 
the Pax7 suggesting larger volumes of this marker than the definitive Pax7 content.  
 
Figure 6.4 - Screen shot of PCR output graph showing 18s and Pax7 expression of 
all 11 samples. ΔCt values (difference between cycle number that expression 









Table 6.2 – Mean cycle at which markers become linear and ΔCt values  
 
 Specific marker 18s Control gene Delta ct 
    
 Run 1 Run 2 Mean Run 1 Run 2 Mean Run 1 Run 2 Mean 
          
Pax7 34.8 33.8 34.3 12.5 13.2 12.85 21.3 19.5 20.4 
          
NCAM 36.8 37.3 37.05 13.5 12.9 13.2 23.3 24.7 24.0 
          
CD34 32.4 32.6 32.5 12.8 13.8 13.3 18.9 18.3 18.6 
          
 
Mean values expressed for the individual runs are calculated from the results of the 2 rows 
of 12 samples (i.e. 24 results) per satellite cell marker. 
 
 
Expression relative to the control 
 
Gene expression of each sample was expressed as a relative amount compared 
against the control sample, in this case a muscle sample from a young patient 
(reference to summary Table 6.3 and Figures 6.5 and 6.6). Wide variation in content 
of the satellite cell markers were found in the samples compared to the control and 
each other suggesting differing levels of satellite cell content in individual patients 
confirming the results of the previous experiment. No gene expression was recorded 

































             
NCAM 1 1.81 0.88 2.55 0.30 0.35 0.00 0.00 1.17 0.00 1.70 0.00 
 1 0.00 0.95 1.89 1.08 0.66 1.25 0.00 0.57 0.00 0.21 0.00 
             
 1 1.81 0.91 2.22 0.69 0.50 1.25 0.00 0.87 0.00 0.95 0.00 
             
PAX-7 1 0.43 0.28 1.07 0.79 0.53 0.23 0.00 0.86 0.00 0.38 0.00 
 1 0.51 0.35 1.82 0.73 0.42 0.20 0.00 0.37 0.14 0.13 0.16 
             
 1 0.47 0.32 1.45 0.76 0.47 0.22 0.00 0.61 0.14 0.26 0.16 
             
CD34 1 0.00 0.47 0.34 0.57 0.06 0.31 0.00 0.26 0.60 0.41 1.06 
 1 0.28 0.70 0.23 0.18 0.13 0.23 0.00 0.10 0.18 0.17 0.13 



























Data displayed by individual sample for both PCR runs, then mean value (red) below. Note 
that mean value of the two runs was calculated where two values were obtained. In the 
absence of a second sample, the value of the single successful run was used. 
 
 
Figure 6.5 - Relative expression of all satellite cell markers. Satellite cell content 
expressed relative to the control patient. Note the individual variation between the 
individual samples compared to the control, and also that the 3 markers of satellite 






All three markers showed considerable individual variation among the samples 
(Figures 6.5 and 6.6), highlighting different satellite cell content between the 
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patients. Most of the TKA patients had increased levels of activated cells, and lower 
levels of quiescent cells than the control. 
 
Figure 6.6 - Individual plots of satellite cell markers and relative gene expression 
relative to the control sample. No data was obtained on sample 7 suggesting a 
problem with the processing or storage of that specific tissue that prevented 
analysis. Pax7 expression (A) demonstrates the expected individual variation in 
satellite cell content. The NCAM expression (B) generally shows increased levels of 
activated satellite cells compared to the control sample though was not detected at 
all in 2 further samples, while the marker of quiescent cells CD34 (C) was 







Good correlation was observed between the expression of Pax7 and NCAM in the 
samples (r = 0.72, p = 0.01). However no correlation existed between the Pax7 and 






Mean maximal lower limb power output of the group was 16.73 (SE of mean 6.87) 
W at pre-operative assessment, 35.73 (7.75) W at 6 week assessment and 63.3 (12.1) 
W at 26 week assessment. This reflected a mean power-body weight ratio of 22.7 
(SE of mean 6.8) % at pre-op assessment, 44.6 (8.0) % at 6 week assessment, and 
73.6 (9.5) % at 26 week assessment. Wide variation was noted in individual leg 
extensor power output (Table 6.4). 
 
Table 6.4 – individual patient power output 
 



























         
1 39 66 135 69 0.3 0.6 1.1 0.5 
2 10 37 53 15 0.2 0.7 0.9 0.2 
3 72 66 121 55 0.7 0.6 1.1 0.5 
4 14 33 58 25 0.2 0.4 0.8 0.4 
5 19 23 43 20 0.3 0.3 0.6 0.3 
6 30 37 49 12 0.3 0.4 0.6 0.2 
7 14 17 38 21 0.3 0.3 0.6 0.3 
8 44 83 107 24 0.5 1 1.2 0.2 
9 0 18 21 3 0 0.4 0.4 0 
10 1 6 57 51 0 0.1 0.6 0.5 
11 0 7 14 7 0 0.1 0.2 0.1 
         
 
Power output for the 11 patients as assessed using the leg extensor power rig pre and post 
operatively. As in the previous experiment, output is expressed both as maximal power and 




Change in power output between assessments 
 
Improvement in power output was generally observed between assessment points. 
Paired samples t-tests were carried out to determine the mean difference between 
groups between the assessment points. Mean improvement in maximal power output 
between pre-op and 6 week assessment was 19.0 W. this difference is statistically 
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significant, 95% CI for mean difference: 3.19, 34.81 p = 0.023. Mean improvement 
between 6 and 26 weeks was 27.55 W. This difference was statistically significant, 
95% CI for mean difference: 13.23, 41.86 p = <0.002. 
 
The improvement in maximal power output reflected an improvement of power-body 
weight ratio of 21.8% between pre-op and 6 weeks. This difference was statistically 
significant 95% CI for mean difference: 0.08, 0.35 p = 0.005. A further 29% mean 
improvement in power to body weight ratio was found between 6 and 26 week 
assessments, which was also statistically significant 95% CI for mean difference: 
0.17, 0.40 p = <0.000. 
 
Again substantial differences between individual scores were noted. Mean 
improvement of maximal power output between 6 and 26 weeks was 25.6 (6.9) W, 
which reflected a mean change of 23.6 (5.3) % in power to body weight ratio. 
 
Correlation of satellite cell content and power output 
 
The relative expression of the Pax-7 gene (as the definitive satellite cell marker) was 
correlated against the change in lower limb power (as per the previous experiment). 
Good correlation was observed between the change in maximal lower limb power 
output between 6 and 26 weeks and the expression of pax-7 (r = 0.58, p = 0.06), 
Figure 6.7, and between the change in power-body weight ratio and the expression of 




Figure 6.7 - Linear relationship found between the patients Pax7 expression and 
change in their maximal power output post TKA. Good correlation between the 










































Figure 6.8 - Linear relationship found between the patients Pax7 expression and their 
change in power-bodyweight ratio post TKA. Strong correlation between variables: r = 












































Correlation with markers of cell activation 
 
Particularly strong correlation was observed between the relative expression of 
activated satellite cells (detected by expression of NCAM) and the change in the 
patients maximal power output between 6 and 26 weeks post TKA (r = 0.83, p = 
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0.002). An equally strong correlation is observed when NCAM was plotted against 
the patients power- body weight ratio (r = 0.84, p = 0.001) Figures 6.9 and 6.10. 
 
Figure 6.9 - Linear relationship found between the patients Pax7 expression and 
change in their maximal power output post TKA. Strong correlation between the 











































Figure 6.10 - Linear relationship found between the patients Pax7 expression and their 
change in power-bodyweight ratio post TKA. Strong correlation between variables: r = 













































No correlation was observed between the inactive cells (marked by the expression of 
CD34) and changes in the patients maximal power output between 6 and 26 weeks 
post TKA (r = -0.07, p = 0.84). Equally no correlation was detected when plotted 
against power-body weight ratio (r = -0.02, p = 0.95) Figures 6.11 and 6.12. 
 
Figure 6.11 - No correlation was found between the patients CD34 expression and their 
change in maximal power output, between 6 and 26 weeks post TKA. Correlation between 












































Figure 6.12 - No correlation was found between the patients CD34 expression and their 
change in power-bodyweight ratio post between 6 and 26 weeks post TKA. Correlation 













































Uni-variant regression analysis demonstrated that 26% of the improvement in 
maximal power output between 6 and 26 weeks could be attributed to the variation in 
the expression of Pax-7 in the muscle samples (R
2
 adjusted 26.0%). Further, 58% of 
the variation in power-bodyweight ratio could be attributed to the Pax7 expression of 
the muscle sample (R
2
 adjusted 58.2%). Full analysis displayed in Appendix H.  
 
Separately, uni-variant regression analysis demonstrated that 65% of the of the 
improvement in maximal power output between 6 and 26 weeks could be attributed 
to the variation in the expression of NCAM in the muscle samples (R
2
 adjusted 
64.5%). Further, 67% of the variation in power-bodyweight ratio could be attributed 
to the NCAM expression of the muscle sample (R
2
 adjusted 66.7%). Full analysis 
displayed in Appendix H. 
 
Uni-variant regression analysis demonstrated that none of the variation in 
improvement in maximal power output between 6 and 26 weeks could be attributed 
to the variation in the expression of CD34 in the muscle samples (R
2
 adjusted = 0.0). 
Further, none of the variation in power-bodyweight ratio could be attributed to the 
CD34 expression of the muscle sample (R
2
 adjusted 0.0%). Full analysis displayed in 
Appendix H. 
 
Stepwise regression modelling was performed (alpha to enter or remove p = 0.05) to 
assess the relative contribution of each factor to the change in power output. The 
only factor associated with change in post-operative power output (both maximal 
watts and proportion of body-weight) was the expression of NCAM in the muscle 






This is the first description of quantitative PCR analysis, being employed to assess 
the content of muscle satellite cells in a clinical population. There are four notable 
findings of this analysis. Firstly that variation in satellite cell content was found 
among the patient samples and compared to the control patient (concurrent with the 
result of the previously presented immunohistochemistry analysis). Secondly, that 
this variation was correlated with change in power output between 6 and 26 weeks 
post TKA, in support of the previous experiment. Thirdly, that a stronger correlation 
with power output was observed with the marker of activated cells than with the 
generic satellite cell marker, and that this accounted for two thirds of the variance in 
power output. Fourthly, that that the marker of quiescent cells did not correlate with 
power output at all.  
 
As with results reported in Chapter 5, the definitive satellite cell marker Pax7 was 
found to vary among patients, and in this analysis to a control subject (Figure 6.5 and 
6.6). This supports the findings of the previous chapter. It is disappointing that the 
IHC analysis attempted in this chapter was unable to determine a satellite cell 
staining profile that would enable direct comparison to the previous work. 
Irrespective, the qPCR analysis confirmed the previous conclusions of varying 
satellite cell content in the quadriceps muscle of TKA patients, and that this 
correlated to physical recovery (Figures 6.7- 6.10).  The primary focus of this 
experiment was to quantify the amount of satellite cell markers in the biopsy using a 
sensitive method of analysis; this has been achieved.  
 
The Pax7 marker correlated well with maximal lower limb power output (r = 0.58) 
and very well with power-bodyweight ratio (r = 0.79), broadly in line with the 
previous results. Uni-variant regression analysis demonstrates that the cell content 
accounts for around 26% of the variance in maximal power output (which was 
remarkably similar to the findings presented in Chapter 5), but in excess of 50% of 
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the variance of change in lower limb power output when scaled for bodyweight. The 
NCAM marker correlated very well with both maximal lower limb power output (r = 
0.83) and with the power-bodyweight ratio (r = 0.84). Uni-variant regression of this 
demonstrates that around 66% of the variance in both maximal lower limb power 
output and power-bodyweight ratio could be attributed to the underlying satellite cell 
content (Appendix H).  
 
Stepwise linear regression modelling demonstrated that the variation in the 
expression of NCAM in the muscle samples alone was the strongest predictor of 
variation in power output both in terms of maximal watts, and proportional to 
bodyweight. These proportions were substantial and potentially explained most of 
the differing physical outcome among knee replacement populations.  
 
While this figure is far larger, than was suggested in the preceding chapter, the 
technique used to determine the results was more sensitive and reliable as all of the 
tissue was used for analysis, as opposed to thin sections. Specific genetic sequences 
were used to detect the amount of the markers in question, and the amount found per 
sample is likely to be correct. The findings would be strengthened by an increase in 
the size of the cohort of TKA patients from which physical data was collected, due to 
the large standard deviations noted for this assessment in previous chapters. The 
power output changes (Table 6.4) were however largely comparable to those of the 
previous cohort (Table 5.2) and this lent further support to the conclusions of this 
chapter. 
 
The finding that the quiescent cells do not correlate with the power output is not 
surprising. However the expression of CD34 detected was greater than that of Pax7, 
suggesting that there was more of the CD34 marker in the samples. This was not 




CD34 is a cell surface glycoprotein and functions as a cell-cell adhesion factor that 
has been used previously as a marker of quiescent satellite cells (Beauchamp et al, 
2000). Neilson and McNagny (2008) however have demonstrated expression of this 
factor on early haematopoietic and vascular associated tissue. As such it is probable 
that the content reported incorporated some of this other tissue, and was not unique 
to quiescent satellite cells. As there was no correlation between the content of the 
CD34 marker with either Pax7 or with NCAM, common levels of over expression 
cannot be assumed, and the correlation between quiescent cells and power output 
should be interpreted cautiously. Good correlation was detected between Pax7 and 
NCAM content in the samples (r = 0.72) and this supports the use of these markers. 
 
In conclusion, these results suggest strong correlation between satellite cell number 
at the time of surgery and subsequent change in power output post operatively. They 
largely corroborate the results presented with a differing analysis technique in 
Chapter 5. It was further found that the expression of the marker of the satellite cells 
that were activated, as opposed to being quiescent, was most strongly correlated with 
the change in post-operative lower limb power output, and potentially explains 
around two thirds of the variation in change in post-operative power output.  
 
The results presented support the hypothesis that the size of the individual’s satellite 
cell pool and the number of activated cells within are directly relevant to the 
subsequent recovery of muscle power and thus physical function following TKA. 
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The aim of this thesis was to determine whether mechanically advantageous 
prosthetic design and / or the regenerative capacity of the patient’s muscle influenced 
the patient’s physical function following total knee arthroplasty. This was 
specifically investigated by assessing power output of the extensor mechanism. 
 
A randomised controlled trial was conducted to compare a new knee prosthesis 
designed with a single radius of curvature femoral component, which suggested 
beneficial muscle function through its design, with a traditional ‘multi-radius’ knee 
replacement model. Patients with the new implant design reported superior outcome 
at 1 year (as demonstrated by the Oxford Knee Score) and specifically demonstrated 
enhanced lower limb power output. The time course of improvement in power output 
over the first year post-operatively was also enhanced in patients with the new 
implant compared to the control group.  
 
Muscle satellite cells isolated from biopsies of the quadriceps muscle of patients at 
the time of surgery accounted for a third of the variance of the change in power 
output post operatively. Activated satellite cells were found to account for around 
two thirds of the change in post-operative power output. 
 
A further research question was to assess the relationship between patient reported 
outcome and direct functional evaluation. This was done to enable comment on the 
ability of the patient report tools to identify changes in the physical performance of 
the individual, the capacity of which is currently debated. This allows further 
interpretation of the changes in extensor mechanism power detected within the 
context of overall patient post-operative outcome.  
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Analysis of direct testing of outcome and patient reported outcome demonstrated a 
changing relationship between function and patient report of that function over time, 
with a closer relationship between the two types of assessment as the influence of 
pain diminished post-operatively. This confirmed that patient reported assessments 
are not equivalent to direct physical evaluation, and suggests that specific functional 
testing is required to assess the magnitude of the influence of mechanical and 
physiological factors investigated in this thesis. Correlation of this specific 
assessment can then be drawn to overall functional outcome as measured by patient 
report methods. The clinical assessment model derived suggests a means by which to 





A new design of total knee arthroplasty femoral component that is hypothesised to 
mechanically advantage the extensor mechanism of the knee was introduced in 
Chapter 2. Clinical demonstration of this theoretical advantage had not been 
previously been confirmed. 
 
A double blind randomised controlled trial of 212 TKA patients to compare the new 
implant design with a traditional model was presented in Chapter 3, where patient 
outcome was assessed at four time points over a one year period. Patient outcome at 
one year was superior in measures of knee flexion, lower limb power output and by 
patient report questionnaire (Oxford Knee Score), Two-way ANOVA, p = <0.001 in 
all cases. Specifically, the extensor mechanism power was significantly increased 
between all four assessment points in the new implant group, the control group 
demonstrating change between the second and third assessment only (p= <0.001), as 




Many factors relating to both the patient and the surgeon are thought to influence 
post-operative patient function. In this investigation, randomisation of the study 
participants accounted for factors relating to the patient, while the use of a limited 
number of orthopaedic surgeons at the same institution and adherence to standardised 
local protocol for post-operative management and rehabilitation limits any affect due 
to the surgeon. Controlling for these known variables allowed investigation of any 
specific effects based on differing prosthesis implanted.  
 
The influence of the improved lower limb power output found with the new single 
radius design was considered in Chapter 4. Patient outcome in the wider literature is 
typically assessed with patient reported questionnaire methods, the merits of which 
were considered in Chapter 2. Patient reports of their levels of function were found to 
differ to direct assessment of functional ability, and the influence of pain on patient 
report of function was highlighted. The relationship between patient report of 
function and direct assessment of function was found to change over time; the worst 
association was found prior to surgery, while post-operatively an improvement in the 
relationship was found at each sequential assessment at six weeks, six months and 
twelve months post TKA. The clinical assessment framework presented suggested 
that the influence of pain was most apparent at the level of the person, and that 
separate assessment at the level of the limb was required to ascertain specific 
information relating to physical performance.  
 
Assessing global outcome by patient report questionnaires alone allowed other 
factors relating to the patients functioning in society to affect the overall report of 
function. In this context the substantial improvements in extensor mechanism power 
found in the single radius implant group were perhaps not fully reflected in the 
corresponding Oxford Knee Scores. Despite this potential limitation, statistically 
significant differences were found in OKS between the implant groups at a 






The second specific research question concerned the role of the intrinsic number and 
activation state of muscle satellite cells present in the patient’s quadriceps muscle on 
the patient’s post-operative recovery of muscle power. The known association 
between muscle power and patient outcomes following TKA was presented in 
Chapter 2. The mechanisms by with satellite cells differentiate to provide new 
myoblasts to facilitate hypertrophy or hyperplasia of muscle tissue was also 
reviewed. The physical recovery that follows TKA was hypothesised to be dependant 
on the intrinsic number of satellite cells, though the lack of clinical investigation of 
human muscle satellite cells was also highlighted.   
 
A pilot study was conducted to determine if the number of satellite cells in the 
quadriceps muscle influenced post-operative recovery. Muscle satellite cells were 
isolated from biopsies of the quadriceps muscle of 18 patients at the time of surgery 
and counted by an immunofluorescent staining technique was presented in Chapter 5. 
The number of satellite cells detected accounted for a third of the change in power 
output post-operatively (R
2
 = 36.6%), and was demonstrated to explain 10 times the 
variance of post operative power output than the patient’s pre-operative power output 
values. The wide variation found in individual power output and strong relationship 
to the muscle satellite cell number in this patient cohort (r = 0.64) suggests the 
importance of these cells in post-operative recovery. A larger sample size is required 
to ascertain the implications of this pilot work, as is data concerning the cell numbers 
in a healthy control population. 
 
The wide standard error of the mean of the power data in this cohort was due to the 
large variation in power output among the individual patients. Though partly 
compensated for by the use of change in power output and by scaling the power 
relative to the patient’s body weight, larger numbers of patients would be required to 
reduce the error of the mean of the power output data. The wide variation seen in the 
standard error of the mean of the power output of the 200 patient’s assessed in 
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Chapter 3 suggested that a substantial volume of patients may need to be investigated 
before definitive conclusions could be drawn. Despite this, normal distributions were 
found in both maximal power scores and of the change in power scores, which 
allowed parametric testing of between time point differences and for linear 
correlation between variables. 
 
General function was not specifically assessed in this pilot work, though previous 
studies of large numbers of patients have shown a relationship between muscle 
power and post-operative function (Faulkner et al, 2010; Lingard et al, 2004). 
Additionally the modest - good correlation and linear association between lower limb 
power and both functional assessment and patient report of their function (through 
the Oxford Knee Score) found in Chapter 4, suggested that an improvement in lower 
limb power output would be indicative of improvement in other functional 
parameters. Again, the difference found in functional assessment and patient report 
of function in Chapter 4 suggested that no one outcome measure is suitable to 
ascertain overall patient function. 
 
A preservation of the muscle satellite cell pool has been previously shown in elderly 
subjects who undertake regular exercise. It is possible that typical osteoarthritic 
patients exercise less than the healthy population due to the pain associated with the 
disease and thus may have less well preserved satellite cell pools. This may then 
limit muscle regeneration post-operatively, and subsequently physical function. This 
is an attractive explanation for the continued muscle power deficits found in long 
term post-operative follow-up studies compared to the patient’s contralateral limb 
and to healthy controls.  
 
Confirmation of the relationship found between satellite cell number and change in 
post-operative muscle power output was presented in Chapter 6 in a separate cohort 
of 11 patients. This analysis was conducted using a quantitative PCR technique that 
was more sensitive than immunofluorescent staining as it quantified the expressed 
DNA of the markers of the satellite cells. This was the first example of this technique 
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being employed to detect satellite cells in human samples. It was found that the 
activated satellite cells accounted for twice the variation of change in post-operative 
power compared to the generic marker of satellite cells which would include those in 
a quiescent state. The activated cells explained around two thirds of the change in 
post-operative power output (R
2
 = 66.7%). The assessment of larger numbers of 
patients is required to confirm these exciting results. 
 
7.2 Future directions 
 
Further development of mechanically advantageous implant designs may be 
beneficial; however the mechanical advantage investigated in this thesis was elicited 
by placing the flexion axis more posteriorly in the knee. Attempting to locate this 
axis further posteriorly would in principle be possible, though the current implant 
design was based on a new kinematical theory of knee motion. Moving the axis 
beyond this location (as would be required to enhance the moment arm further) 
would potentially create another situation of a multi-instantaneous centre of rotation 
that has been criticised, and led to the development of the single axis design.  
 
An alternative assessment to the suggestion that the single radius Triathlon implant 
design mechanically advantages the extensor mechanism is that previous multi-
instant centre of rotation designs may have mechanically disadvantaged the extensor 
mechanism function.  This is an attractive idea that may offer some explanation as to 
why some patients’ who were previously able to complete activities of daily living 
can struggle to recover functionally following knee arthroplasty, despite a technically 
well located and well fixed implant. Further work is needed to confirm the findings 
of the randomised trial and also to assess the wider relevance of enhanced quadriceps 





An additional priority for future research in this area would be the comparison of a 
4
th
 generation multi-radius implant design to the single radius Triathlon implant. This 
would determine if any of the additional design modifications beyond the axis of 
rotation are relevant to the outcome of the trial presented here. 
 
The exciting results of the satellite cell studies suggest great potential for further 
research, though the first priority would be to confirm the results presented here in a 
larger sample of patients. 
 
The results presented in this thesis suggest that the number of satellite cells within 
the individual’s cell pool and the activation state of these cells are highly relevant to 
the recovery of physical function post TKA. The mechanisms involved in the 
regulation of skeletal muscle growth and regeneration are of great interest, as through 
the therapeutic manipulation of these mechanisms it may be possible to enhance a 
patients muscle recovery and the quality of life. Spangelberg and Booth (2001) 
comment that in the future it may be possible to regulate the proliferation of the 
satellite cells either via gene delivery to the skeletal muscle, or via isolation of the 
satellite cells, genetic manipulation and delivery back to the muscle via the 
circulation. Substantial further advances in biological technology are however 
required to achieve this goal. 
 
Perhaps a more immediate solution will emerge from the manipulation of the host 
environment to induce quiescent satellite cells into an activated state. Hall et al 
(2010) recently achieved this in a murine experiment and demonstrated substantial 
physical muscle hypertrophy compared to the contralateral limb when injury was 
induced. Corroboration of these results in human populations is first required and it 
is likely that a large volume of experimental work will be required to optimise these 





Further work however is needed before any clinical benefits could be expected using 
therapies such as modifying the satellite cell environment.  Identification of those 
patients at most risk of poor physical recovery would be essential to make this 
technique a realistic therapy. It would be preferable not to have to biopsy the muscle 
in order to determine the satellite cell content. Clinical algorithms of ‘at risk’ patients 
could be developed and these patients at a higher risk of having poor intrinsic muscle 
regenerative capacity could then have their satellite cell content confirmed with a 
biopsy.   
 
Despite these future hurdles, the demonstration that post-operative muscle function 
can be influenced by manipulating the quadriceps / extensor mechanism function, 
both mechanically by implant design, and physiologically by the intrinsic 
‘regenerative potential’ of the muscle tissue (by virtue of the volume and activation 
state of the satellite cell) suggests the potential to enhance patient outcomes 
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Objective: To investigate the comparative patient reported outcome of total hip and knee 
arthroplasty in the first year following surgery  
 
Methods: This prospective study included all elective primary total joint arthroplasty 
procedures (1410 hip and 1244 knee) performed at the Royal Infirmary of Edinburgh over a 2 
year period, between January 2006 and November 2008. Patient reported outcome 
questionnaires for general health (SF12) and joint specific function (Oxford Score) were 
completed pre-operatively and at 6 and 12 months post-operatively. Overall satisfaction was 
assessed at 12 months post-op.  
 
Results: Both groups demonstrated substantial improvement in the year following surgery, 
though the THA group demonstrated greater improvement than the TKA. On the Oxford 
Scores, THA outcome improved on average by 4.9 points more (95% confidence interval 
[4.2, 5.7]) than TKA at 6 months and by 4.4 [3.7, 5.1] points at 1 year. The SF12 physical 
scores were on average 2.6 [3.4, 1.8] points better than TKA at 6 months and 2.7 [3.5, 1.9] 
points better at one year. SF12 mental health scores varied little throughout the post-operative 
year. Analysis of covariance reveals that the type of arthroplasty and pre-operative Oxford 
Score are predictors of outcome.  
 
Conclusions: Both procedures confer substantial improvement in patient outcome one year 
following surgery; however greater joint specific, general health and satisfaction scores are 




Article focus:  
Common perception is of equivalent outcome following hip and knee arthroplasty  
 
Mean changes in patient reported scores are quantified for both hip and knee arthroplasty.  
 
Models that may be used to predict mean scores for patients with given pre-op Oxford 
Score were developed.  
 
 
Key messages:  
THA patients report superior outcomes and faster improvement than TKA patients.  
 
This difference in outcome is predominantly physical in nature, and mostly occurs in the 
first 6 months.  
 
The extent of the difference in outcome may be informatively displayed via our models.  
 
 
Strengths and limitations:  
This is the largest and most comprehensive study to assess this issue.  
 
The models must be considered with some caution due to the discrete and bounded nature 
of the Oxford Score. In addition they explain only a fifth of the variation in outcome.  
 

































































Total hip and knee arthroplasty (THA and TKA) are very common procedures (each in 
excess of 70,000 per year in UK) that are highly successful in treating the morbidity of 




Outcomes of both procedures are commonly perceived by patients and clinicians to be 
equivalent. This has been reinforced in the general medical literature, Gidwani and Fairbank
4
 
writing specifically about TKA noted comparable outcome with THA as a BMJ article 
summary point.  
 
A variety of cohort studies with small numbers of patients and using differing generic 
measures of health outcome have directly compared the outcome of the two procedures and 
reported conflicting results
5-10
. Wylde et al
11
 conducted a ‘mid-term review’ comparing THA 
and TKA at a single centre using only joint specific outcome measures. Oxford Hip and Knee 
scores were directly compared post-operatively to suggest improved comparative function 
following hip replacement. Pre-operative data was not available, thus comparative change in 
scores could not be addressed. The originators of the Oxford Scores however consider this 
analysis inappropriate as the separate hip and knee questionnaires do not ask equivalent 
questions
 




The aim of this study was prospectively to compare the patient outcome of total knee and hip 
arthroplasty in a large cohort, in the first year following surgery, using relevant standardised 
instruments to form comprehensive assessment of general health, joint specific outcome and 
overall patient satisfaction. This information will help inform patients and healthcare 
providers, who are involved with both referrals into orthopaedic services and with subsequent 
post-operative management, as to the expected outcomes of the surgery. 
 
There are two valid approaches to assessing outcome from pre and post operative data, the 
use of change score (difference in post-operative score from pre-operative values) or to use 
the pre-operative data as a covariate in analysing the final outcome. These approaches 
represent two separate research questions, the first asking whether there is a difference in 
average change of the two populations, the second asking whether a member of group 1 is 
expected to change more than a member of group 2 if they have the same initial value
13
. We 
incorporate both these questions into our analysis. 
 
 
MATERIALS AND METHODS 
 
We prospectively followed all elective primary total hip and primary total knee arthroplasties 
performed at the Royal Infirmary of Edinburgh in the 2 years between January 2006 and 
November 2008 inclusive. This reflected some 1410 total hip and 1244 total knee procedures.  
 
The outcome assessments used were the Oxford Hip or Oxford Knee Score, the Short Form 
12 (SF-12) and a separate validated satisfaction question
14
. Patients were asked to complete 
these self-administered questionnaires at the time of pre-operative assessment and then by 
postal survey at 6 and 12 months post operation.  
 
1410 THA and 1244 TKA datasets were available for analysis pre-operatively, 1389 THA 
and 1223 TKA at 6 months and 1381 THA and 1227 TKA at 12 month follow-up. This 
represents a loss to follow-up of 2% THA and 1.4% TKA patients in the year post surgery. 































































Satisfaction data was recorded at the 12 month follow-up, 1348 THA and 1185 TKA patient 





The Oxford Hip or Knee Score results in a single outcome score between 12 and 60 (a high 
score indicates increased levels of disability because of pain and poor function, with a 
reduction in the Oxford Score indicating improvement). Evaluation of comparative change in 
the respective hip and knee scores was performed to compare between procedures. The SF-12 
results in two scores, the physical and mental components (MCS and PCS). Its scoring is 
based on norm-based methods using population mean scores. Both PCS and MCS have a 
population mean score of 50, with standard deviation of 10. Higher scores denote better 
function with these instruments
16
. The satisfaction question consists of a 4 point Likert scale, 




The first analysis performed addressed the change-score approach i.e. does the average 
change in patient report scores differ between the two populations? Fitzmaurice (2001)
17
 
refers to this as an unconditional research question that compares the average (or 
unconditional mean) change-score in one population with the average change-score in a 
second population. The analysis involved use of ANOVA via the GLM facility in Minitab. 
 
The second analysis (analysis of covariance or adjusted change-score analysis) essentially 
addressed what Fitzmaurice
17
 refers to as the conditional research question: Is there any 
difference between the expected change-score of a THA patient and TKA patient if they have 
the same baseline score? In this analysis the opportunity was also taken to investigate the 
potential influence of the covariates age and gender, as these are thought to influence 
individual outcome of joint arthroplasty. This analysis was performed using multiple 
regression methods. All data analysis and display was carried out with the Minitab (Release 







Differences in age profiles of the groups were assessed with independent sample t-tests.  
THA patients were 2 years (95% confidence interval [-2.86, -1.33] p = <0.001) younger at 
68.1 years at time of operation compared to TKA patients at 70.2 years. The male: female 
ratio in both groups was similar, and no significant difference was found between the mean 
ages of male and female patients within hip and knee groups (Table 1). 
 
Table 1 – Age at time of surgery  
 
Hip 
(n = 1410) 
Knee 
















57.2% 70.4 (9.3) 56.8% 
 































































Table 2 displays means and standard deviations of the patient reported outcome measures. 
The means are also displayed in figures 1 and 2 with 95% confidence intervals for the 
corresponding population means.  
 




6 months 12 months  
Hip 
 
Knee Hip Knee Hip Knee 
PCS 
 
29.5 (8.4) 30.2 (10.4) 42.4 (12.6) 39.5 (11.6) 43.2 (13.0) 40.3 (12.4) 
MCS 
 
49.4 (12.2) 51.4 (12.1) 53.3 (11.3) 51.8 (11.6) 52.5 (11.5) 51.7 (11.6) 
OXS 
 
41.6 (8.3) 41.3 (7.6) 22.4 (9.2) 27.4 (10.1) 21.4 (9.5) 25.8 (10.3) 
 










An ANOVA was performed via GLM in Minitab with factors operation (levels THA and 
TKA), patient (nested within operation) and occasion (with levels pre-op, 6-month and Year).  
An operation-occasion interaction term was included in the model and 95% Bonferroni 
confidence intervals (displayed in Table 3 and 4) obtained for all possible operation – 
occasion pairings. 
 




Change in mean 
score 
95% CI 
Hip -20.2 (-20.9, -19.5) Pre-op – 12 months 
Knee -15.4 (-16.2, -14.7) 
Hip -19.2 (-19.9, -10.5) Pre-op – 6 months 
Knee -13.9 (-14.6, -13.1) 
Hip -1.0 (-1.7, -0.3) 
OXS 
6 months – 12 months 
Knee -1.5 (-2.3, -0.8) 
Hip 13.2 (12.4, 14.0) Pre-op – 12 months 
Knee 10.2 (9.4, 11.0) 
Hip 12.3 (11.6, 13.1) Pre-op – 6 months 
Knee 9.4 (8.6, 10.2) 
Hip 0.9 (0.1, 1.6) 
PCS 
6 months – 12 months 
Knee 0.8 (-0.02, 1.6)ns 
Hip 3.1 (2.1, 4.1) Pre-op – 12 months 
Knee 0.3 (-0.8, 1.3)ns 
Hip 3.9 (2.9, 4.9) Pre-op – 6 months 
Knee 0.6 (-0.6, 1.5)ns 
Hip -0.8 (-1.8, 0.2)ns 
MCS 
6 months – 12 months 
Knee -0.2 (-1.2, 1.5)ns 







































































95% CI Estimate 
 














( 4.2, 5.7) -2.6 
 




( 3.7, 5.1) -2.7 
 
(-3.5, -1.9) -0.8 (-1.8, 0.2) 
ns 
 
This analysis provides evidence, via these confidence intervals, that mean Oxford score 
continued to improve significantly over the year for both procedures. Mean PCS improved 
significantly for both procedures in the initial 6 months. Small further improvements were 
seen between 6 months and 12 months, though were not significant in the TKA group. Pre-
operatively the differences in mean MCS were statistically significant for the two groups, 
with TKA patients having the higher mean.  This situation was reversed at 6 months. There 
was no significant difference after a year.  
 
As an example of a between operation comparison, one year post arthroplasty the mean 
reduction in Oxford Score for hip patients is 4.4 points greater than that for knee patients 




In order to carry out this analysis multiple regression was employed with Oxford score, at 
either 6 months or a year, as the response variable, with type of arthroplasty and time as 
factors, and pre-operative Oxford Score, age and gender as covariates. Variable selection 
procedures yielded a model involving operation and pre-op score with an adjusted R-squared 
value of the order of 20%.  It was found that inclusion of age and gender did not improve the 
explanatory power of the models. Logarithmic transformation of the responses yielded 
residual plots that were more satisfactory than those obtained using the untransformed 
response but did not have any impact on the R-squared values. Because of the discrete and 
bounded nature of the Oxford Scores the models must be treated with some caution. George 




The model displayed in figure 3 is the ANCOVA model with the Oxford Score one year post-
op as the response. For example it predicts that THA patients with pre-operative Oxford 
Score of 40 would have mean Oxford Score of the order of 19 points whereas TKA patients 
pre-operative Oxford Score of 40 would have mean Oxford Score of the order of 23 points. 
Readers are cautioned that there is wide variability in individual patient outcomes as 
indicated by the underlying scatter plot. 
 




Figure 4 – ANCOVA models for Oxford Score at 6 months and 1 year post-op 
 
 































































Figure 4 indicates that, taking the same example of a patient presenting with a pre-operative 
Oxford Score of 40 points, on average, THA patients improve by around 1 further point 
between 6 months and 1 year post-op, whereas TKA patients improve by around 2 points. 
 
Satisfaction with outcome 
 
Very high levels of patient satisfaction were recorded for both procedures. However the 
proportions of patients recording overall satisfaction with the outcome of the arthroplasty at 
one year was significantly greater for the THA group (91.1%) than the TKA group (81.4%) 
(p-value <0.001). Thus 18.6% of TKA patients, around twice the proportion of THA patients 






We are aware of no other study that has prospectively assessed a large cohort of hip and knee 
arthroplasty patients at a single centre in order to compare the patient outcomes of the two 
procedures directly.  
 
Hip arthroplasty was found to outperform knee arthroplasty as measured by relative change 
in the Oxford Hip / Knee Scores, SF-12 score and level of patient satisfaction. 
 
When assessing outcome it has been suggested that a combination of a joint specific and 
general health assessment tool offers the best combined analysis. The Oxford Hip and Knee 
Scores and the Medical Outcomes Study Short Form-12 questionnaires are highly validated 





We found the difference in outcome between THA and TKA groups to be predominantly 
physical in nature. At 12 months post-op mental health scores (MCS) were equivalent 
between the THA and TKA groups, whereas physical scores (Oxford Score and PCS) were 
significantly worse in the TKA group. The detected significant differences in MCS between 
our operative groups at pre-op and at 6 months post-op were small in magnitude, within one 
standard deviation of the population mean, and unlikely to be clinically relevant. 
 
Physical outcome scores for both procedures follow the same trend of substantial 
improvement in the first 6 months following surgery, and then subtle further improvement in 
the second 6 months (figures 1 and 2 and table 3). It is in the initial 6 month period where the 
majority of difference in comparative improvement between the hip and knee procedures 
occurs. The small spontaneous improvement between 6 and 12 months suggests that patients 
functioning poorly at 6 months should perhaps be considered for referral to targeted therapy 
at this point. Both groups demonstrated similar improvement in average scores in the second 
6 months (figure 4). Of further interest is that while the mental health scores remain around 
normative values throughout, the physical scores for each group are initially very low then 
improve dramatically following both procedures, but do not reach normative values on the 
SF12 score. 
 
Previous authors have attempted to assess comparative post-operative function by way of 
generic health measures. Ritter et al
6
 assessed 85 THA and 93 TKA patients in terms of 
quality of life and general health by the SF-36 questionnaire and reported no difference in 































































results. Benroth et al
9
 reported on 63 hips and 110 knees and were also unable to detect a 
difference using SF-36 as an outcome measure. Norman-Taylor
7
 reported a small cohort of 
41 THA and 31 TKA and suggested similar outcomes were achieved, however in order to 
compare the different outcome scores, they carefully converted the Harris Hip scores and a 
modified British Orthopaedic Association Knee functional assessment chart into Rossiter 
distress and disability scores and then compared them on the Rossiter index matrix. From this 
they derived quality of life scores but found no significant difference between the operative 
groups.  
 
Conversely Bachmeier et al
8
 reported significantly enhanced WOMAC and SF-36 scores for 
hip arthroplasty patients (n = 86) at 6 and 12 months post-operatively compared to knee 
arthroplasty patients (n = 108). In a review Ethgen et al [1] commented on the conflict in the 
literature concerning the results of THA and TKA. They considered that for quality of life 
outcome measures patients did better following THA, however meta-analysis was not 
performed. Bourne et al
10
 assessed a large Canadian cohort using the WOMAC score and 
willingness to undergo the procedure again as outcome measures. They suggested superior 
outcome with THA, but their study suffered from a 30% loss to follow-up. O’Brein et al
5
 
suggested improved function in hip patients using a comparison of change in the joint 
specific Oxford Hip/Knee Scores as the sole outcome measure. Wylde et al
11
 also reported 
superior outcome of THA compared to TKA using the Oxford Scores. Their analysis was 
limited however by not presenting any pre-operative data. Further Dawson et al
12
 have 
criticised the methodology of Wylde’s paper, highlighting the different population 
characteristics of hip and knee patients and that 3 of 12 questions are different in the 
respective Oxford Hip and Knee Score questionnaires. Dawson et al
12
 commented that direct 
comparison of the respective mean Oxford Scores is not valid and thus the results suggested 
by Wylde et al
11
 potentially misleading.  
 
We concur that directly comparing the means of the Oxford Hip and Oxford Knee Scores is 
controversial but consider that comparing the relative change in the scores to be of value, 
particularly as our operative groups had very similar distributions of baseline Oxford Score. 
The comparative change of approximately 5 points on the Oxford scale is relatively large and 
this magnitude of change on either hip or knee score would be considered clinically 
significant.  
 
Of particular interest was that the overall patient satisfaction with the procedure also differed 
between hip and knee arthroplasty, with more patients in the THA group being satisfied 
(91.1%) compared to the TKA group (81.4%). This supports the finding of superior results 
after hip arthroplasty suggested by SF-12 scores and change in Oxford Scores. 
 
We have attempted to answer two separate research question in our analysis. The first relates 
to the broad question of overall group change and the second sought to take into account any 
important covariates that may influence outcome. Interestingly, both analyses provide the 
same answer of approximately 5 point greater improvement in the Oxford Score in the THA 
group compared to the TKA group. This similarity in output results from the very similar 
baseline values of the two groups and the lack of effect of age and gender on the covariant 
analysis. 
 
Our model identifies that the procedure factor (operation) and baseline score covariate are 
predictors of outcome. However, there is a large proportion of unexplained variation. Current 
work within he orthopaedic community seeks to create more effective models for the 
prediction of post-operative outcome. Statisticians are also addressing issues associated with 































































discrete and bounded responses such as the Oxford Scores
22
. Our model can be seen as a 
useful starting point with which to inform both patients and clinicians as to the likely average 
outcome of each procedure. 
 
In conclusion, our results from a large cohort demonstrate that there is a high level of 
satisfaction and considerable improvement in patient reported outcome measures after both 
total hip and total knee arthroplasty. Patients are however more likely to report a greater 
improvement following total hip arthroplasty compared to total knee arthroplasty. Most 
improvement in patient scores occurs in the initial 6 months period post-op, however small 
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figure 1 - Mean Oxford Scores  
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Figure 2 - Mean SF12 Scores  
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Figure 3 - Scatter plot with ANCOVA model for Oxford Score 1 year post-op  
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figure 4 - ANCOVA models for Oxford Score at 6 months and 1 year post-op  
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(b) Describe any methods used to examine subgroups and interactions  
(c) Explain how missing data were addressed 4 
(d) If applicable, explain how loss to follow-up was addressed 4 
Statistical methods 12 
(e) Describe any sensitivity analyses  
Results  

































































Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
2, 4 
  (b) Give reasons for non-participation at each stage  
  (c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential 
confounders 
4 
  (b) Indicate number of participants with missing data for each variable of interest 2 
  (c) Summarise follow-up time (eg, average and total amount) 2 
Outcome data 15* Report numbers of outcome events or summary measures over time 5, 6 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and why they were included 
5, 6 
  (b) Report category boundaries when continuous variables were categorized  
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  
Discussion    
Key results 18 Summarise key results with reference to study objectives 7, 8, 9 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
8, 9 
Generalisability 21 Discuss the generalisability (external validity) of the study results 8, 9 
Other information    
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on 
which the present article is based 
9 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
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PATIENT REPORTED OUTCOME MEASURES (PROMS) DO NOT FULLY REPRESENT 










University of Edinburgh, Edinburgh, UK, 
2





Most studies now use Patient Reported Outcome Measures (PROMS) as the preferred and 
only method for assessing ‘functional outcome’ following surgery. It is assumed that these 
questionnaires accurately reflect the patient’s pain and physical function. We hypothesised 
that comprehensive functional examination would therefore correlate strongly with PROMS 




We prospectively assessed the function of 100 consecutive knee replacement patients, pre-
operatively, then at 8, 26 and 52 weeks post-operatively. PROMS employed were the Oxford 
Knee Score (OKS), and the Short Form-36. Additionally, leg strength (Leg Extensor Power 
Rig TM), a validated battery of timed functional tasks (Aggregated Locomotor Function, 
ALF), pain scores (numerical rating scale), and range of motion (hand held goniometry) were 
also assessed. Statistical analysis was performed using the Minitab version 15 software. 




7 patients were lost to follow-up leaving 93 data sets available for analysis. All of the 
individual outcome measures showed statistically significant improvement between each of 
the assessment periods (paired sample t-test, p = <0.05). Strong correlation was observed 
between the two PROMS (r = 0.74). Comparatively small correlations were identified 
between the PROMS and physical assessments (r = < 0.41). The pain scores correlated 
modestly well with the OKS (r = 0.61) but comparatively poorly with the physical 




PROMS correlate well with pain, but less well with function following TKA. These results 
suggest that PROMS may not fully represent actual physical function, but rather the patient’s 
perception of their function. We propose the use of a hierarchical assessment framework to 
assess patient function. With the advancement of PROMS as the prime outcome measure of 
most studies, it is important to acknowledge that the assessment provided may be 
incomplete, and though a useful means of assessing large cohorts, their limitation in 
assessing functional outcome should be recognised. 
 
 174 





ASSESSING OUTCOME POST TKA: A MODEL OF OUTCOME ASSESSMENT 
 
D Hamilton (1), AHRW Simpson (1), P Gaston (2) 
 
1 University of Edinburgh, Edinburgh, UK,  




Most studies now use Patient Reported Outcome Measures (PROMS) as the preferred and 
only method for assessing ‘functional outcome’ following surgery. We hypothesised that 
comprehensive functional examination would therefore correlate strongly with PROMS 
following total knee arthroplasty (TKA).  
 
Methods  
We prospectively assessed the function of 100 consecutive knee replacement patients, pre-
operatively, then at 8, 26 and 52 weeks post-operatively. PROMS employed were the Oxford 
Knee Score (OKS), and the Short Form-12. Leg strength (Leg Extensor Power RigTM), a 
validated battery of timed functional tasks (Aggregated Locomotor Function) and pain scores 
(numerical rating scale) were also assessed. Significance was set as p = <0.05.  
 
Results  
93 data sets were available for analysis. All the individual outcome measures showed 
significant improvement between each assessment period (paired sample t-test, p = <0.05). 
Strong correlation was observed between the two PROMS (r = 0.74). Comparatively small 
correlations were identified between the PROMS and physical assessments (r = < 0.41). The 
pain scores correlated comparatively well with the OKS (r = 0.61) but comparatively poorly 
with the physical assessments (r = < 0.37).  
 
Discussion  
PROMS correlate well with pain, but less well with function following TKA. This suggests that 
PROMS may not fully represent actual physical function, but perhaps the perception of 
function. With the advancement of PROMS as the prime outcome measure of most studies, 
it is important to acknowledge that the assessment may be incomplete, and though a useful 













MUSCLE SATELLITE CELL NUMBER INFLUENCES POST OPERATIVE RECOVERY 










Orthopaedic Engineering Collaboration, University of Edinburgh, Edinburgh, UK 
2





Muscle recovery after Total Knee Replacement (TKR) is variable. Satellite cells are 
undifferentiated myogenic precursors considered to be muscle stem cells. We hypothesised 
that the recovery of muscle strength following knee replacement in a given patient would be 




20 patients undergoing TKR were recruited from the waiting list of a single consultant. A 
muscle biopsy was taken at the time of surgery from the distal quadriceps. This was fixed in 
paraffin wax, and sections obtained. Satellite cells were identified with a primary mouse 
antibody for Pax7 - a cytoplasmic protein marker - and an immunofluorescent goat anti-
mouse secondary. Slides were counterstained with DAPI to stain the myonuclei. The positive 
staining index (PSI) was calculated (number of satellite cells/total number of myonuclei x 
100). Recovery of muscle (quadriceps) strength was assessed using the leg extensor power-
rig (LegRig), pre-operatively, at 6 and 26 weeks post-operatively. Statistical analysis was 




3 patients were unable to provide follow-up data. The number of satellite cells varied (PSI 
3.07 to 11.35). Improvement in muscle power varied (0 to 70 W) between the 6 and 26 
weeks assessment periods. This reflected a 0 to 60% improvement in the individual’s 
strength to bodyweight ratio. The improvement in muscle power correlated with the satellite 
cell numbers (determined at the time of surgery). This was true for both absolute 
improvement in wattage generated, r = 0.54 p= 0.038 and improvement in strength relative 
to body weight r = 0.47 p = 0.06. Linear regression analysis demonstrated that the relative 




We have for the first time demonstrated that the magnitude of improvement in muscle 
strength following TKR may be influenced by the patient¹s underlying pool of satellite cells, 




Orthopaedic Research Society, New Orleans, 2010 
 
Patient Report of Outcome Differs to Objective Assessment of Physical Function Following 
Total Knee Arthroplasty 
 
+1Hamilton, D F; 2Simpson, A H R W; 2Gaston, P 
+1University of Edinburgh, Edinburgh, UK, 2Royal Infirmary of Edinburgh, Edinburgh, UK 
 
Introduction 
End-stage osteoarthritis is characterised by pain and 
reduced physical function, for which total knee 
arthroplasty (TKA) is recognised to be a highly effective 
treatment. It is important to quantify improvement 
following surgical intervention, and increasingly Patient 
Reported Outcome Measures (PROMS) are the preferred 
method of assessing pain and physical function following 
TKA, Most studies now utilise these self-report measures 
alone to report patient functional outcome. It is assumed 
that these self-report outcome questionnaires accurately 
reflect the patient’s pain and physical function. Limited 
evidence is now emerging however that this may not be 
the case. We hypothesised that a physical examination of 
patient function would correlate strongly with patient self-
report questionnaires following TKA. 
 
Methods 
Approval was granted by the local ethical research 
committee and 100 consecutive patients with knee 
osteoarthritis listed for TKA at the investigating hospital 
were recruited to the study with informed consent. 
Assessment was carried out pre-operatively and at 8 
weeks and 26 weeks post-operation. Patient report 
questionnaires were completed independently and handed 
to the researcher in a sealed envelope prior to the physical 
assessments. The self-report outcome questionnaires used 
were the Oxford Knee Score (OKS) which assesses pain 
and function following TKA as a single score, and the 
Short Form-36 which assesses physical function (PCS) 
and mental function (MCS) separately. Additionally, 
direct measurement of leg strength was assessed (Leg 
Extensor Power Rig TM), a validated performance battery 
of timed functional tasks was performed (Automated 
Locomotor Function, ALF), pain scores were recorded by 
numerical rating scale, and range of motion was assessed 
by hand held goniometry. All assessments were carried 
out by the same researcher. Statistical analysis was 
performed using the Minitab version 15 software. Level 
of significance was set as p = <0.05. 
 
Results 
Of the 100 recruits, 93 complete data sets were available 
for analysis. All of the individual outcome measures 
showed statistically significant improvement between 
each of the assessment periods (paired sample t-test, p = 
<0.05). Scatter plots were created for the interaction 
between the outcome variables. Normal distribution was 
found in all cases; therefore the Pearson correlation 
coefficient was calculated. Strong correlation was 
observed between the two separate patient report 
measures (r = 0.74, p = <0.001). Lesser correlation was 
observed between the separate physical assessments, ALF 
and leg strength (r = 0.47, p = 0.001). Comparatively 
small correlations were identified between the patient 
report and physical assessments. The OKS correlated with 
the ALF, (r = 0.37, p = < 0.001) and with leg strength (r = 
0.37, p = 0.001), further the PCS correlated with ALF (r = 
0.41, p = < 0.001) and with leg strength (r = 0.18, p = 
0.15). The pain scores correlated moderately well with the 
OKS (r = 0.61, p = < 0.001) and comparatively poorly 
with the other measures; with PCS, r = 0.38 (p = 0.002), 
with ALF, r = 0.37 (p = < 0.001), with leg strength, r = 
0.15 (p = 0.154). Range of motion formed small 
correlations with all of the other outcome assessments; 
with OKS, r = 0.31 (p = 0.002), with PCS, r = 0.26 (p = 
0.04), with ALF, r = 0.34 (p = 0.001), with leg strength, r 
= 0.23 (p = 0.003), with pain score, r = 0.32 (p = 0.002).  
 
Discussion 
As expected, significant improvements in outcome scores 
were detected across all our outcome measures and 
between all the assessment periods, charting the 
improvement that accompanies recovery following TKA 
surgery. Among our outcome assessments, interestingly, 
strong correlation was found between the two separate 
patient questionnaires, but not between the questionnaire 
scores and direct physical assessment. It is notoriously 
difficult to interpret correlation coefficients. It has 
been suggested that any criteria set are in some way 
arbitrary as interpretation depends upon the context of the 
investigation2. In this context, it is reassuring that the 
expected strong correlation between the two separate 
PROMS was found. This puts into perspective the poor-
to-modest correlations found between the patient report 
scores and the physical assessments that these scores are 
supposed to represent. Patient outcome following TKA is 
of complex multifactorial nature. That the leg strength and 
functional assessments correlate only modestly suggests 
that these associated measures assess different aspects of 
patient function. Of further interest is the role of range of 
motion. Our results suggest a small but significant 
interaction between knee flexion and patient outcome, 
with less flexion being associated with poorer outcome 
scores across our assessments. The interaction of these 
factors reinforces this multifactorial nature of functional 
outcome. Our results further confirm the known link 
between patient postoperative pain, and functional 
outcome. It is interesting however, that the patient report 
of pain correlated strongly with the patient report 
questionnaires (that include specific questions addressing 
pain) but substantially less well with the physical 
assessments. This finding, while acknowledging the good 
agreement of pain scores, further questions the 
ability of the PROMS to reflect patient function. It may 
be, as has been suggested1, that the self-report measures 
represent the experience of the patient when performing 
an activity, rather than the patient’s ability to actually 
perform that activity. These results suggest that self-report 
outcome measures may not fully represent actual physical 
function following TKA. With the advancement of 
PROMS in the surgical literature, it is important to 
recognise that the assessment they provide may be  
incomplete, and that the practice of reporting functional 
outcome based solely on patient report methods should be 
questioned. A larger longitudinal study would be 




This work forms part of a PhD award funded jointly by 
the Medical Research Council (UK) Doctoral Training 
Scheme and by Stryker UK.
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PATIENT REPORTED OUTCOME DIFFERS TO ASSESSMENT OF PHYSICAL 
FUNCTION FOLLOWING TOTAL KNEE ARTHROPLASTY 
 
 
DF. Hamilton[1], AHRW. Simpson[1,2], P. Gaston[2] 
 
[1] Edinburgh Orthopaedic Engineering Collaboration, University of Edinburgh, UK  
[2] Royal Infirmary of Edinburgh, UK  
 
Purpose  
To examine the relationship between physical outcome and patient report of outcome 
following total knee arthroplasty (TKA).  
 
Relevance  
Increasingly Patient Reported Outcome Measures (PROMS) are used to assess function 
following TKA. It is assumed that these measures accurately reflect the patient’s pain and 
physical function, however, evidence is emerging that this may incorrect.  
 
Methods  
Approval was granted by the Local Research Ethics Committee, and 26 consecutive patients 
listed for TKA were assessed pre TKA, and at 8 and 26 weeks post-operation. The Oxford 
Knee Score (OKS) and the physical function score (PCS) of the Short Form-36 were utilised 
as self report outcomes. Direct measurement of leg strength was assessed (Leg extensor 
Power Rig TM). Timed assessment of functional tasks was performed (Automated 
Locomotor Function, ALF). Pain scores were recorded by numerical rating scale.  
 
Results  
All the individual measures showed statistically significant improvement between each of the 
assessment periods (paired sample t-test, p = <0.05). The PROMS however were found to 
correlate poorly to the physical assessments. The OKS correlated poorly with the ALF, (r = < 
0.5) and with leg strength (r = < 0.3).The PCS correlated poorly with ALF (r = < 0.2) and with 
leg strength (r = 0.34).  
 
Conclusions  
These results suggest that PROMS do not fully represent actual physical function following 
TKA. With the advancement of PROMS in the literature, it is important to recognise that the 
assessment they provide may be incomplete. A larger study would be beneficial to assess 
this issue fully. 
 
Support 
This work forms part of a PhD award with is jointly funded by the Medical Research Council 
and Stryker UK  
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Poster: TKR Outcome: PROMS not consistent with direct function assessment 
 
 
ABC Travelling Fellows, Edinburgh, 2009 
 
Invited speaker: Outcome assessments – PROMS are not the whole story 
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Appendix C: Statistical output (Chapter 3) 
Oxford Knee Score 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre Ox 1 41.36 7.220 95 
2 40.32 7.915 79 
Total 40.89 7.539 174 
12m Ox 1 21.35 7.679 95 
2 23.19 8.290 79 
Total 22.18 7.992 174 
 
Group * Oxford 
Group oxford Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 41.358 .774 39.830 42.886 
2 21.347 .817 19.735 22.960 
   2 1 40.316 .849 38.641 41.992 
2 23.190 .896 21.422 24.958 
 
Tests of Within-Subjects Contrasts 
Source oxford 
Type III Sum of 
Squares df Mean Square F Sig. 
Oxford Linear 29743.196 1 29743.196 709.462 .000 
Oxford * Group Linear 179.368 1 179.368 4.278 .040 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 
 






6w Ox –  
pre Ox 
6m Ox –  
6w Ox 
12m Ox –  
6m Ox 







Asymp. Sig. (2-tailed) .000 .000 .000 







Asymp. Sig. (2-tailed) .000 .000 .000 
a. Based on positive ranks. 








 Pre Ox 6w Ox 6m Ox 12m Ox 
Mann-Whitney U 3525.000 3396.500 3550.500 3331.000 
Wilcoxon W 6685.000 7674.500 6325.500 8381.000 
Z -.801 -.172 -.120 -2.180 
Asymp. Sig. (2-tailed) .423 .863 .904 .029 





Range of motion – Flexion 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre Flex 1 104.85 14.762 100 
2 104.52 14.543 82 
Total 104.70 14.624 182 
12m Flex 1 110.00 10.863 100 
2 103.88 12.025 82 
Total 107.24 11.772 182 
 
Group * flexion 
Group flexion Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 104.850 1.466 101.956 107.744 
2 110.000 1.140 107.750 112.250 
   2 1 104.524 1.619 101.329 107.720 
2 103.878 1.259 101.394 106.362 
 
Tests of Within-Subjects Contrasts 
Source flexion 
Type III Sum of 
Squares Df Mean Square F Sig. 
flexion Linear 456.923 1 456.923 5.082 .025 
flexion * Group Linear 756.868 1 756.868 8.418 .004 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 












   1  Flex pre – Flex 6w 7.323 14.714 1.502 4.34 10.30 4.876 95 .000 
 Flex 6w – Flex 6m -8.928 9.400 .954 -10.82 -7.03 -9.35 96 .000 
 Flex 6m– Flex 12m -3.673 6.391 .636 -4.94 -2.41 -5.78 100 .000 
   2  preFlex - 6wFlex 10.200 13.032 1.46 7.30 13.1 7.01 79 .000 
 6wFlex - 6mFlex -7.532 8.001 .91 -9.35 -5.72 -8.26 76 .000 
 6mFlex - 12mFlex -2.872 6.925 .78 -4.43 -1.31 -3.66 77 .000 
 
 
Independent Samples Test 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 











assumed .012 .913 3.660 181 .000 6.191 1.692 2.853 9.529 
not assumed   3.620 164.90 .000 6.191 1.710 2.814 9.568 
6m 
Flex 
assumed .005 .944 2.661 177 .009 4.870 1.830 1.258 8.483 
not assumed   2.637 159.84 .009 4.870 1.847 1.223 8.517 
6w 
Flex 
assumed .520 .472 1.701 175 .091 3.380 1.987 -.541 7.301 
not assumed   1.705 170.08 .090 3.380 1.982 -.532 7.292 
Pre 
Flex 
assumed .003 .956 .149 180 .882 .326 2.185 -3.985 4.636 




Range of motion – Extension 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre Ext 1 3.05 5.239 100 
2 3.27 5.698 82 
Total 3.15 5.436 182 
12m Ext 1 .30 1.210 100 
2 1.16 3.320 82 
Total .69 2.433 182 
 
Group * extension 
Group 
extensi
on Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 3.050 .545 1.975 4.125 
2 .300 .240 -.174 .774 
   2 1 3.268 .602 2.081 4.456 
2 1.159 .265 .635 1.682 
 
Tests of Within-Subjects Contrasts 
Source extension 
Type III Sum of 
Squares df Mean Square F Sig. 
extension Linear 532.036 1 532.036 38.703 .000 
extension * 
Group 
Linear 9.234 1 9.234 .672 .414 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 
 












   1  Ext pre – Ext 6w 1.13 5.79 .59 -.05 2.30 1.90 95 .060 
 Ext 6w – Ext 6m 1.22 3.00 .31 .61 1.82 3.99 96 .000 
 Ext 6m – Ext 12m .54 1.56 .15 .23 .84 3.45 100 .001 
   2  Ext pre – Ext 6w 1.29 5.37 .60 .09 2.48 2.14 79 .035 
 Ext 6w – Ext 6m 1.09 3.03 .35 .40 1.78 3.16 76 .002 




Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 











assumed .510 .476 -.269 180 .788 -.218 .812 -1.821 1.384 
not assumed   -.267 166.68 .790 -.218 .819 -1.835 1.398 
Ext 
6w 
assumed .271 .603 .134 175 .894 .081 .605 -1.113 1.275 
not assumed   .134 167.96 .894 .081 .605 -1.114 1.276 
Ext 
6m 
assumed 1.120 .291 -.445 177 .657 -.155 .350 -.846 .535 
not assumed   -.432 144.18 .667 -.155 .360 -.867 .556 
Ext 
12m 
assumed 22.784 .000 -2.42 181 .017 -.862 .356 -1.564 -.159 




Timed functional assessment 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre ALF 1 36.1769 15.63527 101 
2 34.3961 12.32829 82 
Total 35.3790 14.23906 183 
12m ALF 1 25.5044 6.83123 101 
2 25.7340 6.34935 82 
Total 25.6073 6.60270 183 
 
Group * ALF 
Group ALF Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 36.177 1.418 33.379 38.975 
2 25.504 .659 24.205 26.804 
   2 1 34.396 1.574 31.291 37.501 
2 25.734 .731 24.292 27.176 
 
 
Tests of Within-Subjects Contrasts 
Source ALF 
Type III Sum of 
Squares df Mean Square F Sig. 
ALF Linear 8459.149 1 8459.149 127.036 .000 
ALF * Group Linear 91.467 1 91.467 1.374 .243 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 












   1  ALF pre – ALF 6w 4.64 11.82 1.19 2.27 7.01 3.885 97 .000 
 ALF 6w – ALF 6m 4.93 6.66 .67 3.59 6.26 7.317 97 .000 
 ALF 6m – ALF 12m 1.10 3.99 .40 .31 1.89 2.761 100 .007 
   2  ALF pre – ALF 6w 2.82 10.09 1.13 .57 5.06 2.497 79 .015 
 ALF 6w – ALF 6m 5.50 7.74 .88 3.74 7.26 6.233 76 .000 
 ALF 6m – ALF 12m .84 3.99 .45 -.065 1.74 1.848 77 .068 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 











assumed 1.124 .290 .841 181 .402 1.78 2.12 -2.40 5.96 
not assumed   .861 180.86 .390 1.78 2.07 -2.30 5.86 
ALF 
6w 
assumed .161 .689 -.057 176 .955 -.10 1.74 -3.53 3.33 
not assumed   -.057 173.21 .955 -.10 1.73 -3.50 3.31 
ALF 
6m 
assumed .469 .494 .099 177 .921 .12 1.18 -2.20 2.44 
not assumed   .100 169.86 .920 .12 1.17 -2.19 2.42 
ALF 
12m 
assumed .221 .639 -.233 181 .816 -.23 .98 -2.17 1.712 




Lower limb power output 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre LR Max 1 42.20 37.809 99 
2 47.11 44.298 80 
Total 44.40 40.792 179 
12m LR Max 1 87.22 48.380 99 
2 77.59 46.561 80 
Total 82.92 47.686 179 
 
Group * Legrig 
Group Legrig Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 42.202 4.104 34.103 50.301 
2 87.222 4.782 77.786 96.659 
   2 1 47.113 4.565 38.103 56.122 
2 77.586 5.319 67.089 88.084 
 
Tests of Within-Subjects Contrasts 
Source Legrig 
Type III Sum of 
Squares df Mean Square F Sig. 
Legrig Linear 126085.887 1 126085.887 239.985 .000 
Legrig * Group Linear 4681.190 1 4681.190 8.910 .003 





Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 
 












    1  LR pre – LR 6w -11.47 22.49 2.30 -16.03 -6.91 -5.00 95 .000 
 LR 6w  -LR 6m -20.07 21.05 2.13 -24.29 -15.85 -9.44 97 .000 
 LR 6m – LR 12m -12.70 21.93 2.182 -17.03 -8.37 -5.82 100 .000 
    2  LR pre – LR 6w -1.86 30.26 3.43 -8.68 4.96 -.54 77 .589 
 LR 6w – LR 6m -25.47 26.75 3.05 -31.54 -19.40 -8.35 76 .000 
 LR 6m – LR 12m -4.51 24.48 2.77 -10.03 1.01 -1.62 77 .108 
 
 
Independent Samples Test 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 











assumed 1.101 .296 -.800 177 .425 -4.91 6.139 -17.03 7.204 
not assumed   -.787 155.84 .433 -4.91 6.242 -17.24 7.420 
6w  
LR  
assumed 3.338 .069 .876 176 .382 4.745 5.41 -5.940 15.43 
not assumed   .891 175.77 .374 4.745 5.32 -5.761 15.25 
6m  
LR  
assumed .001 .974 .152 177 .879 .972 6.38 -11.61 13.55 
not assumed   .151 157.72 .880 .972 6.45 -11.77 13.71 
12m 
LR  
assumed 1.681 .196 1.435 181 .153 10.062 7.01 -3.777 23.90 




Proportional lower limb power output 
 
1 year outcome ANOVA output 
 
Statistical analysis (SPSS) output: 
 
Descriptive Statistics 
 Group Mean Std. Deviation N 
LR Prop Pre 1 50.4060 32.04205 98 
2 50.4655 36.67287 80 
Total 50.4655 36.67287 80 
LR Prop 12M 1 116.5360 35.91522 98 
2 93.3504 35.77775 80 
Total 93.3504 35.77775 80 
 
Group * Legrig proportional 
Group 
Legrig 
prop Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 50.406 3.455 43.588 57.224 
2 116.536 3.622 109.388 123.684 
   2 1 50.466 3.823 42.920 58.011 
2 93.350 4.009 85.439 101.261 
 




Type III Sum of 
Squares df Mean Square F Sig. 
Legrig prop Linear 261720.588 1 261720.588 249.087 .000 
Legrig prop * Group Linear 11899.586 1 11899.586 11.325 .001 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 
 










95% CI  
Lower Upper 
  1  LR Pre – LR 6w -17.06 36.78 3.77 -24.56 -9.57 -4.52 94 .000 
 LR 6w – LR 6m -34.76 44.68 4.53 -43.76 -25.75 -7.66 96 .000 
 LR 6m – LR 12M -14.07 42.04 4.20 -22.41 -5.73 -3.35 99 .001 
  2  LR Pre – LR 6w -6.92 37.61 4.26 -15.40 1.55 -1.63 77 .108 
 LR 6w – LR 6m -30.87 28.58 3.26 -37.35 -24.38 -9.48 76 .000 
 LR 6m – LR 12M -6.03 28.04 3.18 -12.35 .28 -1.90 77 .061 
 
 
Independent Samples Test 
 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 











assumed 2.354 .127 -.012 176 .991 -.06 5.15 -10.22 10.10 
not assumed   -.011 158.13 .991 -.06 5.22 -10.37 10.25 
LR 
6w 
assumed .029 .865 2.277 175 .024 10.6 4.67 1.42 19.84 
not assumed   2.317 174.98 .022 10.6 4.59 1.58 19.68 
LR  
6m 
assumed 3.941 .049 2.081 176 .039 13.37 6.42 .69 26.04 
not assumed   2.207 165.93 .029 13.37 6.06 1.41 25.33 
LR 
12M 
assumed .007 .934 4.427 180 .000 23.42 5.29 12.98 33.86 




Reported average pain score 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre P  
Ave 
1 5.24 1.511 101 
2 5.54 1.557 82 
Total 5.37 1.535 183 
12m P  
Ave 
1 .83 1.484 101 
2 1.16 1.567 82 
Total .98 1.526 183 
 
Group * Pain ave 
Group 
Pain 
ave Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 5.238 .152 4.937 5.538 
2 .832 .151 .533 1.130 
   2 1 5.537 .169 5.203 5.870 
2 1.159 .168 .827 1.490 
 




Type III Sum of 
Squares df Mean Square F Sig. 
Pain ave Linear 1745.974 1 1745.974 849.934 .000 
Pain ave * Group Linear .018 1 .018 .009 .926 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 
 






6w P Ave –  
pre P Ave 
6m P Ave –  
6w P Ave 
12m P Ave - 
















Asymp. Sig. (2-tailed) .000 .000 .003 
a. Based on positive ranks. 








 Pre P Ave 6w P Ave 6m P Ave 12m P Ave 
Mann-Whitney U 3689.000 3402.500 3493.000 3599.500 
Wilcoxon W 8840.000 8253.500 8644.000 8750.500 
Z -1.302 -1.535 -1.370 -1.741 
Asymp. Sig. (2-tailed) .193 .125 .171 .082 




Reported maximal pain score 
 
1 year outcome ANOVA output 
 




Group Mean Std. Deviation N 
Pre P  
Max 
1 8.29 1.410 101 
2 8.24 1.520 82 
Total 8.27 1.456 183 
12m P  
Max 
1 1.90 2.452 101 
2 2.90 2.618 82 
Total 2.35 2.569 183 
 
Group * pain max 
Group 
Pain 
max Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
   1 1 8.287 .145 8.000 8.574 
2 1.901 .251 1.405 2.397 
   2 1 8.244 .161 7.926 8.562 
2 2.902 .279 2.352 3.453 
 
 




Type III Sum of 
Squares df Mean Square F Sig. 
Pain max Linear 3112.236 1 3112.236 937.000 .000 
Pain max * Group Linear 24.695 1 24.695 7.435 .007 




Longitudinal between assessment and between group output 
 
Statistical analysis (SPSS) output: 
 
 






6w P Max –  
pre p Max 
6m P Max –  
6w P Max 
12m P Max - 
6m P Max 







Asymp. Sig. (2-tailed) .000 .000 .000 







Asymp. Sig. (2-tailed) .000 .000 .055 
a. Based on positive ranks. 








 Pre P Max 6w P Max 6m P Max 12m P Max 
Mann-Whitney U 4141.000 3485.000 3744.500 3148.500 
Wilcoxon W 7544.000 8336.000 8895.500 8299.500 
Z .000 -1.282 -.576 -2.885 
Asymp. Sig. (2-tailed) 1.000 .200 .565 .004 




Appendix D: Statistical output (Chapter 4) 
Multiple linear regression analysis of predictors of OKS (12 month 
assessment) 
 
The regression equation is: 
 
12mOx = 22.2 - 0.0367 12mFlex + 0.314 12mALF + 1.24 12mPMax + 1.12 12mPAve 
        - 0.0317 12mLRMax - 1.12 Gender - 0.0550 Age 
 
182 cases used, 1 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     22.236    5.561   4.00  0.000 
12mFlex    -0.03668  0.03335  -1.10  0.273 
12mALF      0.31418  0.06907   4.55  0.000 
12mPMax      1.2354   0.2218   5.57  0.000 
12mPAve      1.1157   0.3793   2.94  0.004 
12mLRMax   -0.03174  0.01041  -3.05  0.003 
Gender      -1.1166   0.8880  -1.26  0.210 
Age        -0.05498  0.04801  -1.15  0.254 
 
S = 4.83721   R-Sq = 64.0%   R-Sq(adj) = 62.5% 
 
PRESS = 4557.76   R-Sq(pred) = 59.69% 
 
Analysis of Variance 
 
Source           DF       SS      MS      F      P 
Regression        7   7236.4  1033.8  44.18  0.000 
Residual Error  174   4071.4    23.4 
Total           181  11307.7 
 
Stepwise regression model  
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
Response is 12mOx on 7 predictors, with N = 182 
N (cases with missing observations) = 1 N (all cases) = 183 
 
Step             1      2      3        4 
Constant    17.122  7.245  7.776   11.635 
 
12mPMax       2.14   1.88   1.34     1.33 
T-Value      12.97  12.42   6.07     6.16 
P-Value      0.000  0.000  0.000    0.000 
 
12mALF              0.409  0.391    0.317 
T-Value              6.96   6.81     5.02 
P-Value             0.000  0.000    0.000 
 
12mPAve                     1.22     1.16 
T-Value                     3.30     3.16 
P-Value                    0.001    0.002 
 
12mLRMax                          -0.0227 
T-Value                             -2.61 
P-Value                             0.010 
 
S             5.70   5.07   4.93     4.86 
R-Sq         48.30  59.32  61.67    63.09 
R-Sq(adj)    48.01  58.86  61.02    62.25 
Mallows Cp    71.9   20.6   11.2      6.4 
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Multiple linear regression analysis of predictors of OKS (6 month 
assessment) 
 
The regression equation is: 
 
6mOx = 22.8 + 0.0153 6mFlex + 0.415 6mALF + 0.988 6mPMax + 0.841 6mPAve 
       - 0.0322 6mLRMax - 1.19 Sex - 0.152 Age 
 
171 cases used, 12 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     22.823    5.773   3.95  0.000 
6mFlex      0.01531  0.03596   0.43  0.671 
6mALF       0.41537  0.06699   6.20  0.000 
6mPMax       0.9885   0.2805   3.52  0.001 
6mPAve       0.8408   0.4343   1.94  0.055 
6mLRMax    -0.03216  0.01304  -2.47  0.015 
Gender      -1.1914   0.9852  -1.21  0.228 
Age        -0.15233  0.05248  -2.90  0.004 
 
S = 5.37420   R-Sq = 59.2%   R-Sq(adj) = 57.5% 
 
PRESS = 5272.48   R-Sq(pred) = 54.32% 
 
Analysis of Variance 
 
Source           DF        SS      MS      F      P 
Regression        7   6834.01  976.29  33.80  0.000 
Residual Error  163   4707.78   28.88 
Total           170  11541.79 
 
 
Stepwise regression model  
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
Response is 6mOx on 7 predictors, with N = 171 
N (cases with missing observations) = 12 N (all cases) = 183 
 
Step             1      2       3       4 
Constant    19.224  9.117  17.404  22.417 
 
6mPMax        1.93   1.59    1.47    1.45 
T-Value      10.55   9.54    8.72    8.74 
P-Value      0.000  0.000   0.000   0.000 
 
6mALF               0.417   0.474   0.405 
T-Value              7.34    7.96    6.27 
P-Value             0.000   0.000   0.000 
 
Age                        -0.138  -0.153 
T-Value                     -2.72   -3.03 
P-Value                     0.007   0.003 
 
6mLRMax                            -0.029 
T-Value                             -2.51 
P-Value                             0.013 
 
S             6.42   5.60    5.50    5.41 
R-Sq         39.69  54.35   56.29   57.89 
R-Sq(adj)    39.34  53.81   55.50   56.87 
Mallows Cp    74.0   17.4    11.7     7.3 
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Multiple linear regression analysis of predictors of OKS (6 week 
assessment) 
 
The regression equation is: 
 
6wOx = 36.7 - 0.0243 6wFlex + 0.157 6wALF + 0.884 6wPMax + 1.36 6wPAve 
       - 0.0472 6wLRMax - 2.34 Sex - 0.137 Age 
 
166 cases used, 17 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     36.660    6.703   5.47  0.000 
6wFlex     -0.02428  0.04258  -0.57  0.569 
6wALF       0.15668  0.05536   2.83  0.005 
6wPMax       0.8839   0.3135   2.82  0.005 
6wPAve       1.3561   0.3917   3.46  0.001 
6wLRMax    -0.04723  0.02011  -2.35  0.020 
Gender       -2.338    1.284  -1.82  0.071 
Age        -0.13730  0.06168  -2.23  0.027 
 
S = 6.54052   R-Sq = 48.5%   R-Sq(adj) = 46.2% 
 
PRESS = 7452.01   R-Sq(pred) = 43.18% 
 
Analysis of Variance 
 
Source           DF        SS      MS      F      P 
Regression        7   6356.41  908.06  21.23  0.000 
Residual Error  158   6758.99   42.78 
Total           165  13115.40 
 
 
Stepwise regression model 
 
Alpha-to-Enter: 0.05  Alpha-to-Remove: 0.05 
 
Response is 6wOx on 7 predictors, with N = 166 
N (cases with missing observations) = 17 N (all cases) = 183 
 
Step            1      2      3 
Constant    21.10  16.20  16.98 
 
6wPMax       2.10   1.83   1.11 
T-Value      9.46   8.22   3.57 
P-Value     0.000  0.000  0.000 
 
6wALF              0.202  0.179 
T-Value             4.11   3.70 
P-Value            0.000  0.000 
 
6wPAve                     1.29 
T-Value                    3.25 
P-Value                   0.001 
 
S            7.19   6.87   6.67 
R-Sq        35.32  41.38  44.98 
R-Sq(adj)   34.92  40.66  43.96 
Mallows Cp   36.3   19.7   10.7 
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Multiple linear regression analysis of predictors of OKS (Pre-operative 
assessment) 
 
The regression equation is: 
 
preOx = 37.7 - 0.0637 preFlex + 0.153 preALF + 0.904 prePMax + 1.08 prePAve 
        - 0.0341 preLRMax - 1.35 Sex - 0.0751 Age 
 
171 cases used, 12 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     37.731    6.873   5.49  0.000 
preFlex    -0.06375  0.03484  -1.83  0.069 
preALF      0.15347  0.03816   4.02  0.000 
prePMax      0.9043   0.3748   2.41  0.017 
prePAve      1.0796   0.3884   2.78  0.006 
preLRMax   -0.03409  0.01479  -2.30  0.022 
Gender       -1.353    1.111  -1.22  0.225 
Age        -0.07509  0.05630  -1.33  0.184 
 
S = 6.02596   R-Sq = 38.6%   R-Sq(adj) = 36.0% 
 
PRESS = 6525.65   R-Sq(pred) = 32.36% 
 
Analysis of Variance 
 
Source           DF       SS      MS      F      P 
Regression        7  3728.77  532.68  14.67  0.000 
Residual Error  163  5918.89   36.31 
Total           170  9647.66 
 
 
Stepwise regression model 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
Response is preOx on 7 predictors, with N = 171 
N (cases with missing observations) = 12 N (all cases) = 183 
 
Step            1      2      3       4 
Constant    29.25  24.19  18.61   28.77 
 
prePAve      2.17   1.88   1.40    1.21 
T-Value      6.23   5.77   3.81    3.26 
P-Value     0.000  0.000  0.000   0.001 
 
preALF             0.188  0.192   0.169 
T-Value             5.60   5.81    4.98 
P-Value            0.000  0.000   0.000 
 
prePMax                    0.97    0.99 
T-Value                    2.63    2.72 
P-Value                   0.009   0.007 
 
preFlex                          -0.081 
T-Value                           -2.36 
P-Value                           0.020 
 
S            6.81   6.28   6.17    6.08 
R-Sq        18.65  31.43  34.16   36.29 
R-Sq(adj)   18.17  30.62  32.98   34.76 
Mallows Cp   49.1   17.2   11.9     8.3 
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Multiple linear regression analysis of pre-operative predictors of 12 
month OKS 
 
The regression equation is: 
 
12mOx = 31.3 - 0.0429 preFlex + 0.0759 preALF + 0.739 prePMax - 0.491 
prePAve - 0.0444 preLRMax - 2.41 Sex - 0.0700 Age 
 
177 cases used, 6 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     31.311    8.539   3.67  0.000 
preFlex    -0.04294  0.04354  -0.99  0.325 
preALF      0.07592  0.04786   1.59  0.115 
prePMax      0.7388   0.4700   1.57  0.118 
prePAve     -0.4905   0.4612  -1.06  0.289 
preLRMax   -0.04444  0.01879  -2.36  0.019 
Sex          -2.406    1.405  -1.71  0.089 
Age        -0.06998  0.07018  -1.00  0.320 
 
S = 7.66594   R-Sq = 10.6%   R-Sq(adj) = 6.9% 
 
Analysis of Variance 
 
Source           DF        SS      MS     F      P 
Regression        7   1175.44  167.92  2.86  0.008 
Residual Error  169   9931.55   58.77 
Total           176  11106.99 
 
 
Stepwise regression model  
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
Response is 12mOx on 8 predictors, with N = 170 
N (cases with missing observations) = 13 N (all cases) = 183 
 
Step            1 
Constant    9.528 
 
preOx       0.313 
T-Value      4.01 
P-Value     0.000 
 
S            7.68 
R-Sq         8.74 
R-Sq(adj)    8.19 
Mallows Cp    2.6 
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Multiple linear regression analysis of pre-operative predictors of 6 
month OKS 
 
The regression equation is: 
 
6mOx = 38.1 - 0.0750 preFlex + 0.132 preALF + 0.400 prePMax - 0.196 prePAve 
       - 0.0290 preLRMax - 1.41 Sex - 0.125 Age 
 
166 cases used, 17 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     38.097    9.119   4.18  0.000 
preFlex    -0.07495  0.04664  -1.61  0.110 
preALF      0.13214  0.05027   2.63  0.009 
prePMax      0.4004   0.5051   0.79  0.429 
prePAve     -0.1963   0.4858  -0.40  0.687 
preLRMax   -0.02899  0.02000  -1.45  0.149 
Sex          -1.412    1.465  -0.96  0.336 
Age        -0.12453  0.07504  -1.66  0.099 
 
S = 7.80571   R-Sq = 14.3%   R-Sq(adj) = 10.5% 
 
Analysis of Variance 
 
Source           DF        SS      MS     F      P 
Regression        7   1606.79  229.54  3.77  0.001 
Residual Error  158   9626.80   60.93 
Total           165  11233.59 
 
 
Stepwise regression model 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
Response is 6mOx on 8 predictors, with N = 160 
N (cases with missing observations) = 23 N (all cases) = 183 
 
Step            1 
Constant    5.970 
 
preOx       0.466 
T-Value      5.82 
P-Value     0.000 
 
S            7.59 
R-Sq        17.66 
R-Sq(adj)   17.14 
Mallows Cp    1.1 
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Multiple linear regression analysis of pre-operative predictors of 6 week 
OKS 
 
The regression equation is: 
 
6wOx = 28.3 - 0.0111 preFlex + 0.172 preALF + 0.743 prePMax + 0.048 prePAve 
       - 0.0122 preLRMax - 0.09 Sex - 0.0949 Age 
 
162 cases used, 21 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant      28.32    10.10   2.81  0.006 
preFlex    -0.01106  0.05066  -0.22  0.828 
preALF      0.17242  0.05694   3.03  0.003 
prePMax      0.7429   0.5616   1.32  0.188 
prePAve      0.0482   0.5427   0.09  0.929 
preLRMax   -0.01216  0.02220  -0.55  0.585 
Sex          -0.092    1.598  -0.06  0.954 
Age        -0.09494  0.08168  -1.16  0.247 
 
S = 8.48589   R-Sq = 12.6%   R-Sq(adj) = 8.7% 
 
Analysis of Variance 
 
Source           DF        SS      MS     F      P 
Regression        7   1602.68  228.95  3.18  0.004 
Residual Error  154  11089.59   72.01 
Total           161  12692.28 
 
 
Stepwise regression model 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
Response is 6wOx on 8 predictors, with N = 157 
N (cases with missing observations) = 26 N (all cases) = 183 
 
Step            1 
Constant    9.958 
 
preOx       0.549 
T-Value      6.39 
P-Value     0.000 
 
S            7.98 
R-Sq        20.86 
R-Sq(adj)   20.35 
Mallows Cp    0.3 
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Appendix E: Protocols (Chapter 5) 
 
Local cell processing protocols (QMRI) adhered to: 
 
H and E staining protocol 
 
1. Stain in hematoxylin for 5 minutes 
2. Rinse in running tap water for 20 minutes 
3. Decolorize in acid alcohol for 1-3 seconds 
4. Rinse in running tap water for 5 minutes 
5. Immerse in Lithium Carbonate bath for 3 Seconds 
6. Rinse in running tap water for 5 minutes 
7. Counterstain in Eosin bath for 15 seconds 
8. Dehydrate: 
a. Bathe in 90% ethanol for 3 minutes, air dry for 5 seconds 
b. Bathe in 95% ethanol for 3 minutes, air dry for 5 seconds 
c. Bathe in 100% ethanol (bath 1) for 3 minutes, air dry for 5 seconds 
d. Bathe in 100% ethanol (bath 2) for 3 minutes, air dry for 5 seconds 
9. Clear in xylene (bath 1) for 5 minutes, air dry for 5 seconds 




1. Bathe in xylene (bath 1) for 5 minutes, then air dry for 5 seconds 
2. Bathe in xylene (bath 2) for 2 minutes, then air dry for 5 seconds 
3. Bathe in 100% ethanol (bath 1) for 2 minutes, then air dry for 5 seconds 
4. Bathe in 100% ethanol (bath 2) for 2 minutes, then air dry for 5 seconds 
5. Bathe in 90% ethanol for 2 minutes, then air dry for 5 seconds 
6. Bathe in 80 % ethanol for 2 minutes, then air dry for 5 seconds 
7. Bathe in 50% ethanol, for 2 minutes then air dry for 5 seconds 
8. Rinse in distilled water for 5 minutes 
 
Antigen retrieval protocol 
 
1. Rinse for 1 minute in running tap water 
2. Immerse in Sodium citrate and boil for 15 minutes (microwave)  




Appendix F: Statistical output (Chapter 5) 
Regression analysis of satellite cell PSI and post-operative change in 
power output 
 
The regression equation is: 
 
Improvement (W) 6/52-26/52 = - 2.33 + 2.89 cell PSI 
 
 
16 cases used, 2 cases contain missing values 
 
Predictor      Coef  SE Coef      T      P 
Constant     -2.332    9.102  -0.26  0.802 
Cell PSI      2.890    1.128   2.56  0.023 
 
S = 11.9649   R-Sq = 31.9%   R-Sq(adj) = 27.0% 
 
 
Analysis of Variance 
 
Source          DF      SS     MS     F      P 
Regression       1   939.2  939.2  6.56  0.023 
Residual Error  14  2004.2  143.2 
Total           15  2943.4 
 
Regression analysis of satellite cell PSI and post-operative change in 
power-bodyweight ratio 
 
The regression equation is: 
 
Improvement (%BW) 6/52-26/52 = - 0.100 + 0.0459 cell PSI 
 
 
16 cases used, 2 cases contain missing values 
 
Predictor       Coef  SE Coef      T      P 
Constant     -0.0996   0.1191  -0.84  0.417 
Cell PSI     0.04589  0.01476   3.11  0.008 
 
S = 0.156573   R-Sq = 40.8%   R-Sq(adj) = 36.6% 
 
 
Analysis of Variance 
 
Source          DF       SS       MS     F      P 
Regression       1  0.23679  0.23679  9.66  0.008 
Residual Error  14  0.34321  0.02451 
Total           15  0.58000 
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Regression analysis of pre-operative power output and post-operative 
change in power output 
 
The regression equation is: 
 
Improvement (W) 6/52-26/52 = 15.5 + 0.0878 pre-op power 
 
 
16 cases used, 2 cases contain missing values 
 
Predictor           Coef  SE Coef     T      P 
Constant          15.456    4.838  3.19  0.006 
pre-op power     0.08781  0.07059  1.24  0.234 
 
S = 13.7595   R-Sq = 10.0%   R-Sq(adj) = 3.5% 
 
 
Analysis of Variance 
 
Source          DF      SS     MS     F      P 
Regression       1   292.9  292.9  1.55  0.234 
Residual Error  14  2650.5  189.3 
Total           15  2943.4 
 
 
Regression analysis of pre-operative power output and post-operative 
change in power-bodyweight ratio 
 
The regression equation is: 
 
Improvement (%BW) 6/52-26/52 = 0.214 + 0.0677 pre-op (%BW) 
 
 
16 cases used, 2 cases contain missing values 
 
Predictor          Coef  SE Coef     T      P 
Constant        0.21363  0.06964  3.07  0.008 
St to BW ratio  0.06766  0.09037  0.75  0.466 
 
S = 0.199584   R-Sq = 3.8%   R-Sq(adj) = 0.0% 
 
 
Analysis of Variance 
 
Source          DF       SS       MS     F      P 
Regression       1  0.02233  0.02233  0.56  0.466 
Residual Error  14  0.55767  0.03983 
Total           15  0.58000 
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Stepwise regression model of change in power output 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
 
Response is Improvement (W) 6/52-6/12 on 2 predictors, with N = 16 
N (cases with missing observations) = 2 N (all cases) = 18 
 
 
Step              1 
Constant     -2.332 
 
Cell PSI        2.9 
T-Value        2.56 
P-Value       0.023 
 
S              12.0 
R-Sq          31.91 
R-Sq(adj)     27.04 
Mallows Cp      2.2 
 
 
Stepwise regression model of change in power-bodyweight ratio 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
 
Response is Improvement (%BW) 6/52-6/12 on 2 predictors, with N = 16 
N (cases with missing observations) = 2 N (all cases) = 18 
 
 
Step                1 
Constant     -0.09963 
 
Cell PSI        0.046 
T-Value          3.11 
P-Value         0.008 
 
S               0.157 
R-Sq            40.83 
R-Sq(adj)       36.60 
Mallows Cp        1.0 
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Appendix G: Protocols (Chapter 6) 
RNA purification protocol 
 




NucleoSpin® RNA II / NucleoSpin® RNA L 
 
July 2010 / Rev. 12 
 
Total RNA purification from cultured cells and tissue with NucleoSpin® RNA II 
 
Before starting the preparation: 
 
Check if Wash Buffer RA3 and rDNase were prepared according to section 3. 
 
 
1 Homogenize sample 
 
Disrupt up to 30 mg of tissue (for sample amounts see section 2.2; for homogenization methods see 
section 2.3). Up to 5 x 106 eukaryotic cultured cells can be collected by centrifugation and lysed by addition 
of Buffer RA1 directly. 
 
 
2 Lyse cells 
 
Add 350 μL Buffer RA1 and 3.5 μL ß-mercaptoethanol (ß-ME) to the cell pellet or to ground tissue and 
vortex vigorously.  
 
For appropriate sample and lysis buffer amounts see section 2.2. 
 
 
3 Filtrate lysate 
 
Reduce viscosity and clear the lysate by filtration through NucleoSpin® Filter (violet ring): Place 
NucleoSpin® Filter in a Collection Tube (2 mL), apply the mixture, and centrifuge for 1 min at 11,000 x g.  
 
The lysate may be passed alternatively 5 times through a 0.9 mm needle (20 gauge) fitted to a syringe. In case of 
visible pellet formation (depending on sample amount and nature) transfer supernatant without any formed pellet to 
a new 1.5 mL microcentrifuge tube (not supplied). Important:  
 
To process higher amounts of cells (> 1 x 106) or tissue (> 10 mg), the lysate should first be homogenized 
using the 0.9 mm needle (20 gauge), followed by filtration through NucleoSpin® Filters. 
 
 
4 Adjust RNA binding conditions 
 
Discard the NucleoSpin® Filter and add 350 μL ethanol (70 %) to the homogenized lysate and mix by 
pipetting up and down (5 times).  
 
Alternatively, transfer flow-through into a new 1.5 mL microcentrifuge tube (not provided), add 350 μL 
ethanol (70%), and mix by vortexing (2 x 5 s).  
 
After addition of ethanol a stringy precipitate may become visible which will not affect the RNA isolation. Be sure to 
disaggregate any precipitate by mixing and load all of the precipitate on the column as described in step 5. Do not 





5 Bind RNA 
 
For each preparation take one NucleoSpin® RNA II Column (light blue ring) placed in a Collection Tube. 
Pipette lysate up and down 2 – 3 times and load the lysate to the column. Centrifuge for 30 s at 11,000 x g. 
Place the column in a new Collection Tube (2 mL).  
 




6 Desalt silica membrane 
 
Add 350 μL MDB (Membrane Desalting Buffer) and centrifuge at 11,000 x g for 1 min to dry the membrane. 
 
Salt removal will make the following rDNase digest much more effective. If the column outlet has come into contact 
with the flow-through for any reason, discard the flow-through and centrifuge again for 30 s at 11,000 x g. 
 
 
7 Digest DNA 
 
Prepare DNase reaction mixture in a sterile 1.5 mL microcentrifuge tube (not provided): For each isolation, 
add 10 μL reconstituted rDNase (also see section 3) to 90 μL Reaction Buffer for rDNase. Mix by flicking 
the tube. Apply 95 μL DNase reaction mixture directly onto the center of the silica membrane of the column. 
Incubate at room temperature for 15 min. 
 
 
8 Wash and dry silica membrane 
 
1st wash: Add 200 μL Buffer RA2 to the NucleoSpin® RNA II Column. Centrifuge for 30 s at 11,000 x g. 
Place the column into a new Collection Tube (2 mL). Buffer RA2 will inactivate the rDNase. 
 
2nd wash: Add 600 μL Buffer RA3 to the NucleoSpin® RNA II Column. Centrifuge for 30 s at 11,000 x g. 
Discard flowthrough and place the column back into the Collection Tube.  
 
Note: Make sure that residual buffer from the previous wash step is washed away with Buffer RA3. 
 
3rd wash: Add 250 μL Buffer RA3 to the NucleoSpin® RNA II Column. Centrifuge for 2 min at 11,000 x g to 
dry the membrane completely. Place the column into a nucleasefree Collection Tube (1.5 mL, supplied). 
 
If for any reason, the liquid level in the Collection Tube has reached the NucleoSpin® RNA II Column after 
centrifugation, discard flow-through, and centrifuge again. Note: Make sure that residual buffer from the previous 
wash step is washed away with Buffer RA3. 
 
 
9 Elute RNA 
 
Elute the RNA in 60 μL RNase-free H2O, (supplied) and centrifuge at 11,000 x g. for 1 min.  
 
If higher RNA concentrations are desired, elution can be done with 40 μL. Overall yield, however, will decrease 




 cDNA Reverse Transcription Protocol  
 
High Capacity cDNA Reverse Transcription Kits 






Using the High Capacity cDNA Reverse Transcription Kits 
 
RNA Template Guidelines 
 
For optimal performance of the High Capacity cDNA Reverse Transcription Kits, Applied 
Biosystems recommends using RNA that is: 
 
• Free of inhibitors of reverse transcription and PCR 
• Dissolved in PCR-compatible buffer or water 
• Free of RNase activity 
 
Note: If you suspect that the RNA contains RNase activity, add RNase Inhibitor to the 
reverse transcription reaction at a final concentration of 1.0 U/μL. 
 
 
Input Amount of Total RNA 
 
Use up to 2 μg of total RNA per 20-μL reaction. 
 
 
Preparing the 2✕ Reverse Transcription Master Mix 
 
Prepare the 2✕ RT master mix using the kit components before preparing the reaction plate. 
 
To prepare the 2✕ RT master mix (per 20-μL reaction): 
1. Allow the kit components to thaw on ice. 
2. Referring to the table below, calculate the volume of components needed to prepare the    required 
number of reactions. 
 















10✕ RT Buffer 2.0 2.0 
25✕ dNTP Mix (100 mM) 0.8 0.8 






RNase Inhibitor 1.0 — 
Nuclease-free H2O 3.2 4.2 
Total per Reaction 10.0 10.0 
 
IMPORTANT! Include additional reactions in the calculations to provide excess volume for 
the loss that occurs during reagent transfers. 
 
3. Place the 2✕ RT master mix on ice and mix gently. 
 
 
Preparing the cDNA Reverse Transcription Reactions 
 
To prepare the cDNA RT reactions: 
1. Pipette 10 μL of 2✕ RT master mix into each well of a 96-well reaction plate or individual tube. 
2. Pipette 10 μL of RNA sample into each well, pipetting up and down two times to mix. 
3. Seal the plates or tubes. 
4. Briefly centrifuge the plate or tubes to spin down the contents and to eliminate any air bubbles. 
5. Place the plate or tubes on ice until you are ready to load the thermal cycler. 
 
 
Performing Reverse Transcription 
 
To perform reverse transcription: 
1. Program the thermal cycler conditions using one of the thermal cyclers listed in Table 3 on page 4. 
 
IMPORTANT! These conditions are optimized for use with the High Capacity cDNA 
Reverse Transcription Kits. 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time 10 min 120 min 5 min 
 
2. Set the reaction volume to 20 μL. 
3. Load the reactions into the thermal cycler. 





Storing cDNA Reverse Transcription Reactions 
 
You can store cDNA RT plates or tubes prepared using the High Capacity cDNA Reverse 
Transcription Kits for short-term or long-term storage. 
 
Storage Duration Storage Temperature (°C) 
 
Short-term (up to 24 hours before use)‡ 2 to 6 
Long-term 15 to 25 
‡ For prolonged storage at 2 to 6 °C, add EDTA to a final concentration of 1 mM to chelate cations and to prevent 
nucleic acid degradation. 
 
IMPORTANT! If required, briefly centrifuge the archive plates or tubes before storing to spin 






Appendix H: Statistical output (Chapter 6) 
Regression of Pax7 expression and post-operative change in power 
output 
 
The regression equation is: 
 
Improvement (W) = 11.0 + 33.0 Pax-7 
 
 
11 cases used, 1 cases contain missing values 
 
Predictor    Coef  SE Coef     T      P 
Constant   10.965    9.071  1.21  0.258 
Pax-7       33.02    15.54  2.13  0.062 
 
S = 19.6830   R-Sq = 33.4%   R-Sq(adj) = 26.0% 
 
 
Analysis of Variance 
 
Source          DF      SS      MS     F      P 
Regression       1  1749.9  1749.9  4.52  0.062 
Residual Error   9  3486.8   387.4 
Total           10  5236.7 
 
 
Regression of Pax7 expression and post-operative change in power-
bodyweight ratio 
 
The regression equation is: 
 
Improvement (%BW) = 0.0842 + 0.345 Pax-7 
 
 
Predictor     Coef  SE Coef     T      P 
Constant   0.08419  0.05205  1.62  0.140 
Pax-7      0.34466  0.08916  3.87  0.004 
 
S = 0.112950   R-Sq = 62.4%   R-Sq(adj) = 58.2% 
 
 
Analysis of Variance 
 
Source          DF       SS       MS      F      P 
Regression       1  0.19064  0.19064  14.94  0.004 
Residual Error   9  0.11482  0.01276 




Regression of NCAM expression and post-operative change in power 
output 
 
The regression equation is: 
 
Improvement (W) = 3.80 + 26.0 NCAM 
 
 
11 cases used, 1 cases contain missing values 
 
Predictor    Coef  SE Coef     T      P 
Constant    3.797    6.450  0.59  0.571 
NCAM       25.963    5.932  4.38  0.002 
 
S = 13.6377   R-Sq = 68.0%   R-Sq(adj) = 64.5% 
 
 
Analysis of Variance 
 
Source          DF      SS      MS      F      P 
Regression       1  3562.9  3562.9  19.16  0.002 
Residual Error   9  1673.9   186.0 
Total           10  5236.7 
 
Regression of NCAM expression and post-operative change in power-
bodyweight ratio 
 
The regression equation is: 
 
Improvement (%BW) = 0.0678 + 0.201 NCAM 
 
 
11 cases used, 1 cases contain missing values 
 
Predictor     Coef  SE Coef     T      P 
Constant   0.06779  0.04766  1.42  0.189 
NCAM       0.20123  0.04384  4.59  0.001 
 
S = 0.100781   R-Sq = 70.1%   R-Sq(adj) = 66.7% 
 
 
Analysis of Variance 
 
Source          DF       SS       MS      F      P 
Regression       1  0.21404  0.21404  21.07  0.001 
Residual Error   9  0.09141  0.01016 




Regression of CD34 expression and post-operative change in power 
output 
 
The regression equation is: 
 
Improvement (W) = 28.2 - 8.9 Cd34 
 
 
11 cases used, 1 cases contain missing values 
 
Predictor   Coef  SE Coef      T      P  
Constant   28.24    14.60   1.93  0.085 
CD34       -8.87    41.72  -0.21  0.836 
 
S = 24.0614   R-Sq = 0.5%   R-Sq(adj) = 0.0% 
 
 
Analysis of Variance 
 
Source          DF      SS     MS     F      P 
Regression       1    26.2   26.2  0.05  0.836 
Residual Error   9  5210.6  579.0 
Total           10  5236.7 
 
Regression of CD34 expression and post-operative change in power-
bodyweight ratio 
 
The regression equation is: 
 
Improvement (%BW) = 0.243 - 0.021 Cd34 
 
 
11 cases used, 1 cases contain missing values 
 
Predictor     Coef  SE Coef      T      P 
Constant    0.2428   0.1118   2.17  0.058 
Cd34       -0.0211   0.3194  -0.07  0.949 
 
S = 0.184182   R-Sq = 0.0%   R-Sq(adj) = 0.0% 
 
 
Analysis of Variance 
 
Source          DF       SS       MS     F      P 
Regression       1  0.00015  0.00015  0.00  0.949 
Residual Error   9  0.30531  0.03392 




Stepwise regression model of change in power output 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
 
Response is Improvement (W) on 3 predictors, with N = 1O 
N (cases with missing observations) = 1 N (all cases) = 11 
 
 
Step              1 
Constant      3.797 
 
NCAM           26.0 
T-Value        4.38 
P-Value       0.002 
 
S              13.6 
R-Sq          68.04 
R-Sq(adj)     64.48 
 
 
Stepwise regression model of change in power-bodyweight ratio 
 
Alpha-to-Enter: 0.05, Alpha-to-Remove: 0.05 
 
 
Response is Improvement (%BW) on 3 predictors, with N = 10 
N (cases with missing observations) = 1 N (all cases) = 11 
 
 
Step                1 
Constant      0.06779 
 
NCAM            0.201 
T-Value          4.59 
P-Value         0.001 
 
S               0.101 
R-Sq            70.07 
R-Sq(adj)       66.75 




Appendix I: Implant design differences 
 
Highlighted design differences between the implants used. 
 
Further design differences employed in the Triathlon implant compared to the 
Kinemax implant can be visualised in the following images: 
 
1 - Sided patello-femoral grove: AP view (annotated with red arrows) and axial view. 
2 - Reduced anterior bulk of implant, but increased angle of anterior flange: lateral 
view (annotated with blue arrows) and axial view. 
3 - Shorter posterior condylar offset: lateral view (annotated with green bars) 
 
 
Kinemax Total Knee Prosthesis 
 
 
Triathlon Total Knee Prosthesis 
 
 
Images of equivalent sized prostheses. Individual anteroposterior and lateral views. 






Images of equivalent sized prostheses. Combined axial view (Kinemax prosthesis to the left, 
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